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INTRODUCTION
Prostate cancer is a major public health problem as well as an economic burden in the United States and European Union (1-4). Currently, prostate cancer is the most common non-cutaneous cancer and the third leading cause of cancer death in men in the United State and European Union (1, 4). An estimated 234,460 
new cases of prostate cancer will be diagnosed in the United States and 27,350 people will die of the disease in 2006 
(1). In the next decades the increasing natural life expectation will result in a further increase of both the incidence 
of and the related deaths from prostate cancer (1, 5).  
The high incidence and protracted natural history of prostate cancer, combined with earlier detection, and an in-
creasing proportion of patients with smaller-volume and lower-grade lesions at diagnosis, have complicated the 
management of the disease and raised controversial issues regarding screening, selection of patients for treatment, 
and superiority among treatment modalities (1, 6-8). The changes due to prostate-specifi c antigen (PSA) screening 
have led to an unfortunate trend of overdetection and overtreatment of biologically insignifi cant disease (9, 10). One 
challenge that clinicians and patients have to face in the modern PSA era is to diff erentiate men who have disease 
destined to progress and cause morbidity/ mortality from those who will not require immediate, or possibly even 
delayed, therapeutic intervention (11-14). 
Patients with prostate cancer have to choose from a wide range of treatments, and the decision signifi cantly aff ects 
both quality of life (QOL) and survival. Primary therapies with curative intent (surgery or radiation) provide excellent 
long-term cancer control but are accompanied by a risk of treatment-related morbidity (15, 16).There is a growing 
demand for patient-specifi c therapies that can reduce treatment morbidity while maximizing treatment benefi ts. 
An objective prior to any cancer therapy is to obtain a comprehensive and accurate knowledge of tumor location, 
size, locoregional extent, and biologic potential. Better tools are needed to help physicians and patients decide 
what type of treatment is most appropriate, or whether any treatment is needed at all.
Scientifi c discoveries, technologic advances and research eff orts are profoundly changing our understanding of 
prostate cancer and our ability to treat it eff ectively (5). The Nobel prize-winning discoveries of Paul C. Lauterbur (17) 
and Sir Peter Mansfi eld (18) concerning magnetic resonance imaging (MRI) and Richard R. Ernst (19) concerning the 
development of the methodology of high resolution nuclear magnetic resonance spectroscopic imaging (MRSI) 
led to the development of modern MR imaging to take pictures of anatomical structures and MR spectroscopy to 
measure amounts of important chemicals within the body noninvasively - a breakthrough in medical diagnostics 
and research. Historically, in 1984 Hricak, et al used MR imaging as a local staging modality for prostate cancer (20, 
21). In 1991 picture archiving and communication systems (PACS) started to be available for clinical use (22). PACS 
is a collection of technologies used to facilitate digital medical imaging display and distribution. In 1995 Krestin, et 
al demonstrated the use of contrast-enhanced endorectal coil MRI in local staging of prostate cancer (23). In 1995, 
Hricak, et al showed integration of endorectal-pelvic phased-array coils for MRI of prostate cancer (24, 25). In 1996 
Kurhanewicz , et al reported that combined endorectal MRI/MRSI could be considered a “one-stop shop” imaging 
modality for assessing anatomic and metabolic features of prostate cancer (26). In 2002 Harisinghani et al. showed 
that high-resolution MRI with lymphotropic superparamagnetic nanoparticles to detect small and otherwise unde-
tectable lymph node metastasis (LNM) in prostate cancer (27) . 
Although reports on the value of MRI in prostate cancer management have been contradictory, there is no doubt 
that the use of endorectal MRI and MRSI for the noninvasive evaluation of tumor location, local extent [extracapsular 
extension (ECE) and/or seminal vesicle invasion (SVI)], volume, and aggressiveness is generating strong clinical inter-
est (6, 28-34). Advances in prostate MRI have improved the pre-treatment characterization of prostate cancer (35, 
36). In addition to patient selection, MRI may aid in directing therapy, evaluating results, and monitoring for early 
recognition of treatment failure, leading to the best cancer-control and QOL outcomes (6, 37). 
The central subject of this dissertation is the ability of state-of-the-art MRI/MRSI to non-invasively improve stag-
ing, treatment planning, and the assessment of tumor aggressiveness and recurrence-free probabilities in patients 
with prostate cancer. The dissertation also explores the potential clinical application of color-coded parameter im-
aging derived from postprocessing of dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) of abdominal 
tumors.
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OUTLINE OF THE DISSERTATION
Chapter 2 of the dissertation describes the incremental value of endorectal coil MR imaging and combined en-
dorectal MRI/MRSI to the staging nomograms for predicting organ-confi ned prostate cancer (OCPC). Chapter 3 
discusses a study showing that endorectal MR imaging contributes signifi cant incremental value to clinical variables 
in the prediction of ECE. Chapter 4 shows that the predictive value of endorectal MR imaging fi ndings in the de-
tection of ECE is signifi cantly aff ected by the reader’s subspecialty experience. Intraobserver variability, as well as 
inconsistency in the accuracy of diagnoses determined with MR imaging fi ndings, has been reported. Chapter 5 
discusses a study in a large, contemporary cohort of patients that showed that endorectal MRI fi ndings contribute 
incremental value to the Kattan nomogram for the prediction of prostate cancer SVI. Chapter 6 describes a study 
showing that the cross-referencing tool on PACS improves prostate cancer tumor staging by three dimensional (3D) 
endorectal MRI. Chapter 7 presents an investigation of the role of combined endorectal and phased-array MRI in 
the detection of lymph node metastasis (LNM) in a representative sample of the current prostate cancer patient 
population, with its low incidence of LNM. The prospective study described in Chapter 8 shows that the use of 
endorectal MRI before radical prostatectomy (RP) could help the surgeon make a more appropriate management 
decision regarding whether to spare or resect the neurovascular bundles during RP. The surgeon’s ultimate goal is to 
excise the cancer completely while preserving the nearby normal structures, thus avoiding positive surgical margin 
and minimizing the chances of recurrence and allowing recovery of sexual function and avoidance of impotence 
(erectile dysfunction). Chapter 9 investigates whether the addition of endorectal MRI fi ndings to an established 
preoperative nomogram would improve prediction of freedom from biochemical recurrence. Chapter 10 shows 
that signal intensity evaluation of T2-weighted MR images may facilitate noninvasive assessment of prostate cancer 
biological aggressiveness. Chapter 11 illustrates the potential clinical application of color-coded parameter im-
aging derived from postprocessing of dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) of abdominal 
tumors. In Chapter 12 the data presented in the preceding chapters are discussed as a whole and prospects and 
recommendations regarding diagnostic MRI of prostate cancer are given.
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ABSTRACT
Purpose: To assess retrospectively the incremental value of endorectal coil magnetic resonance (MR) imaging and 
combined endorectal MR imaging–MR spectroscopic imaging to the staging nomograms for predicting organ-
confi ned prostate cancer (OCPC). 
Materials and Methods: The institutional review board approved this HIPAA-compliant study and issued a waiver 
of informed consent for review of the MR reports and clinical data. Between November 1, 1999, and November 1, 
2004, 229 patients underwent endorectal MR imaging and 383 underwent combined endorectal MR imaging–MR 
spectroscopic imaging before radical prostatectomy. Mean patient age was 58 years (range, 32–74 years). MR stud-
ies were interpreted prospectively by 12 radiologists who were informed of patients’ clinical data. On the basis of 
the MR reports, the risks of extracapsular extension, seminal vesicle invasion, and lymph node metastasis were 
scored retrospectively from 1 to 5; the highest score was subtracted from 6 to determine a score (from 1 to 5) for the 
likelihood of OCPC on MR studies. The staging nomograms were used to calculate the likelihood of OCPC on the 
basis of serum prostate-specifi c antigen level, Gleason grade at biopsy, and clinical stage. Histopathologic fi ndings 
constituted the reference standard. Logistic regression was used to estimate the multivariable relations between 
OCPC and MR fi ndings. The area under the receiver operator characteristic curve was calculated for each model. The 
jackknife method was used for bias correction. 
Results: MR fi ndings contributed signifi cant incremental value (P ≤ .02) to the nomograms in the overall 
study population. The contribution of MR fi ndings was signifi cant in all risk groups but was greatest in the 
intermediate- and high-risk groups (P < .01 for both). Accuracy in the prediction of OCPC with MR was higher when 
MR spectroscopic imaging was used, but the diff erence was not signifi cant. 
Conclusion: Endorectal MR imaging and combined endorectal MR imaging–MR spectroscopic imaging contribute 
signifi cant incremental value to the staging nomograms in predicting OCPC. 
© RSNA, 2005
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INTRODUCTION
Today, with the widespread use of screening of prostate-specifi c antigen (PSA)
1 levels and with better methods 
for diagnosis at biopsy, 90% of newly diagnosed cases of prostate cancer are considered to be of a local or 
regional stage (1). When clinically localized cancers are confi ned to the prostate pathologically, more than 
85% are curable with radical prostatectomy (2,3). 
Eff ective treatment planning, whether for radiation treatment or surgery, requires accurate prediction of the patho-
logic stage of the cancer. Various methods have been proposed for predicting that a clinically localized prostate 
cancer is, in fact, pathologically confi ned to the prostate (4–8). An important advance in accurate prediction was 
the development of nomograms that combined clinical stage (determined by means of digital rectal examination), 
serum PSA levels, and the Gleason grade in the biopsy specimen to predict the pathologic stage of the cancer (9,10). 
These “Partin Tables” are a validated predictive tool widely used for patient counseling (11–13). However, as a treat-
ment-planning tool they are limited because they do not incorporate anatomic data that could guide interventions 
to control local disease. If cancer extends outside the prostate, the chances of cure are substantially diminished, 
and the surgical or radiation treatment planning must be adapted to ensure complete eradication of the cancer. 
The role of endorectal magnetic resonance (MR) imaging in prostate cancer management has been emerging with 
improved MR techniques, such as MR spectroscopic imaging, and with better interpretation of MR images of the 
prostate by experienced radiologists (14–19). The present study was designed to assess retrospectively the incre-
mental value of endorectal coil MR imaging and combined endorectal MR imaging–MR spectroscopic imaging to 
the staging nomograms for predicting organ-confi ned prostate cancer (OCPC). 
MATERIALS AND METHODS 
Patients
Between November 1, 1999, and November 1, 2004, 612 consecutive patients with prostate cancer were referred 
from the urology department (P.T.S.) for MR imaging before radical retropubic prostatectomy and pelvic lymphad-
enectomy. Three hundred eighty-three patients underwent endorectal MR imaging combined with MR spectro-
scopic imaging, and 229 underwent endorectal MR imaging alone. From November 1999 through June 2003, imag-
ing was performed as part of an ongoing National Institutes of Health study investigating the use of MR imaging 
in patients with prostate cancer; all patients gave informed consent before enrollment in the prospective National 
Institutes of Health study, which was compliant with the Health Insurance Portability and Accountability Act, or 
HIPAA. Subsequent to June 2003, imaging was performed as part of our accepted practice for patient evaluation. 
Our institutional review board issued a waiver of informed consent for the review of the MR reports and clinical data 
for this retrospective study, which was also HIPAA compliant. Mean patient age was 58 years (range, 32–74 years). 
None of the patients received neoadjuvant hormonal or radiation therapy prior to surgery. A tissue diagnosis of 
prostate cancer was made at biopsy in all patients. Clinical stage (determined by means of digital rectal examina-
tion), serum PSA level, and Gleason grade in the biopsy specimen, as well as MR data, were recorded retrospectively 
from the patients’ medical records by two coauthors (L.W. and K.K.). A segment of the study population (371 of 612 
patients) has been included in previous publications (14,16,17). 
1Abbreviations
ECE = extracapsular extension • LNM = lymph node metastasis • OCPC = organ-confi ned prostate cancer • PSA = prostate-specifi c antigen • ROC = 
receiver operating characteristic • SVI = seminal vesicle invasion 
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Staging Nomograms and Risk Groups
The likelihood of OCPC according to the 2001 version of the Partin Tables was recorded on the basis of the serum 
PSA level, Gleason grade, and clinical staging (L.W. and K.K.) (10). Furthermore, the same coauthors divided the pa-
tients into three categories: low, intermediate, or high risk for cancer spread outside the prostate. The low-risk group 
had clinical stage T1 or T2 prostate cancer, with a Gleason score of 6 or less and a PSA level lower than 10 ng/mL. 
The intermediate-risk group had clinical stage T1 or T2 prostate cancer, with a Gleason score of 7 and/or a PSA level 
of 10.1–20 ng/mL. The high-risk group had clinical stage T3 or T4 prostate cancer or a Gleason score greater than 7 
or a PSA level greater than 20 ng/mL (20–22). 
Imaging and Interpretation
Endorectal MR imaging and hydrogen 1 MR spectroscopic imaging had been performed by using a 1.5-T whole-
body MR imager (Signa Horizon; GE Medical Systems, Milwaukee, Wis). Patients were examined in the supine posi-
tion by using the body coil for excitation and a pelvic phased-array coil (GE Medical Systems) in combination with 
a commercially available balloon-covered expandable endorectal coil (Medrad, Pittsburgh, Pa) for signal reception. 
T1-weighted transverse and spin-echo MR images were obtained from the aortic bifurcation to the symphysis pubis 
by using the following parameters: repetition time msec/echo time msec, 700/8; section thickness, 5 mm; intersec-
tion gap, 1 mm; fi eld of view, 24 cm; matrix, 256 x 192; frequency direction, transverse (to prevent obstruction of 
the pelvic node by endorectal coil motion artifact); and one signal acquired. Thin-section, high-spatial-resolution 
transverse and coronal T2-weighted fast spin-echo MR images of the prostate and seminal vesicles were obtained 
by using the following parameters: repetition time msec/eff ective echo time msec, 5000/96; echo train length, 16; 
section thickness, 3 mm; intersection gap, 0 mm; fi eld of view, 14 cm; matrix, 256 x 192; frequency direction, antero-
posterior (to prevent obstruction of the prostate by endorectal coil motion artifact); and three signals acquired. MR 
spectroscopic imaging was performed by using point-resolved spectroscopy voxel excitation, with band-selective 
inversion with gradient dephasing water and lipid suppression (23) and spatial encoding by means of chemical shift 
imaging (24) at 6.25-mm resolution in all three dimensions. Timing parameters were 1000/130, and imaging time 
was 17 minutes. 
Data processing was performed at a workstation (Sun Ultra 10; Sun Microsystems, Mountain View, Calif) and includ-
ed 2-Hz Lorentzian spectral apodization, four-dimensional Fourier transform, and automated frequency, phase, and 
baseline correction. Spectral data were zero fi lled to 3.1-mm resolution in the superior-inferior dimension and over-
laid on corresponding transverse T2-weighted MR images. Peak areas were calculated by using numeric integration. 
To provide a noise measurement, we calculated the standard deviation of the MR signal intensity in a region of the 
spectrum containing only noise. Metabolite peak areas were then normalized with respect to the noise standard 
deviation to yield an approximate signal-to-noise ratio. 
MR studies had been interpreted prospectively by 12 MR radiologists during their regular clinical assignment to the 
MR imaging service. All of the readers were trained in body MR imaging (nine had an MR imaging fellowship and 
the others had been involved with MR imaging since it was introduced to clinical practice). The level of experience 
reading MR images since fellowship ranged from 4 to 17 years among the readers. Each radiologist made his or her 
determination of MR prostate fi ndings on the basis of his or her own continuous medical training and knowledge of 
previously described MR imaging features of extracapsular extension (ECE), seminal vesicle invasion (SVI), and lymph 
node metastasis (LNM) (16,25–31). All readers had access to the patients’ medical records, including PSA level and 
biopsy fi ndings as per their regular clinical practice. In addition, all readers had access to MR spectroscopic imag-
ing data when available. The use of MR spectroscopic imaging data consisted of the evaluation of the location and 
number of abnormal voxels (voxels classifi ed as suspicious or defi nitive for cancer by a spectroscopist). As described 
by Yu et al (25), when there are more than 4 voxels of cancer per section present at spectroscopy, the probability of 
ECE increases. Spectroscopy does not play a role in the assessment of the probability of SVI or LNM. 
On the basis of the radiologists’ written reports, the likelihood of ECE, SVI, and LNM was scored retrospectively by 
a single observer (L.W., 4 years of experience with research on MR imaging of the prostate). Three separate scores 
were assigned (one for ECE, one for SVI, and one for LNM) by using the following rating scale: score of 5, defi nite 
yes; score of 4, probable yes; score of 3, possible yes; score of 2, probable no; and score of 1, defi nite no. The greatest 
of the three scores was then used to calculate the likelihood of OCPC at MR evaluation with the following formula: 
OCPC = 6 – maximal score (ie, the ECE, SVI, or LNM score). The rating scale for the likelihood of OCPC at MR evalu-
ation was as follows: score of 1, defi nitely no OCPC; score of 2, probably no OCPC; score of 3, possible OCPC; score 
219
of 4, probable OCPC; and score of 5, defi nite OCPC. Thus, if the scores for ECE, SVI, and LNM were 1 (defi nitely no 
ECE), 1 (defi nitely no SVI), and 1 (defi nitely no LNM), respectively, the score for the likelihood of OCPC was 5 (defi nite 
OCPC). The formula is an attempt to assess one minus the probability of the patient’s highest risk factor, though on a 
fi ve-point ordinal scale. It was designed and validated by a statistician (M.W.K.) with extensive experience in prostate 
cancer outcome research. 
Histologic Evaluation
Core biopsies had been evaluated for Gleason grade, greatest percentage of cancer in all biopsy cores, percent-
age of positive cores in all biopsy cores, and perineural invasion. Histology reports were reviewed by one author 
(L.W.). Radical prostatectomy specimens were examined by the institutional pathology department, as previously 
described by Yossepowitch et al (32). Specimens were fi xed in formalin, with the external surface of the right and left 
sides dyed in two colors. The apical prostate was truncated perpendicular to the prostatic urethra and subsequently 
sectioned as slices parallel to the prostatic urethra. The bladder neck margin was obtained by sampling portions 
of soft tissue at the junction of the rough prostatic capsule and smooth bladder neck or most proximal portion of 
the submitted specimen corresponding to the anatomic bladder neck. The remaining prostate was completely 
transected at 3–5-mm intervals in a plane perpendicular to the urethra. The fi nal pathology report following surgery 
was used to determine the presence of OCPC. OCPC was defi ned as the absence of cancer cells beyond the prostate 
capsule. Patients with LNM were considered not to have OCPC regardless of whether there was penetration through 
the prostate capsule. 
Statistical Analysis
Logistic regression was used to estimate the relations between clinical variables and MR fi ndings and the predic-
tion of OCPC. Model discrimination was assessed by using the receiver operator characteristic (ROC) curves, which 
were plotted, calculated, and compared. When the staging nomograms were combined with MR results in the 
model, the jackknife method, a form of resampling that reduces the optimistic bias, was used to obtain the bias-cor-
rected predicted probabilities and construct the ROC curves (33). The areas under the ROC curves were evaluated 
for models of OCPC prediction on the basis of the staging nomograms alone, MR fi ndings alone (from endorectal 
MR imaging or combined endorectal MR imaging–MR spectroscopic imaging), and the staging nomograms plus 
MR fi ndings (H.N.C., M.W.K.). To assess the incremental value of MR fi ndings to the staging nomograms, the model 
for the prediction of OCPC based on the staging nomograms plus MR fi ndings was compared with the model of 
Figure 1a: Images in a 55-year-old man 
with a small palpable clinical stage T2 
prostate nodule and PSA level of 0.80 ng/
mL. Sextant biopsy results showed Glea-
son grade 3 + 3 cancer involving 10% of 
submitted tissue from the right side (50% 
of the cores) and no perineural invasion. 
By using staging nomograms, the likeli-
hood of OCPC was determined to be 
81%. (a–c) T2-weighted fast spin-echo 
MR images. (a) Transverse 3-mm-thick MR 
(4900/118) image shows OCPC (arrow) in 
the right apex. (b) Sagittal 4-mm-thick MR 
(6000/97) image shows a focus of cancer 
(arrow) in the right apex and midgland. 
(c) Coronal 3-mm-thick MR (4666/96) 
image shows cancer (arrow) in the right 
apex and midgland. (d) Whole-mount 
serial section of the removed prostate 
shows organ-confi ned cancer (arrow) 
involving the right posterior quadrant of 
the prostate. 
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Figure 1b: Images in a 55-year-old man 
with a small palpable clinical stage T2 pros-
tate nodule and PSA level of 0.80 ng/mL. 
Sextant biopsy results showed Gleason 
grade 3 + 3 cancer involving 10% of sub-
mitted tissue from the right side (50% of 
the cores) and no perineural invasion. By 
using staging nomograms, the likelihood 
of OCPC was determined to be 81%. (a–c) 
T2-weighted fast spin-echo MR images. 
(a) Transverse 3-mm-thick MR (4900/118) 
image shows OCPC (arrow) in the right 
apex. (b) Sagittal 4-mm-thick MR (6000/97) 
image shows a focus of cancer (arrow) in 
the right apex and midgland. (c) Coronal 3-
mm-thick MR (4666/96) image shows can-
cer (arrow) in the right apex and midgland. 
(d) Whole-mount serial section of the 
removed prostate shows organ-confi ned 
cancer (arrow) involving the right posterior 
quadrant of the prostate. 
Figure 1c: Images in a 55-year-old man 
with a small palpable clinical stage T2 
prostate nodule and PSA level of 0.80 ng/
mL. Sextant biopsy results showed Glea-
son grade 3 + 3 cancer involving 10% of 
submitted tissue from the right side (50% 
of the cores) and no perineural invasion. By 
using staging nomograms, the likelihood 
of OCPC was determined to be 81%. (a–c) 
T2-weighted fast spin-echo MR images. (a) 
Transverse 3-mm-thick MR (4900/118) im-
age shows OCPC (arrow) in the right apex. 
(b) Sagittal 4-mm-thick MR (6000/97) im-
age shows a focus of cancer (arrow) in the 
right apex and midgland. (c) Coronal 3-
mm-thick MR (4666/96) image shows can-
cer (arrow) in the right apex and midgland. 
(d) Whole-mount serial section of the 
removed prostate shows organ-confi ned 
cancer (arrow) involving the right posterior 
quadrant of the prostate. 
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  Clinical Variable Finding
  PSA level*†
5.64 ± 7.82
          (0.10 - 13.40)
  Gleason grade
  3 + 3 377 (62)
  3 + 4 145 (24)
  4 + 3 48 (8)
  4 + 4/3 + 5 10 (2)
  4 + 5 10 (2)
  5 + 5 2 (0)
  Greatest percentage of cancer*‡
0.21 ± 0.27
          (0.01 - 1.00)
  Percentage of positive cores*§
0.38 ± 0.26
          (0.04 - 1.00)
  Perineural invasion
  Absent 530 (87)
  Present 82 (13)
  Clinical stage
  T1 371 (61)
  T2 241 (39)
  T3a 0 (0)
  T3b 0 (0)
  T4 0 (0)
  TanyN1 0 (0)
Figure 1d: Images in a 55-year-old man 
with a small palpable clinical stage T2 
prostate nodule and PSA level of 0.80 
ng/mL. Sextant biopsy results showed 
Gleason grade 3 + 3 cancer involving 
10% of submitted tissue from the right 
side (50% of the cores) and no perineural 
invasion. By using staging nomograms, 
the likelihood of OCPC was determined 
to be 81%. (a–c) T2-weighted fast spin-
echo MR images. (a) Transverse 3-mm-
thick MR (4900/118) image shows OCPC 
(arrow) in the right apex. (b) Sagittal 4-
mm-thick MR (6000/97) image shows a 
focus of cancer (arrow) in the right apex 
and midgland. (c) Coronal 3-mm-thick 
MR (4666/96) image shows cancer (ar-
row) in the right apex and midgland. (d) 
Whole-mount serial section of the re-
moved prostate shows organ-confi ned 
cancer (arrow) involving the right poste-
rior quadrant of the prostate. 
(Color version available in chapter 18).
Table 1. Distribution of Preoperative Clinical Variables
Note.—Unless otherwise indicated, data are numbers of patients, and data in 
parentheses are percentages. 
* Data are median results ± standard deviations, and data in parentheses are 
ranges. 
† Results obtained in all 612 patients. 
‡ Greatest percentage of cancer in all biopsy cores (results obtained in 599 pa-
tients). 
§ Percentage of positive cores in all biopsy cores (results obtained in 539 pa-
tients). 
|| Indicates lymph node metastasis. 
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Finding
  Risk Group No. of Patients Mean Standard Deviation Range
  Low risk 332 0.77 0.41 0.46 - 0.9
  Intermediate risk 224 0.45 0.18 0.07 - 0.8
  High risk 56 0.29 0.16 0.06 - 0.62
 TNM Stage No. of Patients
  pT1 2 (0)
  pT2 443 (72)
  pT3a 115 (19)
  pT3b 38 (6)
  pT4 14 (2)
  pTanyN1* 30 (5)
  Patient Group
No. of 
Patients
MR 
Findings
Partin 
Tables
MR Findings
and Partin Tables*
P Value†
  All 612 0.81 1.80 0.88 <.01
  MR group‡
 Endorectal imaging only 229 0.77 0.79 0.84 .045
 Combined imaging 383 0.84 0.81 0.90 <.01
  Risk Group
 Low 332 0.76 0.60 0.78 .02
 Intermediate 224 0.80 0.70 0.83 <.01
 High 56 0.83 0.74 0.87 <.01
Table 2. Predicted Probability of OCPC according to the 2001 Partin Tables 
Table 3. Final Pathologic Stage 
Note.—Data in parentheses are percentages. Staging is according to the 2002 American Joint Committee on Cancer. 
* Indicates lymph node metastasis. 
Table 4. Areas under ROC Curves of OCPC Prediction Models 
* Jackknife method used. 
† P values are for Partin Tables alone versus MR fi ndings and Partin Tables. 
‡ Patients underwent endorectal coil MR imaging alone or in combination with MR spectroscopic imaging. 
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prediction based on the staging nomograms alone. P < .05 was considered to indicate a statistically signifi cant dif-
ference. Software programs used for data analysis were SAS (version 8.2; SAS Institute, Cary, NC) and S-PLUS (version 
2000; Insightful, Seattle, Wash). 
RESULTS
At surgical histopathologic evaluation, 445 (73%) of 612 patients had evidence of OCPC (Fig 1). Table 1 summarizes 
the distribution of the preoperative clinical variables, Table 2 shows the predicted probabilities of OCPC (derived 
from the 2001 Partin Tables) according to risk group, and Table 3 demonstrates the distribution of fi nal pathologic 
staging. 
 Overall, in the prediction of OCPC, the area under the ROC curve for the staging nomograms was 0.80, while the 
area under the ROC curve for the staging nomograms plus MR fi ndings was 0.88; the diff erence was signifi cant (P 
< .01) (Table 4) (Fig 2). 
Risk Groups
The incremental value of MR fi ndings to the staging nomograms was signifi cant in all three risk groups, 
although it was greater in the intermediate- and high-risk groups (P < .01 for both) than in the low-risk group (P = 
.02) (Table 4). 
Figure 2: Graph shows ROC 
curves for jackknife-predicted 
probabilities of OCPC for two 
models for the study popula-
tion: one based only on clini-
cal staging nomograms (Par-
tin OCPC) and one based on 
staging nomograms plus MR 
fi ndings (Partin OCPC + MR 
OCPC). The model with MR 
fi ndings has a signifi cantly 
greater area under the ROC 
curve (AUC) than does the 
model lacking MR fi ndings 
(0.876 vs 0.80, P < .01). 
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MR Spectroscopic Imaging and Endorectal MR Imaging
In the combined endorectal MR imaging–MR spectroscopic imaging group, the areas under the ROC curves were 
0.81 for the staging nomograms and 0.90 for the staging nomograms plus MR fi ndings; the diff erence was signifi -
cant (P < .01) (Table 4). 
Prediction of OCPC with MR fi ndings plus the staging nomograms was better in the endorectal MR imaging–MR 
spectroscopic imaging group (area under the ROC curve, 0.84; 95% confi dence interval: 0.79, 0.89) than in the en-
dorectal MR imaging–only group (area under the ROC curve, 0.77; 95% confi dence interval: 0.70, 0.84), but the dif-
ference was not signifi cant (P > .05) (Table 4). The incremental value of MR spectroscopic imaging to endorectal MR 
imaging was slightly greater in the low- and intermediate-risk groups than in the high-risk group (Table 5), but the 
diff erence was not signifi cant in any of the risk groups. 
DISCUSSION
Pretreatment knowledge of OCPC is important for treatment selection and planning, regardless of whether the 
treatment method ultimately chosen is watchful waiting, surgery, or radiation therapy. Radical prostatectomy in 
patients with pathologically organ-confi ned cancer results in a survival rate comparable with that of age-matched 
controls without prostate cancer (34–39). Since the introduction of the Partin Tables in 1997, investigators have 
repeatedly validated the nomograms’ capacity to help predict the pathologic stage of clinically localized prostate 
cancer (11–13). In 2001, the nomograms were updated based on a more contemporary cohort of disease features 
(10). The accuracy of the staging nomograms in predicting OCPC is high, with reports of the area under the ROC 
curve ranging from 0.79 to 0.82 (12,13). Our study results demonstrated similar accuracy for the staging nomograms 
in predicting OCPC, with an overall area under the ROC curve of 0.80. Despite the strong predictive ability and the 
cost-eff ectiveness of the staging nomograms, there is room for improved accuracy of prediction, particularly since 
clinical staging in the staging nomograms is based only on digital rectal examination. Moreover, the staging nomo-
grams cannot assist in the localization of ECE, which is critical for optimal treatment planning (5,9). 
Debate persists regarding whether MR imaging should be used routinely for presurgical evaluation of prostate 
cancer. Because of the high incidence of prostate cancer and the high cost of MR examinations, it has been stated 
that routine use of endorectal MR imaging alone or in combination with MR spectroscopic imaging might merely 
Risk Group and Type of MR*
No. of 
Patients
Area under the 
ROC Curve†
P Value
  All
 Combined 383 0.84 (0.79, 0.89) >.05
 Endorectal imaging only 229 0.77 (0.70, 0.84)
  Low
 Combined 206 0.81 (0.69, 0.92) >.05
 Endorectal imaging only 126 0.72 (0.59, 0.85)
  Intermediate
 Combined 146 0.84 (0.77, 0.90) >.05
 Endorectal imaging only 78 0.74 (0.63, 0.85)
  High
 Combined 31 0.85 (0.71, 0.99) >.05
 Endorectal imaging only 25 0.80 (0.66, 0.95)
Table 5. Accuracy of MR Imaging Prediction of Prostate Cancer with and without MR Spectroscopic Imaging 
* Patients underwent endorectal coil MR imaging alone or in combination with MR spectroscopic imaging. 
† Data in parentheses are 95% confi dence intervals. 
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add a fi nancial burden to the health care system unless it prevents unnecessary surgery or improves treatment 
planning and outcomes (40). It has been shown that endorectal MR imaging adds value in all risk groups (5,41); in 
the prediction of ECE, the greatest incremental value of endorectal MR imaging to the Partin Tables has been found 
in high-risk patients (14,16). In our study, the addition of MR fi ndings to the Partin Tables (2001 version) signifi cantly 
improved the prediction of OCPC for the overall patient population (P < .01). The addition of MR fi ndings also 
increased the area under the ROC curve signifi cantly in the low-risk group (P = .02) and in the intermediate- and 
high-risk groups (P < .01 for both). 
The contribution of MR spectroscopic imaging fi ndings to endorectal MR imaging in the prediction of OCPC was 
also assessed in our study. The magnitude and extent of metabolic abnormality on MR spectroscopic images is 
indicative of tumor aggressiveness, volume, and stage (42,43). Yu et al (25) demonstrated that the combined use of 
endorectal MR imaging and MR spectroscopic imaging decreased interobserver variability and, for less experienced 
radiologists, signifi cantly improved the detection of ECE. In our study, the accuracy of radiologists’ predictions of 
OCPC was higher in the combined MR group than in the endorectal MR imaging–only group, but the diff erence was 
not signifi cant; MR fi ndings contributed signifi cant incremental value to the staging nomograms in the prediction 
of OCPC in both of these groups. 
Our study was limited by the fact that it was designed to assess the value of MR readings as used in clinical practice; 
the readers were not blinded to clinical data such as PSA level and biopsy results. Furthermore, only one reader 
evaluated each case once, so we could not assess interobserver and intraobserver variability. With respect to the 
assessment of the incremental value of MR spectroscopic imaging, separate readings with and without MR spectro-
scopic imaging were not performed and therefore the true incremental value of MR spectroscopic imaging needs 
further analysis. 
In conclusion, although further multicenter confi rmatory studies would be helpful, our results show that MR fi nd-
ings (from endorectal MR imaging or combined endorectal MR imaging–MR spectroscopic imaging) contribute 
signifi cant incremental value to clinical staging nomograms in the prediction of OCPC. The incorporation of en-
dorectal MR imaging into future staging nomograms for the prediction of OCPC may therefore be warranted. 
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ABSTRACT
Purpose: To assess the incremental value of endorectal magnetic resonance (MR) imaging fi ndings in addition to 
clinical variables for prediction of extracapsular extension (ECE) in patients with prostate cancer. 
Materials and Methods: In this cohort study, 344 consecutive patients with biopsy-proved prostate cancer 
underwent endorectal MR imaging prior to surgery; 216 of these patients also underwent MR spectroscopic imag-
ing. MR images were interpreted by 10 attending radiologists. The likelihood of ECE was scored retrospectively on 
the basis of MR imaging reports. Clinical variables included serum prostate-specifi c antigen (PSA) level, Gleason 
score, clinical stage of tumor, greatest percentage of cancer in all core biopsy specimens, percentage of cancer-posi-
tive core specimens in all core biopsy specimens, and presence of perineural invasion. For data analysis, receiver op-
erating characteristic (ROC) curves and univariate and multivariate logistic regression analyses were used. Jackknife 
analysis was used for prediction of probability from a model that included clinical variables as tested comparatively 
with a model that included the clinical variables plus endorectal MR imaging fi ndings. A diff erence with P < .05 was 
considered signifi cant. 
Results: At univariate analysis, all variables were associated with ECE. At ROC univariate analysis, endorectal MR imag-
ing fi ndings had the largest area under the ROC curve. At multivariate analysis, serum PSA level, percentage of can-
cer in all core biopsy specimens, and endorectal MR imaging fi ndings (P = .001, P = .001, and P < .001, respectively) 
were predictors of ECE. Areas under ROC curve for two models, with and without endorectal MR imaging fi ndings, 
were 0.838 and 0.772, respectively (P = .022). 
Conclusion: A model containing endorectal MR imaging fi ndings has a signifi cantly larger area under the ROC curve 
than a model containing only clinical variables; thus, endorectal MR imaging fi ndings add incremental value in the 
prediction of ECE. 
© RSNA, 2004 
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INTRODUCTION
Prostate cancer continues to be the second leading cause of cancer death in American men. In 2003, 28,900 men were expected to die from the disease (1). In the past decade, because of screening with prostate-spe-cifi c antigen (PSA)1 level, there has been a dramatic downward trend in the stage of prostate cancer deter-
mined at the time of diagnosis (2). As demonstrated by the Surveillance, Epidemiology, and End Results Program of 
the National Cancer Institute, in 2003, 85% of prostate cancers were local or regional at diagnosis, compared with 
72% in 1993 (1,3). This change in stage at diagnosis brings new challenges to the presurgical detection of extracap-
sular extension (ECE) in patients who are at risk for it. 
Various methods for the prediction of ECE have been proposed. The established presurgical clinical variables for the 
prediction of pathologic stage are clinical tumor stage, which includes digital rectal examination fi ndings; serum 
PSA level; and Gleason score (4–6). Nomograms that are based on presurgical data were introduced to help evaluate 
patient risk for ECE, seminal vesicle invasion, and metastasis to lymph nodes, as well as 5-year freedom from cancer 
recurrence. These models have high accuracy for prediction with either aggressive or clinically indolent tumors. The 
assessment of additional presurgical variables to enhance the specifi city and sensitivity of the present models is of 
great interest. 
The aim of this study was to assess the incremental value of endorectal magnetic resonance (MR) imaging fi ndings 
in addition to clinical variables for prediction of ECE in patients with prostate cancer. 
MATERIALS AND METHODS
Patients
Between May 1999 and January 2003, 344 consecutive patients with prostate cancer were referred from the urol-
ogy department at our institution to undergo endorectal MR imaging before they underwent radical retropubic 
prostatectomy. Two hundred sixteen patients underwent endorectal MR imaging combined with MR spectroscopic 
imaging, and 128 patients underwent endorectal MR imaging alone. Approval of the institutional review board was 
obtained, and informed consent was obtained from all patients. 
Mean patient age was 57.5 years (range, 32–74 years). None of the patients received neoadjuvant hormonal or 
radiation therapy prior to surgery. Tissue diagnosis of prostate cancer was established with biopsy specimens in 
all patients. Clinical and MR imaging data were recorded retrospectively from the patients’ medical records by one 
author (L.W.). Data in the same patient cohort are reported in the study by Mullerad et al (7). 
Imaging and Image Interpretation
Endorectal MR imaging and hydrogen 1 MR spectroscopic imaging were performed with a 1.5-T whole-body MR 
imaging unit (Signa Horizon; GE Medical Systems, Milwaukee, Wis). The examination was performed with patients in 
the supine position. A body coil was used for excitation, and a pelvic phased-array coil (GE Medical Systems) com-
bined with a commercially available balloon-covered expandable endorectal coil (Medrad, Pittsburgh, Pa) was used 
for signal reception. Transverse T1-weighted and spin-echo MR images were obtained from the aortic bifurcation to 
the symphysis pubis with the following parameters: repetition time msec/echo time msec, 700/8; section thickness, 
5 mm; intersection gap, 1 mm; fi eld of view, 24 cm; matrix, 256 x 192; and frequency direction, transverse (to prevent 
obstruction of the pelvic node from endorectal coil motion artifact). One signal was acquired. 
Transverse and coronal thin-section high-spatial-resolution T2-weighted fast spin-echo MR images of the prostate 
and seminal vesicle were obtained with the following parameters: 5,000/96 (eff ective); echo train length, 16; section 
thickness, 3 mm; intersection gap, 0 mm; fi eld of view, 14 cm; matrix, 256 x 192; frequency direction, anteroposte-
rior (to prevent obstruction of the prostate from endorectal coil motion artifact); and number of signals acquired, 
three. 
1Abbreviations
ECE = extracapsular extension, PNI = perineural invasion, PSA = prostate-specifi c antigen, ROC = receiver operating characteristic 
CHAPTER
32
MR spectroscopic imaging was performed by using point-resolved spectroscopic voxel excitation (8), band-selec-
tive inversion with gradient dephasing water and lipid suppression (9), and spatial encoding with chemical shift im-
aging (10) at 6.25-mm resolution in all three dimensions (left-right, anterior-posterior, superior-inferior dimensions). 
Parameters were 1,000/130, and imaging time was 17 minutes. 
Data processing was performed at a workstation (Sun Ultra 10; Sun Microsystems, Mountain View, Calif) and in-
cluded 2-Hz lorentzian spectral apodization; four-dimensional Fourier transform; and automated frequency, phase, 
and baseline correction (11). Spectral data were zero fi lled to 3.1-mm resolution in the superior-inferior dimension 
and overlaid on corresponding transverse T2-weighted MR images. Peak areas were calculated by using numeric 
integration. To provide a noise measurement, we calculated the SD of the MR signal intensity in a region of the 
spectrum containing only noise. Metabolite peak areas were then normalized with respect to the noise SD to yield 
an approximate signal-to-noise ratio. 
MR images were interpreted by 10 body MR imaging radiologists (including H.H., S.C.E.) during their clinical assign-
ment to the MR imaging service. The readers’ experience in interpretation of clinical MR images since fellowship 
ranged from 4 to more than 15 years. Offi  cial pretreatment MR image readings were used for the data analysis. There 
was no initial meeting or training to establish the criteria for ECE. Rather, radiologists made their determinations on 
the basis of their own continuing medical training and knowledge of previously described MR imaging features of 
ECE. The diagnostic criteria used by the radiologists to determine ECE on endorectal MR images included irregular 
capsular bulge, periprostatic fat infi ltration, obliteration of the rectoprostatic angle, and asymmetry or direct in-
volvement of the neurovascular bundles (12). MR spectroscopic imaging results, when available, were provided for 
all readers. The extent to which MR spectroscopic imaging data were used in image interpretation diff ered among 
radiologists. On the basis of the radiologists’ written reports, one author (L.W.) retrospectively scored the likelihood 
for ECE with a fi ve-point scale as follows: score 1, no ECE; score 2, probably no ECE (cannot be ruled out though there 
is no clear evidence of it); score 3, possible ECE (a lesion is suspected of demonstrating ECE); score 4, probable ECE 
(a lesion is highly suspected of demonstrating ECE); score 5, defi nite ECE. 
Histologic Analysis
Histologic analysis reports at core biopsy were evaluated for Gleason score, greatest percentage of cancer in all 
core biopsy specimens, percentage of cancer-positive core specimens in all core biopsy specimens (the number of 
cancer-positive core specimens divided by the total number of core biopsy specimens), and presence of perineural 
invasion (PNI). The greatest percentage of cancer was determined in each patient by examining each core biopsy 
specimen and dividing the length of the core specimen tissue with cancer by the whole core specimen length; 
the core specimen with the highest percentage of cancer defi ned the patient’s greatest percentage of cancer. This 
parameter has been previously described by Rubin et al (13) and Bismar et al (14). 
Specimens removed at radical prostatectomy were examined in the pathology department at our institution, as 
previously described by Yossepowitch et al (15). In short, specimens were fi xed in formalin, with the external surface 
of the right and left sides inked with two colors. The apical prostate was truncated perpendicular to the prostatic 
urethra and was subsequently sectioned as slices parallel to the prostatic urethra. The bladder neck margin was 
obtained by sampling portions of soft tissue at the junction of the rough prostatic capsule and smooth bladder 
neck or the most proximal portion of the submitted specimen that corresponded to the anatomic bladder neck. 
The remaining prostate was completely transected at 3–5-mm intervals in a plane perpendicular to the urethra. The 
fi nal pathologic report following surgery was used to determine the presence of ECE. The presence of cancer cells 
beyond the capsular margin was used as the defi nition of ECE. 
Statistical Analysis
Both univariate and multivariate analyses were performed for all clinical and imaging variables tested. Predictor 
variables that we tested included serum PSA level, Gleason score, clinical stage of tumor, greatest percentage of 
cancer in all core biopsy specimens, percentage of cancer-positive core specimens in all core biopsy specimens, 
and presence of PNI. With receiver operating characteristic (ROC) univariate analysis, the incremental value of MR 
spectroscopic imaging fi ndings was assessed by comparing fi ndings in the group of 216 patients who underwent 
both endorectal MR imaging and MR spectroscopic imaging with those in the group of 128 patients who under-
went only endorectal MR imaging. 
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We evaluated the area under the ROC curve for each variable. In addition, we compared two models: one that 
contained all clinical variables plus endorectal MR imaging fi ndings and another that contained only the clinical 
variables. To judge the value of endorectal MR imaging fi ndings as a marker, the predictions analyzed with jackknife 
methods from these models were compared for their ability to predict ECE. By using bootstrapping for bias correc-
tion, a P value was derived to test for a diff erence in the predictive ability of these two models (16). A diff erence with 
P < .05 was considered signifi cant. Software programs (SAS, version 8.2, SAS Institute, Cary, NC; S-Plus, version 2000, 
Insightful, Seattle, Wash; and Stata, version 7.0, Stata, College Station, Tex) were used for data analysis. 
RESULTS 
At surgical histopathologic analysis, 83 (24.1%) of 344 patients had evidence of ECE. Table 1 summarizes the distribu-
tion of the presurgical clinical variables, and Table 2 demonstrates the distribution of clinical and fi nal pathologic 
stages. Performance characteristics for each variable are listed in Table 3. In the evaluation of ECE, endorectal MR 
imaging fi ndings had sensitivity, specifi city, positive predictive value, and negative predictive value of 42.2%, 95.4%, 
74.5%, and 83.8%, respectively (Table 3). Specifi city of endorectal MR imaging fi ndings was the highest among all 
variables, while sensitivity was second best after that of clinical stage of tumor. 
Table 1. Distribution of Presurgical Variables 
* Data are the mean ± SD. Data in parentheses are ranges. 
† Data are the range. 
‡ Data were not recorded in 22 patients. 
§ Values were calculated by dividing the number of cancer-positive core specimens by the total number of core biopsy specimens. 
|| Clinical stage of tumor was categorized according to TNM classifi cations. 
  Presurgical Variable
No. of 
Patients
Value
  PSA level (ng/mL) 344 7.64 ± 9.19 (0.74 - 113.40)*
  Gleason score 344 5-10†
  Greatest percentage of cancer in all core 
  biopsy specimens
322‡ 41 ± 27 (4-100)*
  Percentage of cancer-positive core 
  specimens in all core biopsy specimens§
344 33.71 ± 27.29 (1-100)*
  PNI
 Present 48 14.0%
 Not present 296 86.0%
  Clinical stage||
 T1c 195 56.7%
 T2a and T2b 116 33.7%
 T2c 33 9.6%
 T3, T4, N+, and M+ 0 0%
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  Stage of Tumor No. of Patients
  Clinical*
 T1c 195 (56.7)
 T2a and T2b 116 (33.7)
 T2c 33 (9.6)
 T3a and T3b 0
 T3c 0
 T4 0
 N1 0
 M 0
  Final pathologic† 116
 T0 2 (0.6)
 T2a 64 (18.6)
 T2b 189 (54.9)
 T3a 57 (16.6)
 T3b 19 (5.5)
 T4 13 (3.8)
 N1 17 (4.9)
 M 0
  Presurgical Variable Sensitivity Specifi city
Positive
Predictive
Value
Negative
Predictive
Value
  Serum PSA level* 27.7 (23/83) 87.4 (228/261) 41.1 (23/56) 79.2 (228/288)
  Gleason score† 30.1 (25/83) 90.4 (236/261) 50.0 (25/50) 80.3 (236/294)
  Clinical stage of tumor‡ 56.6 (47/83) 60.9 (159/261) 31.5 (47/149) 81.5 (159/195)
 Greatest percentage of cancer in all core   
  biopsy specimens§
36.1 (30/83) 89.6 (232/259) 52.6 (30/57) 81.4 (232/285)
  Percentage of cancer-positive core speci
  mens in all core biopsy specimens§
35.0 (28/80) 81.0 (196/242) 37.8 (28/74) 79.0 (196/248)
  PNI presence at needle biopsy|| 25.3 (21/83) 89.7 (234/261) 43.8 (21/48) 79.1 (234/296)
  Endorectal MR imaging fi ndings# 42.2 (35/83) 95.4 (249/261) 74.5 (35/47) 83.8 (249/297)
Table 2. Clinical and Final Pathologic Stage of Tumor 
Note.—Data in parentheses are percentages. 
* Clinical stage of tumor was categorized according to TNM classifi cations (17). 
† Final pathologic stage of tumor was categorized according to TNM classifi cations (18).
 Table 3. Performance Characteristics of Presurgical Variables at Select Cutoff s for Prediction of ECE 
Note.—Data are percentages. Data in parentheses are the numbers used to calculate the percentages. 
* Cutoff  was 0–10.00 ng/mL versus 10.10 ng/mL or more. 
† Cutoff  was 3 + 2, 3 + 3, and 3 + 4 versus 3 + 5, 4 + 3, 4 + 4, 4 + 5, and 5 + 5. 
‡ Cutoff  was T1c versus T2a, T2b, and T2c (categorized according to TNM classifi cations). 
§ Cutoff  was 0%–60% versus more than 60%. 
|| Cutoff  was present versus not present. 
# Cutoff  was one to three versus four to fi ve. 
335
Univariate analysis (Table 4) results showed that all variables were associated with ECE. At ROC univariate analysis, 
however (Fig 1), endorectal MR imaging fi ndings had the largest area under the ROC curve, followed by greatest 
percentage of cancer in all core biopsy specimens and presurgical PSA level. Figure 1 demonstrates that at high 
specifi city MR imaging fi ndings had the best sensitivity, compared with all other variables. In a comparison of image 
interpretation between 216 patients who underwent both endorectal MR imaging and MR spectroscopic imaging 
(area under ROC curve = 0.777) and 128 patients who underwent only endorectal MR imaging (area under ROC 
curve = 0.697), there was no signifi cant diff erence (P < .206). 
Table 4. Univariate Analysis: Assessment of Variables for Prediction of ECE 
* Predictor variables were treated as continuous variables except for Gleason score (categorized as 3 + 2, 3 + 3, and 3 + 4 vs 3 + 5, 4 + 3, 4 + 4, 4 + 5, 
and 5 + 5) and clinical stage of tumor (categorized according to TNM classifi cations as T1c vs T2a, T2b, and T2c).
Figure 1. Graph shows comparison of ROC curves of sev-
en variables for prediction of ECE. Area under ROC curve 
for MR imaging fi ndings is 0.743. Diagonal line indicates 
area under ROC curve of 0.500 (ie, no separation between 
patients with and patients without ECE). Predictor vari-
ables treated as continuous variables except for Gleason 
score (categorized as 3 + 2, 3 + 3, and 3 + 4 vs 3 + 5, 4 + 
3, 4 + 4, 4 + 5, and 5 + 5) and clinical stage of cancer (cat-
egorized as T1c vs T2a, T2b, and T2c). % Ca = greatest per-
centage of cancer in all core biopsy specimens, % of Pos 
Cores = percentage of cancer-positive core specimens in 
all core biopsy specimens. 
 
  Predictor Variable* P Value Area under ROC Curve
  PSA level <.001 0.670
  Gleason score <.001 0.603
  Clinical stage of tumor <.001 0.588
  Greatest percentage of cancer in all core
  biopsy specimens
<.001 0.738
  Percentage of cancer-positive core 
  specimens in all core biopsy specimens
<.001 0.635
  PNI presence <.001 0.575
  Endorectal MR imaging fi ndings <.001 0.743
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With multivariate analysis, serum PSA level, greatest percentage of cancer in all core biopsy specimens, and en-
dorectal MR imaging fi ndings were signifi cant predictors of ECE (P = .001, P = .001, and P < .001, respectively) (Figs 
2, 3). The Gleason score had borderline signifi cance as a predictor in both models, with and without endorectal MR 
imaging fi ndings (P = .074 and .057, respectively) (Table 5). When the two models were compared, the area under 
the ROC curve of 0.838 for the model with clinical variables and endorectal MR imaging fi ndings was greater than 
that of 0.772 for the model with clinical variables alone (P = .022) (Table 5). The ROC curves for the models are shown 
in Figure 4. 
Figure 2. Transverse T2-weighted fast spin-echo 3-
mm-thick MR image (5,266/121) in 61-year-old man with 
clinical stage T1c cancer shows no ECE. PSA level was 
13.67 ng/mL, sextant biopsy results indicated PNI in 
right middle area, and tumors with Gleason score of 4 + 
5 involved 50% of submitted tissue in both sides (14% of 
cores). Findings at fi nal histopathologic analysis of step 
section indicated that tumor invaded prostate capsule 
but did not extend beyond it. 
 
Figure 3. Transverse T2-weighted fast spin-echo 3-mm-
thick MR image (5,933/121) in 61-year-old man with clini-
cal stage T1c cancer and PSA level of 5.00 ng/mL shows 
ECE (arrow) at left posterior area. Sextant biopsy results 
were negative for PNI, and tumors with Gleason score of 
4 + 4 involved 30% of submitted tissue in the left side 
(43% of cores). Findings at fi nal histopathologic analysis 
of step section indicated focal ECE at left posterior area. 
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Table 5. Multivariate Analysis: Assessment of Variables for Prediction of ECE 
* Area under ROC curve was 0.772, corrected with bootstrap method, for this model. 
† Variables analyzed as continuous variables. 
‡ Gleason score was obtained at biopsy (categorized as 3 + 2, 3 + 3, and 3 + 4 vs 3 + 5, 4 + 3, 4 + 4, 4 + 5, and 5 + 5). 
§ Clinical stage of tumor was categorized according to TNM classifi cations as T1c versus T2a, T2b, and T2c. 
|| Area under ROC curve was 0.838, corrected with bootstrap method, for this model. This model had a signifi cantly larger area under the ROC 
curve (0.838 vs 0.772, P = .022). 
 Figure 4. Graph shows ROC curves for comparison of 
models with and without MR imaging for prediction of 
ECE. Base model included the following variables: PSA 
level, Gleason score, clinical stage of tumor, greatest 
percentage of cancer in all core biopsy specimens, per-
centage of cancer-positive core specimens in all core 
biopsy specimens, and presence of PNI. Base model with 
endorectal MR imaging fi ndings included MR imaging 
fi ndings with all other variables. Predicted probability of 
both logistic regression models was bias corrected with 
jackknife method. Base model with endorectal MR imag-
ing fi ndings has greater area under ROC curve of 0.838. 
(Color version available in chapter 18).
  Predictor Variable P Value
  Model without MR fi ndings*
 PSA level† <.001
 Gleason score‡ .057
 Clinical stage of tumor§ .323
 Greatest percentage of cancer in all score biopsy 
 specimens†
<.001
 Percentage of cancer-positive core specimens in all core  
 biopsy specimens†
.497
 PNI presence .987
  Model with MR fi ndings||
 PSA level† .001
 Gleason score‡ .074
 Clinical stage of tumor§ .523
 Greatest percentage of cancer in all core biopsy 
 specimens†
<.001
 Percentage of cancer-positive core specimens in all core
 biopsy specimens†
.910
 PNI presence .914
 ECE on MR images† .001
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DISCUSSION
 
Pretreatment knowledge of ECE is important for both treatment selection and treatment planning. In treatment 
planning for surgery or radiation therapy, knowledge of ECE location is helpful for selection of the appropriate treat-
ment approach. During the past years, studies in which the association between a number of clinical variables and 
the prediction of ECE was examined have been performed. The variables included serum PSA level, Gleason score, 
clinical stage of tumor, greatest percentage of cancer in all core biopsy specimens, percentage of cancer-positive 
core specimens in all core biopsy specimens, and presence of PNI (4,19–21). 
Findings in another investigation (22) and in our study indicate that serum PSA levels are associated with ECE with 
both univariate and multivariate analysis (P ≤ .001). In our study, Gleason score and clinical stage of tumor were 
signifi cantly associated with ECE only with univariate analysis (P < .001 and P = .005, respectively). With multivariate 
analysis, Gleason score had borderline signifi cance as a predictor in both models, with and without endorectal MR 
imaging fi ndings (P = .074 and .057, respectively), while clinical stage of tumor was not signifi cant. Similar fi ndings 
were reported by Horiguchi et al (23). They demonstrated that MR imaging fi ndings, along with Gleason score 
(categorized as  6 or  7) and PSA density, were signifi cantly associated with ECE with multivariate logistic regression 
analysis (P < .01). 
Several features demonstrated at prostate biopsy were extensively examined as predictors of fi nal pathologic stage 
(eg, greatest percentage of cancer in all core biopsy specimens, percentage of cancer-positive core specimens in 
all core biopsy specimens, and presence of PNI). Both Ravery et al (24) and Freedland et al (25) found percentage of 
cancer at core biopsy to be predictive of pathologic stage and risk of biochemical recurrence when they used mul-
tivariate analysis. Linson et al (26), however, found that only the percentage of cancer-positive core specimens was 
predictive of biochemical recurrence with multivariate analysis and therefore concluded that pursuing percentage 
of cancer in cancer-positive core specimens is an unnecessary and time-consuming task. In our study, with univari-
ate analysis, both greatest percentage of cancer in all core biopsy specimens and percentage of cancer-positive core 
specimens in all core biopsy specimens were signifi cant for the prediction of ECE (P < .001 for both values). When 
multivariate analysis was used, however, only greatest percentage of cancer in all core biopsy specimens remained a 
signifi cant predictor (P < .001). This fi nding was not aff ected when results of endorectal MR imaging were integrated 
into the analysis. 
Although there is controversy in regard to the value of PNI for the prediction of ECE, some urologists still use the 
fi nding of PNI in surgical planning (27). It has been suggested that the ipsilateral nerve bundle should be excised 
during radical prostatectomy when PNI is present (27,28). Investigators in several studies (20,29,30) address the utility 
of the fi nding of PNI in the prediction of ECE. Our results agree with the fi ndings of Vargas et al (20) and of Egan and 
Bostwick (31) and show that the presence of PNI is a signifi cant predictor of ECE with univariate analysis. In addition, 
progression of disease has also been examined. 
In a regression analysis, Stone et al (32) found that the presence of PNI in a biopsy specimen correlated with lymph 
node metastasis at radical prostatectomy (P = .04). D’Amico et al (33) and de la Taille et al (34) demonstrated that 
presence of PNI signifi cantly correlates with PSA recurrence after radical prostatectomy. O’Malley et al (35), however, 
were not able to show a signifi cant diff erence in PSA recurrence when they compared patients with PNI and pa-
tients without it who were treated with radical prostatectomy (29,36). With our multivariate analysis, presence of PNI 
was not signifi cant for the prediction of ECE (P = .987). 
The quest for a better diagnostic test that can help diff erentiate between advanced and localized disease and assist 
a physician in treatment planning led to the evaluation of endorectal MR imaging in prostate cancer localization and 
staging. The routine use of MR imaging for presurgical evaluation of prostate cancer is controversial. The high inci-
dence of the disease combined with the high cost of the test might burden the health care system with additional 
expenses unless its use prevents unnecessary surgery or aids in treatment planning and results in better outcomes 
(37). D’Amico et al (38) concluded that although MR imaging fi ndings add signifi cant predictive value (ie, prediction 
of the risk of developing biochemical failure following radical prostatectomy in 20% of patients), this result did not 
justify the routine use of the technique. Furthermore, endorectal MR imaging results demonstrated high interob-
server variability, which limited the widespread use of the technique (39,40). 
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It has been suggested that treatment decisions should not be altered because of either endorectal MR imaging 
or transrectal ultrasonographic fi ndings (41). In our study of the comparison of the value of endorectal MR imag-
ing fi ndings and clinical and histologic variables, endorectal MR imaging fi ndings had a high negative predictive 
value and a high positive predictive value (83.8% and 74.5%, respectively). When assessed with univariate analysis, 
endorectal MR imaging fi ndings demonstrated excellent prediction of ECE (P < .001). In our study, the addition of 
MR spectroscopic imaging did not result in a signifi cant improvement in image interpretation (P < .206). Previously 
published data support the value of MR spectroscopic imaging in the detection and staging of prostate cancer (12). 
The incremental value of MR spectroscopic imaging was greater for the less experienced reader (12). Notably, MR 
spectroscopic technology in our institution was introduced in 2000, and there was a steep learning curve in the 
acquisition and interpretation of MR spectroscopic imaging data during the past 4 years. 
With multivariate analysis, endorectal MR imaging fi ndings, PSA level, and greatest percentage of cancer in all core 
biopsy specimens were all predictors of ECE (P < .001). Because we recognized that results of such an analysis are 
insuffi  cient for judgment of endorectal MR imaging fi ndings as a new marker (16), we examined the incremental 
eff ect of endorectal MR imaging fi ndings on predictive accuracy. When we compared the two models, one with 
and one without endorectal MR imaging fi ndings, at multivariate analysis, we found that the area under the ROC 
curve of 0.838 for the model with endorectal MR imaging fi ndings was signifi cantly greater than that of 0.772 for 
the model without endorectal MR imaging fi ndings (P = .022). These data demonstrate the incremental value of 
endorectal MR imaging fi ndings. In addition, endorectal MR imaging fi ndings are spatially localized, and therefore, 
unlike clinical variables, they have the potential to allow tailored treatment modifi cations (12,42–44). 
The strengths and limitations of our study are drawn from the fact that it was conducted in the routine clinical set-
ting of the radiology department. Ten body MR imaging radiologists interpreted the images as part of their routine 
clinical assignments. There were diff erences in training and experience in prostate imaging among the readers, and 
their experience in interpretation of clinical MR images ranged from 4 to more than 15 years since fellowship. This 
may have resulted in a lack of data uniformity and in interobserver variability in the diagnosis of ECE. Since each 
image was interpreted by one reader, we could not assess the eff ect of interobserver variability on the accuracy 
of prediction of ECE at endorectal MR imaging. In a recently published study of tumor staging with meta-analysis 
at MR imaging, Engelbrecht et al (45) demonstrated considerable heterogeneity between endorectal MR imaging 
studies; they concluded that further studies are needed to establish the eff ect of the reader’s experience, as well as 
the eff ect of the clinical information given to the reader, as they hypothesized that these factors may cause consid-
erable diff erences in staging accuracy between the studies. A contrast material–enhanced study was not used in 
our protocol, though recent data suggest that such a study might improve accuracy in tumor staging (46). 
With consideration of all these factors, our results show that endorectal MR imaging fi ndings have remarkable 
strength in the prediction of ECE. Although further multicenter confi rmatory study fi ndings would be helpful, we 
suggest that endorectal MR imaging fi ndings play an important role in the evaluation of prostate cancer and the 
prediction of ECE. 
In conclusion, endorectal MR imaging fi ndings are signifi cant presurgical predictors of ECE in patients with prostate 
cancer, and they add incremental value to clinical variables. 
REFERENCES
1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26. 
2. Polascik TJ, Oesterling JE, Partin AW. Prostate specifi c antigen: a decade of discovery—what we have learned and where we are going. J 
 Urol 1999; 162:293-306. 
3. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 43:7-26. 
4. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin 
 Tables) for the new millennium. Urology 2001; 58:843-848. 
5. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized 
 prostate carcinoma. Cancer 1997; 79:528-537. 
6. Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical 
 prostatectomy for localized prostate cancer. J Clin Oncol 2002; 20:951-956. 
7. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT. Prostate cancer: detection of extracapsular extension at MR imaging by 
 genitourinary and general body radiologists. Radiology 2004; 232:140-146. 
8. Bottomley PA. Selective volume method for performing localized MR spectroscopy. U.S. patent 4 480 228 1984. 
CHAPTER
40
9. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band 
 selective inversion with gradient dephasing (BASING). Magn Reson Med 1997; 38:311-321. 
10. Brown TR, Kincaid BM, Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A 1982; 79:3523-3526. 
11. Nelson S, Day MR, Carvajal L, et al. Methods for analysis of serial volume MRI and 1H MRS data for the assessment of response to therapy 
 in patients with brain tumors (abstr) In: Proceedings of the Society of Magnetic Resonance in Medicine and the European Society of 
 Magnetic Resonance in Medicine and Biology. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1995. 
12. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-
 dimensional proton MR spectroscopic imaging. Radiology 1999; 213:481-488. 
13. Rubin MA, Bassily N, Sanda M, Montie J, Strawderman MS, Wojno K. Relationship and signifi cance of greatest percentage of tumor and 
 perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol 2000; 24:183-189. 
14. Bismar TA, Lewis JS, Jr, Vollmer RT, Humphrey PA. Multiple measures of carcinoma extent versus perineural invasion in prostate needle 
 biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 2003; 27:432-440. 
15. Yossepowitch O, Sircar K, Scardino PT, et al. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not 
 an independent prognostic factor. J Urol 2002; 168:2011-2015. 
16. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003; 95:634-635. 
17. American Joint Committee on Cancer. Manual for staging of cancer 4th ed. Philadelphia, Pa: Lippincott, 1992. 
18. American Joint Committee on Cancer. AJCC cancer staging manual 5th ed. Philadelphia, Pa: Lippincott-Raven, 1997. 
19. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after 
 radical prostatectomy. J Clin Oncol 2002; 20:3206-3212. 
20. Vargas SO, Jiroutek M, Welch WR, Nucci MR, D’Amico AV, Renshaw AA. Perineural invasion in prostate needle biopsy specimens: correlation 
 with extraprostatic extension at resection. Am J Clin Pathol 1999; 111:223-228. 
21. Roach M, 3rd, Chen A, Song J, Diaz A, Presti J, Jr, Carroll P. Pretreatment prostate-specifi c antigen and Gleason score predict the risk of 
 extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer. Semin Urol 
 Oncol 2000; 18:108-114. 
22. Paquette EL, Connelly RR, Sun L, Paquette LR, Moul JW. Predictors of extracapsular extension and positive margins in African American 
 and white men. Urol Oncol 2003; 21:33-38. 
23. Horiguchi A, Nakashima J, Horiguchi Y, et al. Prediction of extraprostatic cancer by prostate specifi c antigen density, endorectal MRI, and 
 biopsy Gleason score in clinically localized prostate cancer. Prostate 2003; 56:23-29. 
24. Ravery V, Chastang C, Toublanc M, Boccon-Gibod L, Delmas V. Percentage of cancer on biopsy cores accurately predicts extracapsular 
 extension and biochemical relapse after radical prostatectomy for T1–T2 prostate cancer. Eur Urol 2000; 37:449-455. 
25. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure 
 or adverse pathology after radical prostatectomy than prostate specifi c antigen or Gleason score. J Urol 2002; 167:516-520. 
26. Linson PW, Lee AK, Doytchinova T, et al. Percentage of core lengths involved with prostate cancer: does it add to the percentage of 
 positive prostate biopsies in predicting postoperative prostate-specifi c antigen outcome for men with intermediate-risk prostate cancer? 
 Urology 2002; 59:704-708. 
27. Epstein JI, Potter SR. The pathological interpretation and signifi cance of prostate needle biopsy fi ndings: implications and current 
 controversies. J Urol 2001; 166:402-410. 
28. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular 
 penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993; 17:336-341. 
29. Bastacky SS, Epstein JI. The sensitivity and specifi city of perineural invasion on needle-biopsy of prostate-cancer in predicting capsular 
 penetration at radical prostatectomy (abstr). Lab Invest 1991; 64:A43. 
30. de la Taille A, Katz A, Bagiella E, Olsson CA, O’Toole KM, Rubin MA. Perineural invasion on prostate needle biopsy: an independent 
 predictor of fi nal pathologic stage. Urology 1999; 54:1039-1043. 
31. Egan AJ, Bostwick DG. Prediction of extraprostatic extension of prostate cancer based on needle biopsy fi ndings: perineural invasion 
 lacks signifi cance on multivariate analysis. Am J Surg Pathol 1997; 21:1496-1500. 
32. Stone NN, Stock RG, Parikh D, Yeghiayan P, Unger P. Perineural invasion and seminal vesicle involvement predict pelvic lymph node 
 metastasis in men with localized carcinoma of the prostate. J Urol 1998; 160:1722-1726. 
33. D’Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Perineural invasion as a predictor of biochemical outcome following radical 
 prostatectomy for select men with clinically localized prostate cancer. J Urol 2001; 165:126-129. 
34. de la Taille A, Rubin MA, Bagiella E, et al. Can perineural invasion on prostate needle biopsy predict prostate specifi c antigen recurrence 
 after radical prostatectomy? J Urol 1999; 162:103-106. 
35. O’Malley KJ, Pound CR, Walsh PC, Epstein JI, Partin AW. Infl uence of biopsy perineural invasion on long-term biochemical disease-free 
 survival after radical prostatectomy. Urology 2002; 59:85-90. 
36. D’Amico AV. Perineural invasion as a predictor of PSA outcome following local therapy for patients with clinically localized prostate 
 cancer. Cancer J 2001; 7:375-376. 
37. Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol 2003; 169:1653-1661. 
38. D’Amico AV, Whittington R, Malkowicz B, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after 
 radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000; 164:759-763. 
39. Tempany CM. MR staging of prostate cancer: how we can improve our accuracy with decisions aids and optimal techniques. Magn Reson 
 Imaging Clin N Am 1996; 4:519-532. 
40. Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison 
 of three MR imaging techniques. Radiology 1994; 192:47-54. 
41. May F, Treumann T, Dettmar P, Hartung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography 
 in the staging of clinically localized prostate cancer. BJU Int 2001; 87:66-69. 
42. Cornud F, Flam T, Chauveinc L, et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of 
 positive endorectal MR imaging examination results. Radiology 2002; 224:203-210. 
43. D’Amico AV, Cormack RA, Tempany CM. MRI-guided diagnosis and treatment of prostate cancer. N Engl J Med 2001; 344:776-777. 
44. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—
 clinicopathologic study. Radiology 1999; 213:473-480. 
341
45. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance 
 imaging: a meta-analysis. Eur Radiol 2002; 12:2294-2302. 
46. Ogura K, Maekawa S, Okubo K, et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular 
 bundle involvement of prostate cancer: correlation with histopathologic results. Urology 2001; 57:721-726.
CHAPTER4
 Prostate Cancer: Detection of 
 Extracapsular Extension by 
 Genitourinary and General Body 
 Radiologists at MR Imaging 
CHAPTER
44
Prostate Cancer: Detection of Extracapsular 
Extension by Genitourinary and General Body 
Radiologists at MR Imaging
Supported by National Institutes of Health grant R01 CA76423.  
Michael Mullerad, Hedvig Hricak, Liang Wang, Hui-Ni Chen, Michael W. Kattan, and Peter T. Scardino
From the Departments of Urology (M.M., M.W.K., P.T.S.) and Radiology (H.H., L.W., H.N.C.), Memorial Sloan-Kettering 
Cancer Center, 1275 York Ave, New York, NY 10021. Received August 6, 2003; revision requested September 18; revi-
sion received December 19; accepted January 13, 2004. 
ABSTRACT
Purpose: To determine whether predictive value of endorectal magnetic resonance (MR) imaging fi ndings in detec-
tion of prostate cancer extracapsular extension (ECE) is signifi cantly aff ected by the reader’s subspecialty experi-
ence. 
Materials and Methods: In this cohort study, 344 consecutive patients with biopsy-proved prostate cancer under-
went endorectal MR imaging followed by surgery. Likelihood of ECE described in MR imaging reports was com-
pared with clinical predictor variables. ECE was determined from the fi nal pathologic report on specimens resected 
at surgery. Readers of MR images were classifi ed into genitourinary MR imaging radiologists (n = 4) and general 
body MR imaging radiologists (n = 6). For data analysis, Wilcoxon rank sum and  2 tests, as well as receiver operating 
characteristic (ROC) curves and univariate and multivariate logistic regression analyses, were used. A diff erence with 
P < .05 was considered signifi cant. 
Results: Univariate analysis results demonstrated that all predictors except clinical stage were signifi cantly associ-
ated with detection of ECE in both groups of readers (P < .05). In the genitourinary MR imaging radiologist group 
of patients, area under the ROC curve for endorectal MR imaging fi ndings (0.833) was larger than areas under the 
curves for all other predictors (0.566–0.701). In the general body MR imaging radiologist group of patients, area 
under the ROC curve for endorectal MR imaging fi ndings (0.646) was not larger than areas under the curves for all 
other predictors (0.582–0.793). Results of multivariate analysis of two models, one with all predictors and another 
with all predictors except endorectal MR imaging fi ndings, demonstrated a signifi cant increase in area under the 
ROC curve with endorectal MR images interpreted by genitourinary MR imaging radiologists (P = .019 and .31, re-
spectively). 
Concusion: Endorectal MR imaging fi ndings are signifi cant predictors for detection of ECE when MR images are 
interpreted by genitourinary radiologists experienced with MR imaging of the prostate. 
© RSNA, 2004 
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INTRODUCTION
The increase in early detection of prostate cancer has created new challenges in diagnosis and treatment. Today, the treatment of prostate cancer is customized to the status of the disease in each patient. As a result, a precise determination of disease extension and of risk of cancer recurrence must be made before treatment 
can be applied. 
Presurgical variables commonly used for the prediction of pathologic stage of prostate cancer are prostate-specifi c 
antigen (PSA)1 level, Gleason score, and clinical tumor stage (evaluated with fi ndings at digital rectal examination 
and transrectal ultrasonography) (1–3). Nomographic models have been created to help physicians predict the fi nal 
pathologic stage of the tumor and the risk of cancer recurrence within 5 years on the basis of the patient’s individual 
parameters (1–3). These nomograms provide a statistical prediction but lack anatomic data that can assist in inter-
vention aimed to control local disease. Therefore, the quest for a better diagnostic test that would enable physicians 
to diff erentiate between advanced and localized disease and improve treatment planning led to the evaluation 
of the role of endorectal magnetic resonance (MR) imaging in the localization and the staging of prostate cancer. 
Researchers in early studies reported inter- and intraobserver variability, as well as inconsistency in the accuracy 
of diagnoses determined with MR imaging fi ndings (4–8). Data in these reports in part may explain why 20 years 
after the introduction of MR imaging to clinical practice, referring physicians tend to regard this modality as having 
limited value for evaluation of patients with prostate cancer (9). 
The aim of our study was to determine whether the predictive value of endorectal MR imaging fi ndings in the de-
tection of ECE is signifi cantly aff ected by the reader’s subspecialty experience. 
MATERIALS AND METHODS
Patients
Between May 1998 and January 2003, patients referred for endorectal MR imaging of the prostate prior to radi-
cal prostatectomy were enrolled in the study; all had biopsy-proved prostate cancer. Mean patient age was 57.5 
years (range, 32–74 years). Patients who received neoadjuvant hormonal or radiation therapy before surgery were 
excluded from the study. Overall, 344 patients were included in the data analysis; 216 of these patients underwent 
endorectal MR imaging and MR spectroscopic imaging. The same patient population was used for the study of 
Wang et al (10). The study was approved by the institutional review board, and each patient signed an informed 
consent form before enrollment. 
Imaging and Image Interpretation
Endorectal MR imaging and hydrogen 1 MR spectroscopic imaging were performed with a 1.5-T whole-body MR 
imaging unit (Signa Horizon; GE Medical Systems, Milwaukee, Wis). The examination was performed with patients in 
the supine position. A body coil was used for excitation, and a pelvic phased-array coil (GE Medical Systems) com-
bined with a commercially available balloon-covered expandable endorectal coil (Medrad, Pittsburgh, Pa) was used 
for signal reception. Transverse T1-weighted and spin-echo MR images were obtained from the aortic bifurcation to 
the symphysis pubis with the following parameters: repetition time msec/echo time msec, 700/8; section thickness, 
5 mm; intersection gap, 1 mm; fi eld of view, 24 cm; matrix, 256 x 192; and frequency direction, transverse (to prevent 
obstruction of the pelvic node from endorectal coil motion artifact). One signal was acquired. 
Transverse and coronal thin-section high-spatial-resolution T2-weighted fast spin-echo MR images of the prostate 
and seminal vesicle were obtained with the following parameters: 5,000/96 (eff ective); echo train length, 16; section 
thickness, 3 mm; intersection gap, 0 mm; fi eld of view, 14 cm; matrix, 256 x 192; frequency direction, anteroposte-
rior (to prevent obstruction of the prostate from endorectal coil motion artifact); and number of signals acquired, 
three. 
1Abbreviations
 ECE = extracapsular extension, PNI = perineural invasion, PSA = prostate-specifi c antigen, ROC = receiver operating characteristic 
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MR spectroscopic imaging was performed by using point-resolved spectroscopic voxel excitation (11), band-selec-
tive inversion with gradient dephasing water and lipid suppression (12), and spatial encoding with chemical shift 
imaging (13) at 6.25-mm resolution in all three dimensions (left-right, anterior-posterior, superior-inferior dimen-
sions). Parameters were 1,000/130, and imaging time was 17 minutes. 
Data processing was performed at a workstation (Sun Ultra 10; Sun Microsystems, Mountain View, Calif) and in-
cluded 2-Hz Lorentzian spectral apodization; four-dimensional Fourier transform; and automated frequency, phase, 
and baseline correction (14). Spectral data were zero fi lled to 3.1-mm resolution in the superior-inferior dimension 
and overlaid on corresponding transverse T2-weighted MR images. Peak areas were calculated by using numeric 
integration. To provide a noise measurement, we calculated the SD of the MR signal intensity in a region of the 
spectrum containing only noise. Metabolite peak areas were then normalized with respect to the noise SD to yield 
an approximate signal-to-noise ratio. 
MR images were interpreted by 10 MR imaging radiologists (four genitourinary MR imaging radiologists and six 
general body MR imaging radiologists), including one of the authors (H.H.), during their regular clinical assignment 
to the MR imaging service. All readers were trained in body MR imaging (seven had an MR imaging fellowship and 
the others had been involved with MR imaging since it was introduced to clinical practice), but the genitourinary 
MR imaging radiologists had extensive experience in genitourinary imaging and more than 3 years of experience in 
prostate imaging. They regularly attended urology grand rounds and prostate tumor board conferences and were 
involved in the fi eld academically. Experience in interpretation of MR images ranged from 4 to 15 years since fellow-
ship for the genitourinary MR imaging radiologists and from 6 to 10 years since fellowship for the general body MR 
imaging radiologists. 
In 344 patients, MR images in 163 patients were evaluated by the genitourinary MR imaging radiologists and those 
in the remaining 181 patients were evaluated by the general body MR imaging radiologists. There was no initial 
meeting or training to establish the diagnostic criteria for ECE on endorectal MR images. Rather, radiologists made 
their determinations on the basis of their own continuing medical training and knowledge of previously described 
MR imaging features of ECE. The diagnostic criteria used by the radiologists included irregular capsular bulge, peri-
prostatic fat infi ltration, obliteration of the rectoprostatic angle, and asymmetry or direct involvement of the neuro-
vascular bundles (15). All readers had access to MR spectroscopic imaging data when available, but such data were 
not always used. In addition, all readers had access to the patients’ medical records, including PSA level and biopsy 
fi ndings. On the basis of the radiologists’ written reports, one observer (L.W.) retrospectively scored the likelihood 
of ECE with a fi ve-point scale as follows: score 1, no ECE; score 2, probably no ECE (cannot be ruled out though there 
is no clear evidence of it); score 3, possible ECE (a lesion is suspected of demonstrating ECE); score 4, probable ECE 
(a lesion is highly suspected of demonstrating ECE); score 5, defi nite ECE. 
Clinical Data and Reference Standards
Presurgical clinical data, as well as pathologic reports at biopsy were evaluated for PSA level, Gleason score, greatest 
percentage of cancer in all core biopsy specimens, percentage of cancer-positive core specimens in all core biopsy 
specimens (the number of cancer-positive core specimens divided by the total number of core biopsy specimens), 
presence of perineural invasion (PNI), and clinical stage of tumor. The greatest percentage of cancer was determined 
in each patient by examining each core biopsy specimen and dividing the length of the core specimen tissue with 
cancer by the whole core specimen length; the core specimen with the highest percentage of cancer defi ned the 
patient’s greatest percentage of cancer. This parameter has been previously described by Rubin et al (16) and Bismar 
et al (17). Results from the fi nal pathologic report following surgery were used to determine ECE. ECE was defi ned as 
the presence of tumor cells outside the prostate capsule. All 344 patients had undergone radical prostatectomy. 
Specimens removed at radical prostatectomy were examined by the institutional pathology department, with 
methods previously described by Yossepowitch et al (18). Biopsy was performed at our institution, or biopsy fi nd-
ings were reviewed by our pathologists. 
Statistical Analysis
The Wilcoxon rank sum test was used to compare the presurgical continuous predictor variables of the two groups 
of patients (one composed of patients whose MR images were interpreted by general body MR imaging radiolo-
gists and the other composed of patients whose MR images were interpreted by genitourinary MR imaging radi-
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ologists). Hereafter, these groups will be referred to as the general body radiologist group and the genitourinary 
radiologist group, respectively. The  2 test was used to evaluate the diff erences between the categorical predictor 
variables of the two groups, as well as to evaluate the diff erence between the percentages of the two groups in 
regard to the number of fi nal pathologic specimens that showed ECE. Predictor variables that we tested included 
PSA level, Gleason score, greatest percentage of cancer in all core biopsy specimens, percentage of cancer-positive 
core specimens in all core biopsy specimens, presence of PNI, and clinical stage of tumor, as well as the probability 
of ECE as scored retrospectively on the basis of fi ndings in endorectal MR imaging reports. We calculated the area 
under the receiver operating characteristic (ROC) curve for each variable in the univariate regression analysis for 
the prediction of ECE. To determine the predictive value of endorectal MR imaging fi ndings, we used multivariate 
regression analysis. Two models were constructed: One model included all the clinical variables with endorectal MR 
imaging fi ndings, and the other model included only the clinical variables without endorectal MR imaging fi ndings. 
Jackknife-predicted probabilities of ECE for models with and without endorectal MR imaging fi ndings were used to 
construct the ROC curves. P values were bias corrected by using the bootstrap method. A diff erence with P < .05 
was considered signifi cant. 
RESULTS 
Tables 1–4 summarize the distribution of clinical variables between the genitourinary radiologist group and the 
general body radiologist group, as well as the prevalence of ECE in fi nal pathologic specimens. Eighty-three (24.1%) 
patients with prostate cancer had evidence of ECE in the fi nal pathologic specimen. There were no signifi cant dif-
ferences in predictor variables or in the prevalence of ECE between the two groups. 
Table 1. Distribution of Predictor Variables according to Group 
Note.—P values in both groups were as follows: PSA level, .95; Gleason score, .96; greatest percentage of cancer, .40; and percentage of cancer-
positive core specimens, .73. 
* Measured in nanograms per milliliter. 
† In all core biopsy specimens. Data missing for two patients. 
‡ In all core biopsy specimens. Data missing for 22 patients. 
  Predictor Variable
Genitourinary 
Radiologist Group
General Body 
Radiologist Group
  PSA level
 No. of patients 163 181
 Mean ± SD* 7.76 ± 9.81 7.54 ± 8.61
 Range* 1.23 - 113.40 0.74 - 78.44
  Gleason score
 No. of patients 163 181
 Mean ± SD 6.44 ± 0.66 6.47 ± 0.76
 Range 6 - 9 5 - 10
  Greatest percentage of cancer†
 No. of patients 163 179
 Mean ± SD 34.55 ± 27.39 32.95 ± 27.26
 Range 1.00 - 98.00 1.00 - 100.00
  Percentage of cancer-positive core biopsy   
  specimens‡
 No. of patients 157 165
 Mean ± SD 40 ± 25 42 ± 28
 Range 4 - 100 6 - 100
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Table 2. Clinical Stage of Tumor according to Group 
Note.—Data are numbers of patients. Data in parentheses are percentages. Percentages were rounded. P = .20,  2 test. 
* According to TNM classifi cations. 
Table 3. Presence of PNI at Biopsy according to Group 
Note.—Data are numbers of patients. Data in parentheses are percentages. Percentages were rounded. P = .48,  2 test. 
Table 4. Prevalence of ECE in Final Pathologic Specimens according to Group 
Note.—Data are numbers of patients. Data in parentheses are percentages. Percentages were rounded. P = .24,  2 test. 
 In Figure 1, the ROC curve for endorectal MR imaging fi ndings in the genitourinary radiologist group demonstrates 
a combination of sensitivity and specifi city that is superior to that of every other variable in the patient population. 
In the general body radiologist group, however, the ROC curve for endorectal MR imaging fi ndings demonstrates 
a combination of sensitivity and specifi city that is similar to those of the other predictors. With univariate analysis 
(Table 5), all variables tested were signifi cantly associated with fi ndings of ECE, with the exception of clinical stage 
of tumor in the genitourinary radiologist group. 
Clinical Stage of Tumor*
Genitourinary 
Radiologist Group
General Body 
Radiologist Group
Total
  T1c 94 (57.7) 101 (55.8) 195
  T2a 43 (26.4) 36 (19.9) 79
  T2b 14 (8.6) 23 (12.7) 37
  T2c 12 (7.4) 21 (11.6) 33
  Overall 163 181 344
PNI
Genitourinary 
Radiologist Group
General Body 
Radiologist Group
Total
  Not present 138 (84.7) 158 (87.3) 296
  Present 25 (15.3) 23 (12.7) 48
  Overall 163 181 344
ECE
Genitourinary 
Radiologist Group
General Body 
Radiologist Group
Total
  Not present 119 (73.0) 142 (78.4) 261
  Present 44 (27.0) 39 (21.5) 83
  Overall 163 181 344
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Figure 1. Graph shows ROC curves of univariate analysis results 
for all predictors of ECE. Predictors analyzed as continuous vari-
ables are indicated (*). Gleason score was categorized as 3 + 2 
and 3 + 3 versus 3 + 4, 4 + 3, 3 + 5, 4 + 4, 4 + 5, and 5 + 5. Clinical 
stage of tumor was categorized according to TNM classifi ca-
tions as T1c versus T2a, T2b, and T2c. Diagonal line indicates 
area under ROC curve of 0.500. General MRI = endorectal MR 
imaging fi ndings for general body radiologist group, % Ca = 
greatest percentage of cancer in all core biopsy specimens, GU 
MRI = endorectal MR imaging fi ndings for genitourinary radi-
ologist group, % of Pos Cores = percentage of cancer-positive 
core specimens in all core biopsy specimens. 
(Color version available in chapter 18).
Table 5. Univariate Analysis: Assessment of Variables for Prediction of ECE according to Group 
* Predictor analyzed as continuous vari-
able. 
† Gleason score was categorized as 3 + 
2 and 3 + 3 versus 3 + 4, 4 + 3, 3 + 5, 4 + 
4, 4 + 5, and 5 + 5. 
‡ Clinical stage of tumor was catego-
rized as T1c versus T2a, T2b, and T2c ac-
cording to TNM classifi cations. 
  Predictor Variable P Value Area under ROC Curve
  Genitourinary radiologist group
  PSA level* .002 0.701
  Gleason score† <.001 0.688
  Greatest percentage of cancer in all core
  biopsy specimens*
<.001 0.681
  Percentage of cancer-positive core 
  specimens in all core biopsy specimens*
.012 0.639
  PNI presence <.042 0.566
  Clinical stage of tumor‡ <.120 0.568
  MR imaging fi ndings* <.001 0.833
  General body radiologist group
  PSA level* .021 0.645
  Gleason score† <.001 0.683
  Greatest percentage of cancer in all core
  biopsy specimens*
<.001 0.793
   Percentage of cancer-positive core 
  specimens in all core biopsy specimens*
.016 0.634
  PNI presence .009 0.582
  Clinical stage of tumor‡ .015 0.611
  MR imaging fi ndings* <.001 0.646
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With multivariate analysis (Table 6), we examined the accuracy of prediction of ECE of our two models of variables 
(one with and one without endorectal MR imaging fi ndings). Both models were used for both the genitourinary 
radiologist and the general body radiologist groups. The area under the ROC curve was calculated for each model. 
Table 6. Multivariate Analysis: Assessment of Variables for Prediction of ECE according to Group and Model 
In the genitourinary radiologist group, in the model without MR imaging fi ndings, PSA level (P = .009), Gleason score 
(P = .016), and greatest percentage of cancer in all core biopsy specimens (P = .032) were all signifi cant predictors 
of ECE. When included in the model, endorectal MR imaging fi ndings were signifi cant predictors of ECE (P < .001) 
(Table 6). Furthermore, the model with endorectal MR imaging fi ndings had a greater area under the ROC curve 
than did the model without endorectal MR imaging fi ndings (area under the ROC curve = 0.854 and 0.760, respec-
tively; P = .019) (Fig 2a). 
  Predictor Variable P Value
  Genitourinary radiologist Group Model with imaging fi ndings
 PSA level* .032
 Gleason score† .097
 Greatest percentage of cancer in all core
 biopsy specimens*
.476
 Percentage of cancer-positive core 
 specimens in all core biopsy specimens*
.862
 PNI presence .915
 Clinical stage of tumor‡ .795
 MR imaging fi ndings <.001
  Model without MR imaging fi ndings
 PSA level* .009
 Gleason score† .016
 Greatest percentage of cancer in all core
 biopsy specimens*
.032
 Percentage of cancer-positive core 
 specimens in all core biopsy specimens*
.412
 PNI presence .863
 Clinical stage of tumor‡ .729
  General body radiologist group model with MR imaging fi ndings
 PSA level .032
 Gleason score† .206
 Greatest percentage of cancer in all core
 biopsy specimens*
.001
 Percentage of cancer-positive core 
 specimens in all core biopsy specimens*
.446
 PNI presence .929
 Clinical stage of tumor .281
 MR imaging fi ndings .002
  Model without MR imaging fi ndings
 PSA level .048
 Gleason score† .188
 Greatest percentage of cancer in all core
 biopsy specimens*
.002
 Percentage of cancer-positive core 
 specimens in all core biopsy specimens*
.682
 PNI presence .918
 Clinical stage of tumor‡ .277
Note.—The model with endorectal MR imag-
ing fi ndings (area under ROC curve = 0.854) 
had a signifi cantly larger area under the ROC 
curve than did the model without these fi nd-
ings (area under ROC curve = 0.760) for the 
genitourinary radiologist group (P = .019). 
The area under the ROC curve for the model 
with MR imaging fi ndings was 0.813 and that 
for the model without these fi ndings was 
0.788 for the general body radiologist group 
(P = .31). All areas under the ROC curves were 
corrected with the bootstrap method. 
* Predictor variable analyzed as continuous 
variable.
† Gleason score at biopsy was categorized as 
3 + 2 and 3 + 3 versus 3 + 4, 4 + 3, 3 + 5, 4 + 
4, 4 + 5, and 5 + 5. 
‡ Clinical stage of tumor was categorized 
as T1c versus T2a, T2b, and T2c according to 
TNM classifi cations. 
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Figure 2a. Graphs show comparison of ROC 
curves for detection of ECE, with base model 
without and with endorectal MR imaging fi nd-
ings. Base model included the following variables: 
PSA level, Gleason score, greatest percentage of 
cancer in all core biopsy specimens, percentage 
of cancer-positive core specimens in all core bi-
opsy specimens, presence of PNI, and clinical 
stage of tumor. Base model with endorectal MR 
imaging fi ndings included MR imaging fi ndings 
with all other variables. Predicted probability was 
calculated with jackknife method. Diagonal line 
indicates area under ROC curve of 0.500. (a) Graph 
shows ROC curves for genitourinary radiologist 
group. (b) Graph shows ROC curves for general 
body radiologist group. 
Figure 2b. Graphs show comparison of ROC 
curves for detection of ECE, with base model 
without and with endorectal MR imaging fi nd-
ings. Base model included the following variables: 
PSA level, Gleason score, greatest percentage of 
cancer in all core biopsy specimens, percentage 
of cancer-positive core specimens in all core bi-
opsy specimens, presence of PNI, and clinical 
stage of tumor. Base model with endorectal MR 
imaging fi ndings included MR imaging fi ndings 
with all other variables. Predicted probability was 
calculated with jackknife method. Diagonal line 
indicates area under ROC curve of 0.500. (a) Graph 
shows ROC curves for genitourinary radiologist 
group. (b) Graph shows ROC curves for general 
body radiologist group. 
In the general body radiologist group, in the model without MR imaging fi ndings, PSA level (P = .048) and greatest 
percentage of cancer in all core biopsy specimens (P = .002) were predictors of ECE. When included in the model, 
endorectal MR imaging fi ndings were signifi cant predictors of ECE (P = .002) (Table 6). The area under the ROC 
curve of the model with endorectal MR imaging fi ndings, however, was not signifi cantly greater than that of the 
model without endorectal MR imaging fi ndings (area under the ROC curve = 0.813 and 0.788, respectively; P = .31) 
(Fig 2b). 
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DISCUSSION 
The practice of medicine refl ects a combination of knowledge and skills. As medicine advances, ever-narrowing 
subspecialties evolve. Patients benefi t from the added clinical expertise (19–23). It has been demonstrated that the 
gain from treatment of a high volume of patients with a specifi c disease results in a better patient outcome (19). 
Birkmeyer (20) estimated that for cardiovascular surgical procedures, such as coronary artery bypass grafting and 
abdominal aortic aneurysm repair, the mortality rates in patients treated by high-volume medical providers are 
20%–50% lower than the mortality rates in those treated by low-volume providers. The association between patient 
volume and patient outcome does not stop at the cardiothoracic surgical ward. Researchers in studies (19) about 
the evaluation of cancer treatment demonstrated that patient volume can aff ect morbidity, local cancer recurrence, 
long-term survival, and mortality for a variety of cancer-related surgical procedures. 
Investigators in several studies (21–23) have examined the relationship between patient volume and patient out-
come with respect to the hospital or surgeon in patients who were undergoing radical prostatectomy. Findings in 
many of the studies indicated an inverse relationship between patient volume and mortality, morbidity, short- and 
long-term complications, and length of hospitalization (21–23). Not only surgeons succumb to the infl uences of 
experience and subspecialty training. When Gleason scores determined by pathologists were evaluated for ac-
curacy, it was found that the pathologist’s subspecialty infl uenced the disease grade. Gleason scores determined 
by general pathologists displayed only moderate interobserver reproducibility (  = 0.435), whereas Gleason scores 
determined by genitourinary pathologists showed improved interobserver agreement (  = 0.56–0.70) (24,25). 
With consideration of these fi ndings, it is not surprising that the accuracy of endorectal MR imaging fi ndings and of 
MR image interpretation is related to radiologists’ experience and subspecialty training (7,8,26–30). It has been dem-
onstrated that endorectal MR imaging evaluations performed by experienced radiologists (those with more years 
of experience in interpretation of endorectal MR images of the prostate) have less interobserver variability and are 
more accurate than evaluations performed by inexperienced radiologists (31). Since the early reports about interob-
server variability of MR imaging fi ndings (6), both MR imaging technology and radiologists’ skills have improved 
substantially. Yu et al (15) demonstrated that the combined use of endorectal MR imaging and MR spectroscopic 
imaging decreased interobserver variability and, for less experienced radiologists, signifi cantly improved the detec-
tion of ECE in patients with prostate cancer. 
Interobserver variability was not assessed in our study because interpretation of endorectal MR images was per-
formed as part of the routine clinical service, and therefore only one radiologist interpreted the images for each 
case. For our data analysis, the ten MR imaging radiologists were classifi ed as either genitourinary MR imaging 
radiologists or general body MR imaging radiologists. All of the readers were trained in body MR imaging (seven 
had an MR imaging fellowship and the others had been involved with MR imaging since it was introduced to clini-
cal practice), but the genitourinary MR imaging radiologists had extensive experience in genitourinary imaging and 
more than 3 years of experience in prostate imaging. They regularly attended urology grand rounds and prostate 
tumor board conferences and were involved academically in the fi eld. 
Results of our study demonstrated that in the genitourinary radiologist group endorectal MR imaging fi ndings 
displayed a combination of sensitivity and specifi city that was superior to that of all other predictors tested. In the 
general body radiologist group, however, the combination of sensitivity and specifi city of endorectal MR imaging 
fi ndings was similar to that of the clinical predictors. Univariate analysis results revealed that most of the variables 
tested were signifi cantly associated with fi ndings of ECE. Results of multivariate analysis for assessment of two mod-
els of variables (one with and one without endorectal MR imaging fi ndings) for their strength in the prediction of 
ECE demonstrated that in the genitourinary radiologist group a model with endorectal MR imaging fi ndings had a 
greater area under the ROC curve than did a model without endorectal MR imaging fi ndings (area under the ROC 
curve = 0.854 and 0.760, respectively; P = .019). In the general body radiologist group, however, the model with 
endorectal MR imaging fi ndings did not have a signifi cantly greater area under the ROC curve than did the model 
without endorectal MR imaging fi ndings (area under the ROC curve = 0.813 and 0.788, respectively; P = .31). Never-
theless, endorectal MR imaging fi ndings were signifi cant predictors of ECE in both groups of patients. 
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As stated by Kattan (32), predictors should not be judged by their P value but rather by their ability to improve an ex-
isting set of clinically used variables. This argument applies to the evaluation of an expensive test such as endorectal 
MR imaging. Given the high incidence of prostate cancer, the cost of endorectal MR imaging might burden the 
health care system with additional expenses unless it results in fewer unnecessary surgeries or improves treatment 
planning and outcomes (33). D’Amico et al (34) concluded that although MR imaging fi ndings added signifi cant 
predictive value (ie, prediction of the risk of development of biochemical failure following radical prostatectomy 
in 20% of patients), the added predictive value of fi ndings with this modality was not great enough to justify its 
routine use. Recently, it was suggested that treatment decisions should not be altered as a result of endorectal MR 
imaging fi ndings (35). 
One limitation of our study was that the contribution of MR spectroscopic imaging fi ndings to the fi nal MR imaging 
reports could not be assessed. MR spectroscopic technology was introduced at our institution in 2000, and radiolo-
gists experienced a steep learning curve in the acquisition and interpretation of MR spectroscopic imaging data 
during the past 4 years. Although MR spectroscopic imaging fi ndings were accessible at the time of interpretation 
of endorectal MR imaging fi ndings, readers did not always consult them, and therefore the degree of infl uence of 
MR spectroscopic imaging fi ndings on reader impressions could not be quantifi ed. Other limitations resulted from 
the fact that the study was designed to assess the value of endorectal MR image readings as used in clinical practice; 
accordingly, the readers were not blinded to clinical data such as PSA level and biopsy results, and as mentioned 
before, only one reader evaluated images in each case once so that we were unable to assess interobserver and 
intraobserver variability. 
With consideration of the foregoing data, results of this study demonstrate that endorectal MR imaging fi ndings 
add signifi cant value in the diagnosis of ECE in patients with prostate cancer when MR images are interpreted by 
radiologists with experience in MR imaging of the prostate. In light of these results, it is easy to understand why 
referring physicians have experienced frustration about the use of MR image readings for the evaluation of prostate 
cancer. Nevertheless, advances in technology and in the expertise of radiologists dedicated to the genitourinary 
fi eld suggest that endorectal MR imaging could play an increasingly useful role in the treatment of patients with 
prostate cancer. 
In conclusion, results of this study demonstrate that endorectal MR imaging fi ndings can be signifi cant predictors 
for ECE in patients with prostate cancer, after controlling for PSA level, Gleason score, greatest percentage of cancer 
in all core biopsy specimens, percentage of cancer-positive core specimens in all core biopsy specimens, PNI, and 
clinical stage of tumor. A comparison of the ROC curves drawn from the results of readings performed by genito-
urinary MR imaging radiologists and general body MR imaging radiologists showed that endorectal MR imaging 
fi ndings added value to all other predictor variables only when MR images were interpreted by genitourinary MR 
imaging radiologists. 
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ABSTRACT
Purpose: To retrospectively determine whether endorectal magnetic resonance (MR) imaging fi ndings contribute 
incremental value to the Kattan nomogram for predicting seminal vesicle invasion (SVI) in patients with prostate 
cancer. 
Materials and Methods: The institutional review board issued a waiver of authorization, which included a waiver of 
informed consent, for this HIPAA-compliant study. From October 2000 through January 2005, 573 patients (mean 
age, 58.3 years; age range, 36–86 years) underwent endorectal MR imaging before prostate cancer surgery. The en-
dorectal MR imaging results had been prospectively interpreted by seven radiologists, and the likelihood of SVI was 
retrospectively scored on the basis of radiologists’ written reports. MR imaging fi ndings, individual clinical variables 
(serum prostate-specifi c antigen [PSA] level, Gleason grade, clinical stage, greatest percentage of cancer in all biopsy 
cores, percentage of positive cores in all biopsy cores, and perineural invasion), and the Kattan nomogram were 
evaluated with respect to SVI prediction; surgical pathologic analysis was used as the reference standard. Logistic 
regression and receiver operating characteristic (ROC) curve analyses were performed. 
Results: At pathologic analysis, 28 (4.9%) of 573 patients had SVI. At univariate analysis, endorectal MR imaging 
results and all clinical variables except the percentage of positive biopsy cores were signifi cantly associated with 
SVI (P < .02); endorectal MR imaging (0.76) had a larger area under the ROC curve (AUC) than any clinical variable 
(0.62–0.73). At multivariate analysis, endorectal MR imaging results, Gleason grade, PSA level, and the percentage of 
cancer in all biopsy cores were signifi cantly associated with SVI (P ≤ .02). The Kattan nomogram plus endorectal MR 
imaging (0.87) had a signifi cantly larger (P < .05) AUC than either endorectal MR imaging alone (0.76) or the Kattan 
nomogram alone (0.80). 
Conclusion: The addition of endorectal MR imaging contributes signifi cant incremental value to the Kattan nomo-
gram for predicting SVI. 
© RSNA, 2006 
ADVANCES IN KNOWLEDGE 
• At univariate and multivariate analyses, endorectal MR imaging fi ndings are a signifi cant presurgical predictor of 
seminal vesicle invasion (P < .001). 
• Endorectal MR imaging fi ndings contribute signifi cant incremental value to the Kattan nomogram for predicting 
seminal vesicle invasion (P = .04). 
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INTRODUCTION
Prostate cancer has the highest incidence of any noncutaneous cancer in the United States and is the third leading cause of cancer death in American men (1). The American Cancer Society has estimated that in 2006 in the United States, 234 460 new cases of prostate cancer will be diagnosed and 27 350 men will die of the 
disease (1). The prevalence of seminal vesicle invasion (SVI)1 in contemporary surgical series (ie, those series per-
formed in the past 10 years) is 5%–23% (2–16). Preoperative identifi cation of SVI is an important factor for staging 
and prognosis and may modify treatment selection and treatment planning (4,12,17). 
The prognosis, however, depends on the status of other tumor prognostic variables and is not always poor. In a 
recent study (4), the 5-year biochemical progression-free rate for patients with SVI was 71.9% when surgical margins 
and nodes were negative, 36.6% when surgical margins were positive and nodes were negative, and 25.9% when 
surgical margins and nodes were positive. 
Clinical factors associated with an increased incidence of SVI include a high prostate-specifi c antigen (PSA) level, a 
high Gleason grade, the presence of tumor at the base of the prostate gland, and lymph node metastasis (3,4,18,19). 
To replace somewhat arbitrary combinations of individual clinical variables, nomograms have been introduced to 
help predict the stage of prostate cancer and to aid in the choice of treatment (3,20–22). The Kattan staging nomo-
gram, which is based on presurgical clinical variables (serum PSA level, Gleason grade at biopsy, clinical stage, and 
systematic needle biopsy cores from the base of the prostate), is a validated predictive instrument that is widely 
used to help direct adjuvant therapy and to guide postoperative counseling for patients with clinical data suggestive 
of SVI (3,23). However, the Kattan staging nomogram cannot predict the location of SVI. Of the modern diagnostic 
imaging modalities, endorectal magnetic resonance (MR) imaging has shown the most promise in the detection of 
prostate cancer SVI, with high specifi city (81%–99%) but widely varying sensitivity (23%–80%) (6–9,14–16,24). 
In historical studies on the detection of SVI with MR imaging, the disease was often relatively advanced, and the 
contribution of MR fi ndings to clinical nomograms was not assessed (5–9,14–16,24). Thus, the purpose of our study 
was to retrospectively determine whether endorectal MR imaging fi ndings contribute incremental value to the Kat-
tan nomogram for predicting SVI in patients with prostate cancer. 
MATERIALS AND METHODS
 
Patients
A total of 592 consecutive patients with prostate cancer were referred from the urology department to undergo MR 
imaging before radical retropubic prostatectomy and pelvic lymphadenectomy, which were performed at our insti-
tution by one of six attending surgeons, one of whom was an author (P.T.S.) (Table 1). For the six attending surgeons, 
the range of experience in prostate surgery was 10–35 years. From October 2000 through June 2003, imaging was 
performed as part of an ongoing National Institutes of Health study investigating the use of MR imaging in patients 
with prostate cancer; all patients gave informed consent before enrollment in the prospective institutional review 
board–approved National Institutes of Health study, which was compliant with the Health Insurance Portability and 
Accountability Act. From July 2003 to January 2005, imaging was performed as part of our accepted clinical practice 
for patient evaluation. The institutional review board of the Memorial Sloan-Kettering Cancer Center issued a waiver 
of authorization (which includes a waiver of informed consent) for retrospective review of the MR imaging reports 
and clinical data; this review was also compliant with the Health Insurance Portability and Accountability Act. 
1Abbreviations
AUC = area under the ROC curve • PNI = perineural invasion • PSA = prostate-specifi c antigen • ROC = receiver operating characteristic • SVI = 
seminal vesicle invasion 
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Table 1. Distribution of Preoperative Clinical Variables 
 For 19 of 592 patients, no needle biopsy cores from the base of the prostate were available, and thus the likelihood 
of SVI on the basis of the Kattan nomogram could not be calculated (3). Therefore, data analysis was based on the 
remaining 573 patients (mean age, 58.3 years; age range, 36–86 years). None of the 573 patients underwent neoad-
juvant hormonal therapy or radiation therapy prior to surgery. The average time between biopsy and MR imaging 
was 71.73 days (range, 1042 days before MR imaging to 114 days after MR imaging), and the average time from MR 
imaging to surgery was 38.40 days (range, 1–185 days). 
In all patients, prostate cancer was diagnosed by means of biopsy specimens. Clinical serum PSA levels, Gleason 
grade at biopsy, clinical stage, the greatest percentage of cancer in all biopsy cores, the percentage of positive cores 
in all biopsy cores, and perineural invasion (PNI) were recorded from the patients’ medical records (K.K.). A portion 
of the patient population has been reported on previously (25–28). 
Kattan Staging Nomogram
For all 573 patients, the likelihood of SVI according to the Kattan nomogram was recorded by two authors (L.W. 
and K.K. working together) on the basis of serum PSA levels, Gleason grade at biopsy, clinical stage, and systematic 
needle biopsy cores from the base of the prostate (3). 
MR Data Acquisition and Interpretation
MR imaging was performed with a 1.5-T whole-body MR imager (Signa Horizon; GE Medical Systems, Milwaukee, 
Wis). Patients were examined in the supine position by using the body coil for excitation and a pelvic phased-array 
  Clinical Variable Value
  PSA level (ng/mL)* 5.4 ± 4.28 (0-50.00)
  Gleason grade at biopsy
 3 + 2 2 (0.3)
 3 + 3 364 (63.5)
 3 + 4 126 (22.0)
 4 + 3 53 (9.2)
 4 + 4 or 3 + 5 22 (3.8)
 4 + 5 5 (0.9)
 5 + 4 1 (0.2)
  Greatest percentage of cancer in all biopsy cores* 0.20 ± 0.23 (0-1.00)
  Percentage of positive cores in all biopsy cores* 0.36 ± 0.26 (0-1.00)
  PNI at biopsy
 Absent 500 (87.3)
 Present 73 (12.7)
  Clinical stage at biopsy
 T1b 2 (0.3)
 T1c 361 (63.0)
 T2a 121 (63.0)
 T2b 50 (8.7)
 T2c 23 (4.0)
 T3 16 (2.8)
Note.—Unless otherwise indicated, 
data are the number of patients; data in 
parentheses are percentages.
* Data are the median ± standard devia-
tion; data in parentheses are ranges.
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coil (GE Medical Systems) in combination with a commercially available balloon-covered expandable endorectal 
coil (Medrad, Pittsburgh, Pa) for signal reception. T1-weighted transverse and spin-echo MR images were obtained 
from the aortic bifurcation to the symphysis pubis by using the following parameters: repetition time, 700 msec; 
echo time, 8 msec; section thickness, 5 mm; intersection gap, 1 mm; fi eld of view, 24 cm; matrix, 256 x 192; trans-
verse frequency direction (to prevent obstruction of the pelvic node by endorectal coil motion artifact); and one 
signal acquired. Thin-section high-spatial-resolution transverse and coronal T2-weighted fast spin-echo MR images 
of the prostate and seminal vesicles were obtained by using the following parameters: repetition time, 5000 msec; 
eff ective echo time, 96 msec; echo train length, 16; section thickness, 3 mm; no intersection gap; fi eld of view, 14 
cm; matrix, 256 x 192; anteroposterior frequency direction (to prevent obstruction of the prostate by endorectal coil 
motion artifact); and four signals acquired. 
MR images were prospectively interpreted by seven attending MR body radiologists, one of whom was an author 
(H.H.); images were interpreted independently during the regular clinical assignment of each radiologist to the MR 
service. Six of the readers had performed a fellowship in body imaging that included MR imaging. The experience 
of each radiologist in reading MR images since fellowship ranged from 1 to 13 years, with one reader having more 
than 20 years of experience interpreting MR images. All of the readers had experience in prostate imaging and were 
members of the institution’s prostate cancer disease management team. As per regular clinical practice, the readers 
were not blinded to clinical data, such as PSA level and biopsy results; however, the amount of clinical data that was 
available varied. Each radiologist made his or her determination regarding the presence of SVI on the basis of his or 
her own continuous medical training and knowledge of previously described MR features of SVI. 
The main diagnostic criteria used by the radiologists to determine the presence of SVI on MR images were the dis-
ruption or loss of the normal architecture of the seminal vesicle, focal or diff use areas of low signal intensity within 
the seminal vesicle, low signal intensity within the seminal vesicle causing mass eff ect, enlarged ejaculatory ducts 
with low signal intensity, and direct extension of the low signal intensity of tumor from the base of the prostate to 
the seminal vesicle (24). On the basis of the radiologists’ written reports, one author (L.W.) independently and retro-
spectively scored the likelihood of SVI on a scale of 1–5, with a score of 1 indicating no SVI; 2, probably no SVI (ie, SVI 
cannot be ruled out, although there is no clear evidence); 3, possible SVI (lesion is suspicious for SVI); 4, probable SVI 
(lesion is highly suspicious for SVI); and 5, defi nite SVI. 
Figure 1a: pT4 prostate cancer (clinical stage T2b with 
PSA level of 12.42 ng/mL) and bilateral seminal vesicle 
involvement in a 63-year-old man. Sextant biopsy re-
sults showed Gleason grade 4 + 3 tumors involving 50% 
of the total submitted tissue on both sides (94% of total 
submitted cores were positive) and PNI in left peripheral 
and transition zones. According to the Kattan staging no-
mogram, the likelihood of SVI was 18%. (a) Transverse T2-
weighted fast spin-echo 3-mm-thick MR image (4900/118 
[repetition time msec/eff ective echo time msec]) and 
(b) coronal T2-weighted fast spin-echo 3-mm-thick MR 
image (4666/96) show bilateral SVI (arrows). (c) Whole-
mount pathologic step section shows prostate cancer 
with bilateral seminal vesicle involvement. The green cir-
cle represents the area with a Gleason grade of 3, and the 
black circle represents the area with a Gleason grade of 4 
or a mixture of Gleason grades 4 and 5. LSV = left seminal 
vesicle, RSV = right seminal vesicle. 
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Histopathologic Analysis
Pretreatment sextant biopsy reports provided the following clinical parameters, which were used for prediction 
of SVI: Gleason grade, the greatest percentage of cancer in all biopsy cores, the percentage of positive cores in all 
biopsy cores, and PNI. Radical prostatectomy specimens had been examined by the institutional pathology depart-
ment. Prostatectomy specimens were inked with tattoo dye (green dye on the right side and blue dye on the left 
side), and the specimens were fi xed in 10% formalin for 36 hours. The distal 5 mm of the apex was amputated and 
coned. The remainder of the gland was serially sectioned from the apex to the base at 3–4-mm intervals and was 
entirely submitted for paraffi  n embedding as whole-mount sections. The seminal vesicles were amputated and 
submitted separately. After paraffi  n embedding, microsections were placed on glass slides and were stained with 
hematoxylin and eosin. One uropathologist (K.K.) subsequently reviewed all the specimens, mapped each tumor 
area with a marker (green for a Gleason grade of 3 and black for a Gleason grade of 4 or a mixture of Gleason grades 
4 and 5), and recorded the presence and location of SVI (Fig 1). 
Figure 1b: pT4 prostate cancer (clinical stage T2b with PSA level 
of 12.42 ng/mL) and bilateral seminal vesicle involvement in a 
63-year-old man. Sextant biopsy results showed Gleason grade 
4 + 3 tumors involving 50% of the total submitted tissue on 
both sides (94% of total submitted cores were positive) and PNI 
in left peripheral and transition zones. According to the Kattan 
staging nomogram, the likelihood of SVI was 18%. (a) Transverse 
T2-weighted fast spin-echo 3-mm-thick MR image (4900/118 
[repetition time msec/eff ective echo time msec]) and (b) coro-
nal T2-weighted fast spin-echo 3-mm-thick MR image (4666/96) 
show bilateral SVI (arrows). (c) Whole-mount pathologic step sec-
tion shows prostate cancer with bilateral seminal vesicle involve-
ment. The green circle represents the area with a Gleason grade 
of 3, and the black circle represents the area with a Gleason grade 
of 4 or a mixture of Gleason grades 4 and 5. LSV = left seminal 
vesicle, RSV = right seminal vesicle. 
Figure 1c: pT4 prostate cancer (clinical stage T2b with 
PSA level of 12.42 ng/mL) and bilateral seminal vesicle 
involvement in a 63-year-old man. Sextant biopsy re-
sults showed Gleason grade 4 + 3 tumors involving 
50% of the total submitted tissue on both sides (94% 
of total submitted cores were positive) and PNI in left 
peripheral and transition zones. According to the Kat-
tan staging nomogram, the likelihood of SVI was 18%. 
(a) Transverse T2-weighted fast spin-echo 3-mm-thick 
MR image (4900/118 [repetition time msec/eff ective 
echo time msec]) and (b) coronal T2-weighted fast spin-
echo 3-mm-thick MR image (4666/96) show bilateral 
SVI (arrows). (c) Whole-mount pathologic step section 
shows prostate cancer with bilateral seminal vesicle in-
volvement. The green circle represents the area with a 
Gleason grade of 3, and the black circle represents the 
area with a Gleason grade of 4 or a mixture of Gleason 
grades 4 and 5. LSV = left seminal vesicle, RSV = right 
seminal vesicle. 
(Color version available in chapter 18).
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Statistical Analysis
Univariate and multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were per-
formed for all clinical and imaging variables to predict SVI (H.N.C., M.W.K.). Univariate logistic regression was used to 
compare the characteristics of patients with SVI with the characteristics of patients without SVI. The area under the 
ROC curve (AUC) was evaluated for models of SVI prediction on the basis of the Kattan nomogram alone and MR 
imaging alone. In addition, a model was constructed for the prediction of SVI on the basis of the Kattan nomogram 
and MR imaging combined. AUC was bias-corrected by using the leave-one-out cross validation method (29). A P 
value of less than .05 was considered to indicate a statistically signifi cant diff erence. The software programs that 
were used for data analysis included SAS (version 8.2; SAS Institute, Cary, NC) and S-PLUS (version 2000; Insightful, 
Seattle, Wash). 
RESULTS
At surgical histopathologic analysis, 28 (4.9%) of 573 patients had evidence of SVI. Unilateral SVI was present in 22 
(3.8%) of 573 patients, and bilateral SVI was present in six (1.0%) of 573 patients (Table 2).
MR imaging was associated with SVI at both univariate and multivariate analysis (P < .001 in both cases) (Table 3). 
Table 2. Prevalence of SVI in Final Pathologic Specimens 
Note.—Data in parentheses are percentages.
Table 3. Strength of Clinical Variables and MR Findings for the Prediction of SVI 
Note.—Data are P values. Predictor variables were treated as continuous except for Gleason grade (categorized as 3 + 3, 3 + 4 vs 3 + 5, 4 + 3, 4 + 4, 
4 + 5, and 5 + 5) and clinical stage (categorized as T1 vs T2).
* Data in parentheses are AUC values.
At univariate analysis, MR fi ndings (P < .001), PSA level (P = .014), Gleason grade (P = .01), clinical stage (P < .001), the 
greatest percentage of cancer in all biopsy cores (P < .001), and PNI (P = .005) were signifi cantly associated with SVI; 
the percentage of positive cores was the only clinical variable that was not signifi cantly associated with SVI (P = .30). 
AUC was larger for MR imaging (0.76) than for any of the clinical variables (0.62–0.73) (Table 3). 
 Clinical Variables and MR Findings Univariate Analysis* Multivariate Analysis*
  MR fi ndings <.001 (0.76) <.001
  Greatest percentage of cancer in all 
  biopsy cores
<.001 (0.73) .02
  PSA level .014 (0.72) .012
  Clinical stage <.001 (0.71) .23
  Gleason grade .01 (0.70) <.001
  PNI .005 (0.62) .55
  Percentage of positive cores in all biopsy 
  cores
.30 (0.67) .08
 SVI
No. of Patients
(n = 573)
Absent 545 (95.1)
Present 28 (4.9)
Unilateral 22 (3.8)
Bilateral 6 (1.0)
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At multivariate analysis, MR fi ndings (P < .001), PSA level (P = .012), Gleason grade (P < .001), and the greatest percent-
age of cancer in all biopsy cores (P = .02) were signifi cantly associated with SVI. The AUC for the Kattan nomogram 
plus MR imaging (0.87) was signifi cantly larger than the AUC for the Kattan nomogram alone (0.80) or for MR imag-
ing alone (0.76) (P < .05 in both cases) (Table 4, Figs 1, 2). 
Table 4. AUC Values for Models Predicting SVI on the Basis of MR Imaging and the Kattan Nomogram 
Note.—The model containing the Kattan nomogram plus MR imaging had a signifi cantly greater AUC value (0.87) than either the Kattan nomo-
gram alone (0.80) or MR imaging alone (0.76) (P < .05 in both cases).
* P values were calculated by comparing each model with MR imaging plus the Kattan nomogram.
Figure 2: Graph shows ROC curves for jack-
knife predicted probabilities of SVI on the 
basis of endorectal MR imaging and the Kat-
tan nomogram plus MR imaging. The model 
containing the Kattan nomogram plus MR 
imaging (0.87) has a signifi cantly greater AUC 
than the model containing only the Kattan 
nomogram (0.80; P = .04) or the model con-
taining only MR imaging (0.76; P < .01). 
DISCUSSION
In patients with prostate cancer, the presence of SVI is associated with an increased risk of lymph node metasta-
sis and recurrence (4,17,23,30). The prediction of SVI before treatment may infl uence treatment selection in favor 
of radiation therapy instead of surgery. Furthermore, while resection of the seminal vesicles has been a standard 
component of radical prostatectomy, it has recently been suggested that if SVI can be confi dently ruled out, the 
surgeon may prefer to spare the seminal vesicles during radical prostatectomy to prevent long-term loss of urinary 
continence (31). 
  Model AUC Value P Value*
  Kattan nomogram 0.80 .04
  MR imaging 0.76 .01
  MR imaging plus Kattan nomogram 0.87
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In our patient population, 4.9% of patients had evidence of SVI at surgical histopathologic analysis. This result is con-
sistent with the dramatic downstaging of prostate cancer at the time of diagnosis that has occurred over the past 2 
decades, as demonstrated by the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. 
Data from this program show that from 1995 to 2001, 91% of prostate cancer cases were of a local or regional stage 
at diagnosis compared with only 74% from 1981 to 1987 (1,32). 
Because of the importance of SVI in patient prognosis and treatment choice, presurgical biopsy of the seminal 
vesicles has been suggested. Terris et al (33) performed biopsies of the seminal vesicles in 73 selected patients, 12 of 
whom had SVI in the radical prostatectomy specimens. They reported a negative predictive value of 97%, a positive 
predictive value of 80%, and a sensitivity of 67%. The low incidence of SVI overall, occasional false-positive results, 
and low sensitivity limit the enthusiasm for performing biopsy in the seminal vesicles (3,12,33). 
In the literature, serum PSA level and Gleason grade are signifi cantly associated with SVI for both univariate and 
multivariate analysis (3,34–36). In our study, MR imaging results, the greatest percentage of cancer in all biopsy cores, 
PSA level, clinical stage, Gleason grade, and PNI were all signifi cantly associated with SVI at univariate analysis, while 
MR imaging results, Gleason grade, PSA level, and the greatest percentage of cancer in all biopsy cores were signifi -
cantly associated with SVI at multivariate analysis. Koh et al (3) found that all prognostic factors, when combined 
in a model, predicted the pathologic stage more accurately than did any single parameter alone—a fi nding that is 
consistent with the fi ndings of our study. Our results show that MR imaging can add signifi cant incremental value to 
clinical variables for the prediction of SVI. 
The role of modern MR imaging in prostate cancer management has been changing not only because of the de-
velopment of new MR techniques, such as endorectal MR imaging, contrast material–enhanced endorectal MR 
imaging, and MR spectroscopic imaging, but also because of radiologists’ increased experience with MR imaging of 
the prostate. The results of previous studies have shown that MR imaging fi ndings, although subject to substantial 
interobserver variability, can add signifi cant incremental value to clinical variables in predicting other features of 
prostate cancer that are relevant to staging, such as extracapsular extension and lymph node metastasis (26,27,37). 
Our study was not designed to assess MR technology but to assess the value of MR imaging, as applied in the clinical 
setting during radiologists’ regular clinical assignments. Accordingly, the readers had access to clinical data, such as 
PSA level and biopsy results when available, in the patient’s medical record. Each study was evaluated only once, 
so we could not assess interobserver and intraobserver variability. Furthermore, we studied a consecutive cohort of 
patients who met eligibility requirements on the basis of pretreatment factors (not SVI outcome) and not a random 
sample. Thus, the estimates of accuracy might be biased. 
In conclusion, our results show that endorectal MR imaging fi ndings can contribute signifi cant incremental value to 
the Kattan nomogram for predicting SVI. Although further multicenter confi rmatory studies would be helpful, we 
suggest that MR imaging has an important role to play in the pretreatment evaluation of prostate cancer, including 
the prediction of SVI. 
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ABSTRACT 
Objective: The purpose of this study was to assess whether use of the PACS cross-referencing tool in 3D MRI im-
proves tumor staging of prostate cancer when pathologic fi ndings are used as the reference standard. 
Materials and Methods: The institutional review board granted a waiver of informed consent for the study. Endorec-
tal MRI at 1.5 T was performed before radical prostatectomy in 255 consecutive patients. Two radiologists unaware 
of the clinical data retrospectively and independently interpreted MR images without and with cross-referencing to 
predict the presence of extracapsular extension (ECE) and seminal vesicle invasion (SVI). Histopathologic fi ndings 
were used as the reference standard. Area under the receiver operating characteristics curve (AUC), sensitivity and 
specifi city, and weighted kappa statistics were calculated. 
Results: At histologic examination, 68 (27%) of the patients were found to have ECE and 13 (5%) of the patients to 
have SVI; the latter all had ECE. In detecting ECE, both reviewers had a higher AUC using cross-referencing (p < 0.001 
for both). The weighted kappa value was 0.56 for MRI alone and 0.76 for MRI with cross-referencing, indicating fair 
to good interobserver agreement. Sensitivity and specifi city for ECE with MRI alone and with cross-referencing were 
43% and 94% and 57% and 100% for reviewer 1 and 40% and 93% and 59% and 98% for reviewer 2, respectively. In 
detecting SVI, both reviewers had a higher AUC with cross-referencing (p = 0.007 and p = 0.056 for reviewers 1 and 
2, respectively). Reviewer 1 benefi ted much more from cross-referencing than did reviewer 2. The weighted kappa 
statistic was 0.69 for MRI alone and the same with cross-referencing, indicating good interobserver agreement. Sen-
sitivity and specifi city for SVI with MRI alone and with cross-referencing, respectively, were 23% and 83% and 46% 
and 93% for reviewer 1 and 31% and 91% and 54% and 95% for reviewer 2. 
Conclusion: PACS cross-referencing signifi cantly improves tumor staging of prostate cancer with 3D MRI. Some 
reviewers benefi t more than others from use of this tool. 
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INTRODUCTION 
Prostate cancer aff ects men of all races, cultures, and ethnic backgrounds and is a major public health and economic burden in the United States and other industrialized countries [1, 2]. In the past decade, there has been a dramatic downward trend in the stage of prostate cancer determined at diagnosis [1, 3]. Preoperative 
identifi cation of extracapsular extension (ECE) and seminal vesicle invasion (SVI) is an important factor in staging 
and prognosis that may modify treatment decisions and treatment planning [4, 5]. Because it improves surgical 
planning, identifi cation of these characteristics increases the chances that the tumor will be resected completely 
with only minimal damage to the surrounding tissue so important to recovery of normal function [6, 7]. 
Fig. 1A: 53-year-old man with clinical stage T1c prostate carcinoma 
with Gleason score of 3 + 3 and prostate-specifi c antigen level of 
11.9 ng/mL. MRI without PACS cross-referencing indicated possible 
extracapsular extension (ECE) at right base and possible right semi-
nal vesicle invasion (SVI) (scores of 3 and 3, respectively). However, 
MRI with PACS cross-referencing indicated defi nite ECE and defi nite 
SVI (scores of 5 and 5, respectively). Axial T2-weighted image shows 
point of interest (crosshairs) selected by reviewer in low-signal-in-
tensity area using cross-referencing tool. Irregular nodularity is seen 
in right seminal vesicle (arrowhead), indicating seminal vesicle inva-
sion. 
Fig. 1B: 53-year-old man with clinical stage T1c prostate carcinoma 
with Gleason score of 3 + 3 and prostate-specifi c antigen level of 11.9 
ng/mL. MRI without PACS cross-referencing indicated possible ex-
tracapsular extension (ECE) at right base and possible right seminal 
vesicle invasion (SVI) (scores of 3 and 3, respectively). However, MRI 
with PACS cross-referencing indicated defi nite ECE and defi nite SVI 
(scores of 5 and 5, respectively). T2-weighted coronal MR image with 
cross-referencing shows ECE (arrow) at right base and right seminal 
vesicle invasion (arrowheads). Crosshairs indicate point of interest 
identifi ed by cross-referencing tool. Relationship between seminal 
vesicle and central zone is shown clearly. 
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Probability of the presence of ECE and SVI currently is best determined from staging nomograms with which patho-
logic stage is estimated from the pretreatment level of prostate-specifi c antigen, clinical stage, and Gleason grade 
in the biopsy specimen [7-9]. However, staging nomograms are limited because they do not incorporate the results 
of imaging studies that could assist in prediction of ECE and SVI [7-9]. 
Because of high spatial resolution, superior contrast resolution, multiplanar capability, and large fi eld of view, MRI 
has played an increasingly important role in prostate cancer staging. However, although it has high specifi city (ECE 
specifi city, 47-99%; SVI specifi city, 81-99%) [10-14], MRI has widely varying sensitivity (ECE sensitivity, 22-80%; SVI 
sensitivity, 34-71%) [15-17]. Many of the diffi  culties in prostate cancer staging have been caused by poor under-
standing of the anatomic features of the prostate owing to its small size, presence of periprostatic structures [18, 
19], and the partial volume eff ect on MRI [20]. The partial volume eff ect arises in volumetric images when more 
than one tissue type is present in a voxel. In such cases, voxel intensity depends not only on the imaging sequence 
and tissue properties but also on the proportion of each tissue type present in the voxel [20]. Depending on the 
direction and thickness of the MRI slice, the border between the tissues can become unclear. Presence of the partial 
volume eff ect can lead to false assessment of tumor capsules and tumor invasion [21]. 
Fig. 1C: 53-year-old man with clinical stage T1c prostate carcinoma 
with Gleason score of 3 + 3 and prostate-specifi c antigen level of 
11.9 ng/mL. MRI without PACS cross-referencing indicated possible 
extracapsular extension (ECE) at right base and possible right semi-
nal vesicle invasion (SVI) (scores of 3 and 3, respectively). However, 
MRI with PACS cross-referencing indicated defi nite ECE and defi nite 
SVI (scores of 5 and 5, respectively). Sagittal T2-weighted MR image 
shows right seminal vesicle invasion (arrowheads). Crosshairs indi-
cate point of interest identifi ed by cross-referencing tool. 
Fig. 1D: 53-year-old man with clinical 
stage T1c prostate carcinoma with Glea-
son score of 3 + 3 and prostate-specifi c 
antigen level of 11.9 ng/mL. MRI without 
PACS cross-referencing indicated pos-
sible extracapsular extension (ECE) at 
right base and possible right seminal 
vesicle invasion (SVI) (scores of 3 and 3, 
respectively). However, MRI with PACS 
cross-referencing indicated defi nite 
ECE and defi nite SVI (scores of 5 and 5, 
respectively). Histologic photograph 
shows whole-mount sections that con-
fi rm presence of ECE (red) at right base 
and right seminal vesicle invasion (blue). 
RSV = right seminal vesicle. 
(Color version available in chapter 18).
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PACS technology facilitates the display and distribution of digital images [22]. With a PACS, medical images obtained 
with various techniques, such as CT, MRI, sonography, and digital projection radiography [23], and other pertinent 
information are transmitted to various, sometimes remote, locations over networks. Display of the images on com-
puter workstations for soft-copy viewing allows simultaneous consultations and almost instant reporting from radi-
ologists working in several locations [23]. The PACS workstation (Centricity RA 1000, GE Healthcare) at our institution 
has a cross-referencing feature whereby selection of a voxel in any one plane highlights the corresponding voxel in 
the intersecting planes. This feature is also available on systems such as the Synapse PACS (Fujifi lm) and iSite PACS 
(Philips Medical Systems). Although it may be tempting to assume that new technology will enhance radiologists’ 
performance, this is not always the case. For example, current literature suggests that accuracy of interpretation of 
sonograms is similar for images interpreted on a monitor and those interpreted on fi lm [24]. The purpose of our 
study was to assess whether use of PACS cross-referencing improves tumor staging of prostate cancer with 3D MRI 
when pathologic fi ndings are the reference standard. 
MATERIALS AND METHODS 
Patient Characteristics
The institutional review board granted exempt status for this retrospective, single-institution cross-sectional study 
with a waiver of informed consent. Patient data were collected and handled in accordance with Health Insurance 
Portability and Accountability Act regulations. From March 22, 2004, through January 7, 2005, 255 patients with 
prostate cancer were consecutively referred from the urology department to undergo endorectal MRI before radical 
retropubic prostatectomy performed by one of six attending surgeons at our institution. Mean patient age was 59 
years (range, 40-86 years). None of the patients received neoadjuvant hormonal or radiation therapy before radical 
prostatectomy. All patients had a tissue diagnosis of prostate cancer based on biopsy results. Clinical serum level of 
prostate-specifi c antigen, Gleason grade at biopsy, clinical stage, greatest percentage of cancer in all biopsy cores, 
percentage of cores with positive results in all biopsy cores, presence of perineural invasion, and MR data were re-
corded retrospectively from medical records. 
MRI Technique
Endorectal MRI was performed with a 1.5-T whole-body MRI system (Signa Horizon, GE Healthcare). Examina-
tions were performed with the patients in the supine position, a body coil for excitation, and a pelvic phased-
array coil (GE Healthcare) in combination with a commercially available balloon-covered expandable endorec-
tal coil (Medrad) for signal reception. T1-weighted axial and spin-echo images were obtained from the aortic 
bifurcation to the symphysis pubis with the following parameters: TR/TE, 700/8; slice thickness, 5 mm; interslice 
Fig. 2A: 63-year-old man with clinical stage T1c prostate carcinoma 
with Gleason score of 4 + 4, prostate-specifi c antigen level of 12.9 
ng/mL. MRI without PACS cross-referencing indicated possible extra-
capsular extension (ECE) at left base and possible left seminal vesicle 
invasion (SVI) (scores of 3 and 3, respectively). However, cross-refer-
enced MR images (A-C) indicated no ECE and no SVI (scores of 1 and 
1, respectively). Axial T2-weighted MR image shows point of interest 
(crosshairs) identifi ed by cross-referencing tool. 
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gap, 1 mm; fi eld of view, 24 cm; matrix size, 256 x 192; frequency direction, transverse (to prevent obstruction of the 
pelvic node by endorectal coil motion artifact); and number of excitations, one. Thin-section, high-spatial-resolu-
tion axial and coronal T2-weighted fast spin-echo images of the prostate and seminal vesicles were obtained with 
the following parameters: TR/eff ective TE, 5,000/96; echo-train length, 16; slice thickness, 3 mm; interslice gap, 0 
mm; fi eld of view, 14 cm; matrix size, 256 x 192; frequency direction, anteroposterior (to prevent obstruction of the 
prostate by endorectal coil motion artifact); and number of excitations, 4. All MRI data were entered into the PACS 
of our radiology department. 
MRI Analysis on PACS Workstation
MR images were retrospectively analyzed independently by two radiologists who were aware of the hypothesis 
being tested but unaware of the clinical, surgical, and histologic fi ndings for the 255 patients who had undergone 
radical prostatectomy. Reviewer 1 had 4 years of research experience in MRI of the prostate during which 
Fig. 2B: 63-year-old man with clinical stage T1c prostate carcinoma 
with Gleason score of 4 + 4, prostate-specifi c antigen level of 12.9 
ng/mL. MRI without PACS cross-referencing indicated possible ex-
tracapsular extension (ECE) at left base and possible left seminal 
vesicle invasion (SVI) (scores of 3 and 3, respectively). However, cross-
referenced MR images (A-C) indicated no ECE and no SVI (scores of 1 
and 1, respectively). Coronal T2-weighted MR image shows interface 
(arrow) between seminal vesicle and central zone of prostate. Cross-
hairs indicate point of interest identifi ed by cross-referencing tool. 
Fig. 2C: 63-year-old man with clinical stage T1c prostate carcinoma 
with Gleason score of 4 + 4, prostate-specifi c antigen level of 12.9 
ng/mL. MRI without PACS cross-referencing indicated possible extra-
capsular extension (ECE) at left base and possible left seminal vesicle 
invasion (SVI) (scores of 3 and 3, respectively). However, cross-refer-
enced MR images (A-C) indicated no ECE and no SVI (scores of 1 and 
1, respectively). Sagittal T2-weighted image with cross-referencing 
shows point of interest selected by reviewer (crosshairs). 
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he had interpreted more than 1,000 prostate MR images. Reviewer 2 had completed a dedicated body-MRI fellow-
ship and had interpreted more than 500 prostate MR images, most in a 1-year span. Criteria for signs of ECE on MR 
images included capsular irregularity, bulging of the capsule, capsular retraction, obliteration of the rectoprostatic 
angle, and asymmetry or direct involvement of the neurovascular bundles [10, 25]. Criteria for SVI were a focal low-
signal-intensity mass or diff use enlargement with low signal intensity and loss of the perceptible vesical wall on 
both T1- and T2-weighted sequences [25]. 
At the PACS workstation, the reviewers opened the examinations in the axial, coronal, and sagittal image series and 
assigned separate scores for the probabilities of ECE and SVI on a scale of 1-5 (1, defi nitely absent; 2, probably absent; 
3, possibly present; 4, probably present; 5, defi nitely present). These scores were designated MRI without PACS cross-
referencing. The reviewers then activated the cross-referencing feature. With this feature, when a reviewer selects a 
point of interest (or voxel) in any one plane (i.e., image series), an image in each intersecting plane is automatically 
displayed with a target symbol (or crosshairs) on the corresponding voxel. After using the cross-referencing tool, the 
radiologists assigned scores for ECE and SVI, again using the 5-point scale. These scores were designated MRI with 
PACS cross-referencing (Figs. 1A, 1B, 1C, 1D, 2A, 2B, 2C, and 2D).
 
Pathologic Assessment and Comparison with MR Images
Core biopsy specimens were evaluated for Gleason grade, greatest percentage of cancer in all biopsy cores, per-
centage of cores with positive fi ndings in all biopsy cores, and presence of perineural invasion. All prostatectomy 
specimens were inked with India ink tattoo dye (green dye on right, blue dye on left) and fi xed in 10% formalin for 
36 hours. The distal 5 mm of the apex was amputated and coned. The rest of the gland was serially sectioned from 
apex to base for acquisition of axial slices at 3-mm intervals (axial step sections) and submitted in entirety for paraf-
fi n embedding as whole mounts. The seminal vesicles were amputated and submitted separately. After paraffi  n 
embedding, microsections were placed on glass slides and stained with H and E. The axial pathologic sections were 
numbered consecutively from apex to base, and the cancerous areas were mapped in each section with marker. 
Pathologic stage and surgical Gleason score were determined for each patient. ECE was defi ned as invasion of pros-
tate cancer beyond the prostate capsule into the periprostatic soft tissue. SVI was defi ned as invasion of prostate 
cancer cells into the seminal vesicles. Presence or absence of ECE and SVI was recorded from the surgical pathology 
report. 
Fig. 2D: 63-year-old man with clinical stage T1c prostate carcinoma with 
Gleason score of 4 + 4, prostate-specifi c antigen level of 12.9 ng/mL. MRI 
without PACS cross-referencing indicated possible extracapsular extension 
(ECE) at left base and possible left seminal vesicle invasion (SVI) (scores of 3 
and 3, respectively). However, cross-referenced MR images (A-C) indicated 
no ECE and no SVI (scores of 1 and 1, respectively). Histopathologic pho-
tograph shows whole-mount sections confi rming absence of extracapsu-
lar extension and seminal vesicle invasion at left base. RSV = right seminal 
vesicle, LSV = left seminal vesicle. 
(Color version available in chapter 18).
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Statistical Analysis
Two of the authors were responsible for statistical analysis. Empirically estimated receiver operating characteristics 
(ROC) curves were used to evaluate the radiologists’ accuracy in detecting SVI and ECE on MRI. For each ROC curve, 
the area under the curve (AUC) and the corresponding confi dence intervals (CI) were estimated with nonparametric 
methods. Comparisons of the AUCs of a single reviewer were conducted with methods described by DeLong et al. 
[26]. To assess interobserver variability in determining the presence of ECE and SVI on MRI alone and MRI with PACS 
cross-referencing, we used a weighted kappa statistic with weights 1 - |i - j| / (5-1) where i, j = 1,..., 5 denotes the rating 
categories for the fi rst and second reviewers [27]. Analyses were performed with Intercooled Stata 8.0 for Windows 
(Stata) and S-Plus for Windows 6.2.1 (Insightful). 
RESULTS 
Surgical Histopathologic Findings
At histopathologic examination, 68 (27%) of 255 patients had ECE and 13 (5%) had SVI. All 13 patients with SVI had 
ECE. 
MRI Findings
Detection of ECE—ROC curves for reviewers 1 and 2 in detecting and localizing ECE are plotted in Figure 3. Re-
viewer 1 had an AUC of 0.66 (95% CI, 0.58-0.73) using MRI alone and an AUC of 0.87 (95% CI, 0.82-0.93) using MRI 
with PACS cross-referencing. Reviewer 1 performed signifi cantly better using MRI with PACS cross-referencing than 
using MRI alone (p < 0.001). Reviewer 2 had an AUC of 0.69 (95% CI, 0.61-0.77) using MRI alone and an AUC of 0.86 
(95% CI, 0.79-0.92) using MRI with PACS cross-referencing. Reviewer 2 also performed signifi cantly better using MRI 
with PACS cross-referencing (p < 0.001). For detection of ECE with MRI alone, the weighted kappa was 0.56, and for 
detection of ECE with MRI and PACS cross-referencing, it was 0.76, indicating fair to good agreement between the 
two reviewers. 
We dichotomized the 5-point scoring system and used 4 cut points to assess the sensitivity and specifi city of MRI in 
the diagnosis of ECE (Table 1). When cut point 3 was chosen (so that values 1-3 indicated absence of ECE and values 
4 and 5 indicated presence of ECE) for reviewer 1, sensitivity and specifi city were 43% and 94% for MRI alone and 
57% and 100% for MRI with PACS cross-referencing. At the same cut point for reviewer 2, sensitivity and specifi city 
were 40% and 93% for MRI alone and 59% and 98% for MRI with PACS cross-referencing. 
Fig. 3: Graph shows results of receiver operating characteristic 
analysis for detection of extracapsular extension with MRI alone 
and MRI with PACS cross-referencing. R1 = reviewer 1, R2 = review-
er 2, MRI = MRI alone, PACS = MRI with PACS cross-referencing, AUC 
= area under curve. 
(Color version available in chapter 18).
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Table 1: Sensitivity and Specifi city for Detection of Extracapsular Extension at 4 Cut Points of the 5-Point Scoring System
Note—All values are percentages. MRI + PACS = MRI with PACS cross-referencing
Detection of SVI—ROC curves for reviewers 1 and 2 in detecting and localizing SVI are plotted in Figure 4. Reviewer 
1 had an AUC of 0.62 (95% CI, 0.48-0.76) using MRI alone and an AUC of 0.87 (95% CI, 0.77-0.96) using MRI with PACS 
cross-referencing. Reviewer 1 performed signifi cantly better using PACS cross-referencing (p = 0.007). Reviewer 2 
had an AUC of 0.73 (95% CI, 0.58-0.88) using MRI alone and an AUC of 0.90 (95% CI, 0.80-0.99) using MRI with PACS 
cross-referencing. Reviewer 2 also performed better using PACS cross-referencing, although for reviewer 2 the dif-
ference had only borderline signifi cance (p = 0.056). In the detection of SVI, the weighted kappa statistic was 0.69 for 
both MRI alone and MRI with PACS cross-referencing, indicating good interobserver agreement. 
Fig. 4: Graph shows results of receiver operating characteristic 
analysis for detection of seminal vesicle invasion with MRI with 
PACS cross-referencing and MRI alone. R1 = reviewer 1; R2 = re-
viewer 2; MRI = MRI alone; PACS = MRI with PACS cross-referencing, 
AUC = area under curve. 
(Color version available in chapter 18).
Cut Point 1
(1 = No; 2–5 = Yes)
Cut Point 2 (
1, 2 = No; 3–5 = Yes)
Cut Point 3 
(1–3 = No; 4, 5 = Yes)
Cut Point 4 
(1–4 = No; 5 = Yes)
  Reviewer 1
 MRI alone
 Sensitivity 51 44 43 3
 Specifi city 73 85 94 98
 MRI + PACS
 Sensitivity 82 68 57 43
 Specifi city 79 95 100 100
  Reviewer 2
 MRI alone
 Sensitivity 69 56 40 10
 Specifi city 53 78 93 98
 MRI + PACS
 Sensitivity 82 74 59 41
 Specifi city 65 95 98 99
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We dichotomized the 5-point scoring system and used 4 cut points to assess the sensitivity and specifi city of MRI in 
the diagnosis of SVI (Table 2). When cut point 3 was used (so that values 1-3 indicated absence of SVI and values 4 
and 5 indicated presence of SVI) for reviewer 1, sensitivity and specifi city were 23% and 83% for MRI alone and 46% 
and 93% for MRI with PACS cross-referencing. At the same cut point for reviewer 2, sensitivity and specifi city were 
31% and 91% for MRI alone and 54% and 95% for MRI with PACS cross-referencing. 
Table 2: Sensitivity and Specifi city for Seminal Vesicle Invasion at 4 Cut Points of the 5-Point Scoring System 
Note—All values are percentages. MRI + PACS = MRI with PACS cross-referencing
DISCUSSION
 
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute has shown a dra-
matic down-staging of prostate cancer at diagnosis over the last 2 decades. SEER data show that from 1995 to 2000, 
90% of cases of prostate cancer were at a local or regional stage at diagnosis, compared with 72% from 1983 to 1987 
[1, 3]. In our patient population, 27% of the patients had evidence of ECE and 5% had evidence of SVI at surgical 
histopathologic examination. These results are consistent with SEER data [2]. 
ECE and SVI are important prognostic factors for recurrence after radical prostatectomy [4, 28]. ECE is associated 
with greater risk of a positive surgical margin, which further decreases the chance of long-term cancer control [4, 7]. 
SVI is associated with an increased incidence of lymph node metastasis and a worse prognosis, even in the absence 
of lymph node involvement [29]. Accurate determination of the presence of ECE and SVI before treatment may alter 
treatment selection and planning [4, 7, 9]. 
MRI is generally considered the most accurate imaging method for local staging of prostate cancer [30-32]. Engel-
brecht et al. [14] conducted a meta-analysis of 146 studies performed from January 1984 to May 2000 and described 
in 71 articles and fi ve abstracts. The fi ndings showed that MRI had an AUC of 0.60 ± 0.19 (SD) in detection of ECE 
and an AUC of 0.62 ± 0.13 in detection of SVI. The role of MRI in prostate cancer management has been changing 
with the development of techniques such as endorectal MRI, MR spectroscopic imaging, and PACS data storage 
[6, 10-12, 25, 33, 34]. With a PACS, medical information can be stored, recalled, displayed, manipulated, and printed 
digitally. Use of a PACS simplifi es workfl ow, enhances productivity, and makes information accessible to multiple us-
ers simultaneously. Examination fi ndings digitally stored in a secure computer system can be quickly transmitted to 
Cut Point 1
(1 = No; 2–5 = Yes)
Cut Point 2 (
1, 2 = No; 3–5 = Yes)
Cut Point 3 
(1–3 = No; 4, 5 = Yes)
Cut Point 4 
(1–4 = No; 5 = Yes)
  Reviewer 1
 MRI alone
 Sensitivity 69 38 23 0
 Specifi city 55 81 83 90
 MRI + PACS
 Sensitivity 92 62 46 23
 Specifi city 73 93 93 95
  Reviewer 2
 MRI alone
 Sensitivity 77 62 31 15
 Specifi city 57 84 91 95
 MRI + PACS
 Sensitivity 92 69 54 31
 Specifi city 76 94 95 98
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referring physicians, who in some cases can view the images in their offi  ces via computer. Improvements in patient 
care include shorter hospital stays, decreased waiting times, faster diagnoses, and protection of personal medical 
information. 
Our study showed that in the detection of ECE and SVI, radiologists performed substantially better using MRI with 
PACS cross-referencing than with MRI alone. PACS cross-referencing is particularly helpful in displaying the relation-
ship between the seminal vesicles and the central zone of the prostate (Figs. 2A, 2B, 2C, and 2D). In our study, one 
reviewer benefi ted more from cross-referencing than did the other. This fi nding may relate to inherent diff erences 
in the way people see things. 
One limitation of our study was that cross-referencing immediately followed the initial image review, so conclusions 
made at the initial review were incorporated into the fi nal review. Thus there was almost no way that the reviewers 
could perform worse with cross-referencing than without it. Another limitation was that ECE and SVI were analyzed 
patient by patient but not according to specifi c location (anterior, lateral, posterior or apex, middle, base), so the ECE 
and SVI predicted were not conclusively and specifi cally located. 
The initial sensitivities (43% and 40%) and AUC (0.66-0.69) of the reviewers for ECE in our study were relatively low 
for a major medical center with experienced reviewers [14]. The sensitivities (57% and 59%) and AUCs (0.87 and 0.86) 
after cross-referencing are more in line with expected fi ndings. Both reviewers use the cross-referencing tool when 
routinely interpreting prostate MRI examinations. Therefore it is possible that when they were required not to use 
this tool at initial review, their accuracy suff ered. It is also possible that the results were aff ected by anticipatory bias; 
that is, the radiologists may have expected better results with cross-referencing and held back in their initial inter-
pretations without consciously intending to do so. In addition, the results may have been infl uenced by verifi cation 
bias because the reviewers were aware that all patients had undergone surgical treatment, which was a decision 
infl uenced by initial MRI results. 
The fact that all patients in this study underwent surgery implies that they had relatively low stages of local disease. 
Our study showed that cross-referencing on a PACS improved detection of relatively subtle ECE and SVI in these 
patients. In addition, the use of cross-referencing improved interobserver agreement in the detection of ECE. To sup-
port our fi ndings and in light of the study limitations, we recommend further prospective multicenter confi rmatory 
studies involving more reviewers with more varied experience. 
In summary, our fi ndings suggest that the PACS cross-referencing tool allows radiologists to more accurately inter-
pret MR images of the prostate, signifi cantly improving tumor staging of prostate cancer with MRI. Some reviewers 
benefi t more than others from use of this tool. 
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ABSTRACT 
Objective: The objectives of our study were to evaluate the accuracy of combined endorectal and phased-array 
MRI in detecting pelvic lymph node metastasis (LNM) in patients with prostate cancer and to determine whether 
radiologists’ predictions of LNM improve with the incorporation of Partin nomogram or MRI fi ndings (or both) re-
garding extracapsular extension or seminal vesicle invasion. 
Subjects and Methods: Between May 1999 and September 2003, 411 consecutive patients with clinically localized 
prostate cancer underwent MRI before surgery. Serum prostate-specifi c antigen (PSA) level, Gleason grade, clinical 
stage, greatest percentage of cancer and percentage of positive cores in all biopsy cores, presence of perineural 
invasion on biopsy, and likelihood of LNM based on the Partin tables (2001 version) were recorded. MRI studies 
were interpreted prospectively, but the risks of LNM, extracapsular extension, and seminal vesicle invasion were 
scored retrospectively on the basis of the MRI reports. Surgical pathology constituted the standard of reference. 
The accuracy of LNM prediction was assessed using areas under receiver operating characteristic curves (AUCs) and 
univariate and multivariate logistic regression analyses. For multivariate models, the jackknife method was used for 
bias correction. A p value below 0.05 denoted statistical signifi cance. 
Results: At surgical pathology, LNM was present in 22 (5%) of 411 patients. MRI was an independent statistically sig-
nifi cant predictor of LNM (p = 0.002), with positive and negative predictive values of 50% and 96.36%, respectively. 
On multivariate analysis, prediction of lymph node status using the model that included all MRI variables (extra-
capsular extension, seminal vesicle invasion, and LNM) along with the Partin nomogram results had a signifi cantly 
greater AUC than the univariate model that included only MRI LNM fi ndings (AUC = 0.892 vs 0.633, respectively; p 
< 0.01). 
Conclusion: Incorporation of the Partin nomogram results and MRI fi ndings regarding both extracapsular extension 
and seminal vesicle invasion improves the MR prediction of LNM in patients with prostate cancer. 
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INTRODUCTION
Prostate cancer is the most common cancer and the second leading cause of cancer death in American men. The American Cancer Society estimated that in 2005 in the United States, 232,090 new cases of prostate cancer would be diagnosed and 39,350 men would die of the disease [1]. In a patient with newly diagnosed 
prostate cancer, the presence of lymphatic metastases is an important prognostic factor, indicating great risk for 
progression to established distant metastases and death [2-5]. The risk of metastatic disease at 10 years is 31% ± 
7% (mean ± SD) for patients with negative nodes compared with 83% ± 7% for patients with positive nodes at the 
time of initial treatment. The risk of dying of prostate cancer is 17% ± 6% at 10 years for patients with negative nodes 
compared with 57% ± 11% for patients with positive nodes [4]. Accurate diagnosis of lymph node metastasis (LNM) 
is essential in treatment selection and planning. 
Since the late 1980s, studies have consistently shown that MRI has limited value in the assessment of LNM in patients 
with prostate cancer [6-14] (Table 1). Although MRI provides images with excellent anatomic detail for the evaluation 
of locoregional disease and has high specifi city for LNM, the sensitivity of MRI for the detection of LNM is relatively 
low [15-17]. Furthermore, the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program has 
shown that there has been a dramatic downstaging of prostate cancer at the time of diagnosis [1, 18]. This change 
has made the MRI evaluation of lymph nodes even more diffi  cult. Not only has the incidence of LNM declined 
steeply (in a study by Soh et al. [19], it decreased from 23% in 1984 to 2% in 1995), but cancerous nodes, when pres-
ent, are likely to be smaller [1, 2, 18, 19]. A recent study by Harisinghani et al. [14] showed that high-resolution MRI 
with lymphotropic superparamagnetic nanoparticles allows the detection of small and otherwise undetectable 
LNMs in patients with prostate cancer. Although these results are excellent and promising, the low incidence of LNM 
raises the question of whether lymphotropic superparamagnetic nanoparticles should be used routinely. Although 
the U.S. Food and Drug Administration (FDA) is expected to approve the clinical use of lymphotropic superpara-
magnetic nanoparticles, the question of patient selection remains unanswered. 
In part, the limitations of imaging in the evaluation of LNM in patients with prostate cancer have been off set by the 
development of Partin staging nomograms or tables (available online as supplemental data), which predict the 
fi nal pathologic stage, including the presence of LNM, on the basis of clinical stage, serum prostate-specifi c antigen 
(PSA) level, and Gleason grade [20, 21]. The Partin staging nomograms are a validated predictive instrument widely 
used for patient counseling [22-25]. However, as a treatment planning tool, they are limited by the fact that they do 
not incorporate anatomic data that could assist in interventions aimed to control the disease. 
We undertook this study to investigate the role of combined endorectal and phased-array MRI in nodal metastasis 
detection in a representative sample of the current prostate cancer patient population, with its low incidence of 
LNM. Our goal was to assess the accuracy of MRI in predicting prostate cancer LNM. In addition, we aimed to deter-
mine whether the prediction of LNM improved with the inclusion of MRI fi ndings regarding extracapsular extension 
or seminal vesicle invasion (or both) or with the use of the Partin nomograms. 
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Table 1: Literature Review Summary: Studies That Used Pathologic Correlation to Evaluate the Prediction of Prostate Cancer 
Lymph Node Metastasis (LNM) by MRI 
Note—PPV = positive predictive value, NPV = negative predictive value, LSN = lymphotropic superparamagnetic nanoparticles. 
a Numbers in this column represent patients in each study who had pathologically proven prostate cancer and correlation of lymph node status 
on pathology to MRI fi ndings 
b High-risk patients 
c With LSN 
SUBJECTS AND METHODS 
Patients
Between November 1999 and September 2003, 411 consecutive patients with clinically localized prostate cancer 
underwent MRI before radical retropubic prostatectomy and pelvic lymphadenectomy (Table 2). For all patients, the 
surgery was performed at our institution. The mean patient age was 57.6 years (range, 32-74 years). None of the pa-
tients received neoadjuvant hormonal or radiation therapy before surgery. All patients had tissue diagnosis of pros-
tate cancer on biopsy specimens. The approval of the institutional review board was obtained, and all patients gave 
informed consent. Patient accrual was done as part of an ongoing National Cancer Institute trial, and some of the 
cases have been previously reported in studies on the locoregional evaluation of prostate cancer by MRI [26-28]. 
  Author(s)
  [reference no.]
No. of 
Patientsa
% LNM
Name (location) 
of Institution(s)
Year of 
Study
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%))
Accuracy
(%)
  Bezzi et al. [6] 51
25 
(13 of 51)
University of 
Pennsylvania 
(Philadelphia, PA)
1988 69 (9 of 13) 95 (36 of 38) 88
  Beer et al. [7] 24
Ludwig-
Maximilians-
Universitat (Munchen, 
Germany)
1989 26
  Kier et al. [8] 27
Yale University 
School of Medicine 
(New Haven, CT)
1993 85
  Nicolas et al. [9] 392
Universitats-
Krankenhaus 
(Hamburg-
Eppendorf, Germany)
1994 54.4
  Jager et al. [10] 63
24 
(15 of 63)
University Hospital 
(Nijmegen, 
The Netherlands)
1996 60 (9 of 15) 98 (47 of 48) 90 95.99 89
  Perrotti et al. [11] 56
Albany Medical 
College (Albany, NY)
1996 0 91 0 94 86
  Tuzel et al. [12] 17
0 
(0 of 17)
Dokuz Eylül University, 
School of Medicine 
Inciralti (Izmir, Turkey)
1998 0 93 88.2
  Borley et al.b [13] 42
26 
(11 of 42)
King’s College 
Hospital (London, UK)
2003 27.3 (3 of 11)
  Harisinghani et al.
  c [14]
80
41 
(33 of 80)
Massachusetts General 
Hospital and Harvard 
Medical School (Boston, 
MA) and University 
Medical Center (Nijmegen, 
The Netherlands)
2003
45.4 (MRI); 
100 (MRI 
with LSN)
78.7 (MRI); 
95.7 (MRI 
with LSN)
60 (MRI); 
94.2 (MRI 
with LSN)
67.2 (MRI); 
100 (MRI 
with LSN)
  Current study 
  (Wang et al.)
411
5 
(22 of 411)
Memorial Sloan-Kettering 
Cancer Center 
(New York, NY)
2004 27.27 98.46 50.00 96.36
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Table 2: Distribution of Preoperative Clinical Variables 
Note—PSA = prostate-specifi c antigen. 
a Degree of primary growth + degree of secondary growth 
The following clinical variables were recorded for each patient: clinical stage, pretreatment serum PSA, biopsy Glea-
son sum, greatest percentage of cancer in all biopsy cores, percentage of positive cores in all biopsy cores, and 
presence of perineural invasion. Clinical stage was assigned using the 1992 American Joint Committee on Cancer 
(AJCC) and the Union Internationale Contre le Cancer (UICC) TNM guidelines based on digital rectal examination 
regardless of the results of sonography or other imaging techniques. Serum PSA was measured using a Hybritech 
assay (Hybritech Tandem-R, Beckman Coulter). Central pathologic review was not performed, but all specimens 
were analyzed by dedicated genitourinary pathologists at our institution. 
Combined Endorectal and Phased-Array MRI Data Acquisition and Interpretation
MRI was performed at 1.5 T with state-of-the-art imaging systems (Signa Horizon, GE Healthcare) and pelvic phased-
array and endorectal coils. Images of the pelvis, extending from the pubic symphysis to the level of the aortic bifur-
cation, were obtained. The MR pulse sequences consisted of axial spin-echo T1-weighted images with the following 
parameters: TR/TE, 700/8; slice thickness, 5 mm; interslice gap, 1 mm; fi eld of view, 24 cm; matrix, 256 x 192; and 1 
excitation. Thin-section high-spatial-resolution axial, coronal, and sagittal T2-weighted fast spin-echo images of 
  Variable No. of Patients Mean Range SD %
  Serum PSA 411 7.68 0.74    113.4 8.90
  Gleason gradea
  3 + 2 2 0.49
  3 + 3 262 63.75
  3 + 4 87 21.17
  3 + 5 1 0.24
  4 + 3 27 6.57
  4 + 4 23 5.60
  4 + 4 or 3 + 5 1 1.24
  4 + 5 7 1.70
  5 + 5 1 0.24
  Greatest % of 
  cancer in all biopsy cores
409 0.33 0.01    1 0.2711
  % of positive cores 
  in all biopsy cores
377 0.40 0.04    1 0.2669
  Presence of perineural
  invasion on biopsy
 Positive 54 86.86
 Negative 357 13.14
  Clinical stage
 T1c 237 57.80
 T2a 95 23.17
 T2b 41 10.00
 T2c 37 9.02
 T3, T4, N +, M + 0 0
~  
~  
~  
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the prostate and seminal vesicles were obtained with the following parameters: TR/TE, 5,000/96; echo-train length, 
16; slice thickness, 3 mm; interslice gap, 0 mm; fi eld of view, 14-20 cm; matrix, 256 x 192; and 3 excitations. Axial T2-
weighted images were postprocessed to correct for the reception profi le of the endorectal coil. 
MRI studies were prospectively interpreted by 11 MR body radiologists during their regular clinical assignment to 
the MR service. Each radiologist made his or her determination regarding the presence of LNM based on his or her 
practice pattern and knowledge of previously described MRI features of LNM. As a basic clinical guideline, the radi-
ologists classifi ed lymph nodes on MRI as malignant if the short-axis diameter was elongated and exceeded 10 mm 
or was rounded and exceeded 8 mm, according to the standard accepted criteria [10]. On the basis of the radiolo-
gists’ written reports, a single observer retrospectively and separately scored the probabilities of LNM, extracapsular 
extension, and seminal vesicle invasion using the following rating scale: 5, defi nite yes; 4, probable yes; 3, possible 
yes; 2, probable no; and 1, defi nite no [14]. 
Partin Staging Nomogram
Based on serum PSA, biopsy Gleason grade, and clinical staging, the likelihood of LNM according to the 2001 version 
of the Partin staging nomograms was recorded [21]. 
Histology
The histology reports from the core biopsies were all recorded at our institution and included the following: Glea-
son grade, greatest percentage of cancer in all biopsy cores, percentage of positive cores in all biopsy cores, and 
presence of perineural invasion. Radical prostatectomy specimens were examined as previously described by 
Yossepowitch et al. [29]. Standard template pelvic lymph node dissection was performed, encompassing all nodal 
tissue from the medial inferior margin of the external iliac vein down to the internal iliac and obturator vessels. 
Step-section histopathology fi ndings were used as the standard of reference for extracapsular extension, seminal 
vesicle invasion, and LNM. Surgical margin status, pelvic lymph node status, presence of seminal vesicle invasion, 
and extracapsular extension were recorded. 
Statistical Analysis
Both univariate and multivariate analyses were performed for all clinical and imaging variables to predict LNM. We 
evaluated the area under the receiver operating characteristic (ROC) curve for each variable. A model combining ex-
tracapsular extension and seminal vesicle invasion on MRI with the prediction of nodal disease and a model for the 
addition of the Partin nomogram to MRI were constructed; the areas under the ROC curves (AUCs) were calculated 
and compared [30]. For the multivariate models, the jackknife method, a form of resampling that reduces the opti-
mistic bias, was used to obtain the bias-corrected probabilities and construct the ROC curves. A p value of less than 
0.05 was considered signifi cant. The sensitivity, specifi city, negative predictive value, positive predictive value, and 
accuracy of MRI for the detection of LNM were determined, with positive LNM on MRI defi ned by a score of 3-5. Soft-
ware programs used for data analysis were SAS, version 8.2 (SAS Institute), and S-PLUS, version 2000 (Insightful). 
RESULTS 
On surgical histopathology, positive lymph nodes were found in 22 (5%) of 411 patients. Table 2 summarizes the 
preoperative distribution of the clinical variables, and Table 3 shows the distribution of fi nal pathologic staging [31]. 
Performance characteristics for each variable are listed in Table 4. In the evaluation of LNM, MRI had sensitivity and 
specifi city of 27.27% and 98.46%, respectively, and positive predictive value and negative predictive value of 50% 
and 95.99%, respectively. 
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Table 3: Distribution of Pathologic Staging According to the American Joint Committee on Cancer [31] 
Table 4: Performance Characteristics at Select Cut Points for Predicting Lymph Node Metastasis 
Note—PPV = positive predictive value, NPV = negative predictive value, PSA = prostate-specifi c antigen. 
Univariate analysis (Table 5) showed that all variables were associated with LNM. In the prediction of LNM, the AUC 
for MRI was 0.633. In multivariate analysis, MRI (p = 0.002), Gleason score (p = 0.007), greatest percentage of cancer 
in all biopsy cores (p = 0.007), and PSA (p = 0.004) were signifi cant predictors of LNM (Table 6). 
In the prediction of LNM, each of the multivariate models that incorporated MRI fi ndings regarding extracapsular 
extension and seminal vesicle invasion with MRI LNM fi ndings had a greater AUC than the univariate model that 
included only MRI LNM fi ndings (Fig. 1). The model that included all MRI variables (extracapsular extension, seminal 
vesicle invasion, and LNM) along with the Partin nomogram results had a signifi cantly greater AUC than the univari-
ate model that included only MRI LNM fi ndings (Fig. 1; Table 7: model I vs model A, 0.892 vs 0.633, respectively; p < 
0.01). 
  Final Pathologic Stage No. (%) of Patients
  T1c 2 (0.49)
  T2a 76 (18.49)
  T2b 220 (53.53)
  T2c 1 (0.24)
  T3a 73 (17.76)
  T3b 26 (6.32)
  T4 13 (3.16)
  N1 22 (5.35)
  Preoperative Variable Cut Points Sensitivity (%) Specificity (%) PPV (%) NPV (%)
  Serum PSA 0–10 vs ≥ 10.1 50.00 (11/22) 85.60 (333?389) 16.42 (11/67) 96.80 (333/344)
  Gleason grade
3 + 2, 3 + 3, 
3 + 4 vs 3 + 5, 
4 + 3, 4 + 4, 
4 + 5, 5 + 5
54.55 (12/22) 87.66 (341/389) 20.00 (12/60) 97.15 (341/351)
  Clinical stage T1c vs T2a, b, c 72.73 (16/22) 59.54 (231/388) 9.25 (16/173) 97.47 (231/237)
  Greatest % of cancer in 
  all biopsy scores
0-60 vs ≥ 60 63.64 (14/22) 86.56 (335/387) 21.21 (14/66) 97.67 (285/295)
  % of positive cores in all
  biopsy cores
0-60 vs ≥ 60 54.55 (12/22) 80.28 (285/355) 14.63 (12/82) 96.61 (285/295)
  Presence of perineural
  invasion on biopsy
Positive vs
negative
40.91 (9/22) 88.43 (344/389) 16.67 (9/54) 96.36 (344/357)
  Combined endorectal 
  and phased-array MRI
1–2 vs 3–5 27.27 (6/22) 98.46 (383/389) 50.00 (6/12) 95.99 (383/399)
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Table 5: Preoperative Prediction of Lymph Node Metastasis: Univariate Analysis 
Note—ROC = receiver operating characteristic, PSA = prostate-specifi c antigen. 
Table 6: Preoperative Prediction of Lymph Node Metastasis: Multivariate Analysis 
Note—PSA = prostate-specifi c antigen. 
Fig. 1: Graph shows that each multivariate model had 
greater area under receiver operating characteristic curve 
(AUC) than model A (green) (Table 7), which included 
only MRI fi ndings for lymph node metastasis (LMN). 
Model combining MRI fi ndings for seminal vesicle inva-
sion and LNM (model F) (red) had greater AUC than mod-
el A: 0.714 vs 0.633, respectively (p = 0.08). Model com-
bining MRI fi ndings for extracapsular extension and LNM 
(model G) (blue) had greater AUC than model A: 0.798 vs 
0.633, respectively (p = 0.15). Model combining MRI fi nd-
ings for extracapsular extension, seminal vesicle invasion, 
and LNM (model H) (yellow) had greater AUC than model 
A: 0.813 vs 0.633, respectively (p = 0.11). Model combining 
MRI fi ndings for extracapsular extension, seminal vesicle 
invasion, and LNM and Partin tomogram prediction of 
LNM (model I) (black) had signifi cantly greater AUC than 
model A: 0.892 vs 0.633, respectively (p < 0.01). 
(Color version available in chapter 18).
  Preoperative Variable P Area Under ROC Curve
  Gleason grade < 0.001 0.852
  Greatest percentage of cancer in all biopsy cores < 0.001 0.844
  PSA 0.002 0.699
  % of positive cores in all biopsy cores 0.006 0.688
  Clinical stage 0.005 0.662
  Presence of perineural invasion on biopsy < 0.001 0.647
  Combined endorectal and phased-array MRI < 0.001 0.633
  Preoperative Variable P
  Combined phased-array and endorectal MRI 0.002
  Gleason grade 0.007
  Greatest % of cancer in all biopsy cores 0.007
  % of positive cores in all biopsy cores 0.006
  PSA 0.004
  Presence of perineural invasion on biopsy 0.442
  % of positive cores in all biopsy cores 0.819
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Table 7: Univariate and Multivariate Analyses: Assessing Factors Predicting Lymph Node Metastasis (LNM) 
a Scored on a scale of 1–5 
b 2001 version [21] 
c If the models are multivariate, the area under the curve values are bias-corrected using the jackknife method 
DISCUSSION 
Pretreatment knowledge of prostate cancer LNM is important for patient counseling and appropriate treatment 
selection and planning. The presence of LNMs at the time of prostate cancer diagnosis is associated with a high 
probability of progression after treatment and a poor prognosis [2, 4, 32]. 
Over the years, studies examining the association between a number of clinical variables and the prediction of 
LNM have been performed. The variables studied included serum PSA, Gleason grade, clinical stage, greatest per-
centage of cancer in all biopsy cores, percentage of positive cores in all biopsy cores, and perineural invasion [21, 
 Model Type of Analysis P Area under ROC Curve
  Model A Univariate 0.633
 Probability of LMNa based on MRI report < 0.0001
  Model B Univariate 0.639
 Probability of seminal vesicle invasiona based on MRI report < 0.0001
  Model C Univariate 0.770
 Probability of extracapsular extensiona based on MRI report < 0.0001
  Model D Univariate 0.899
 Probability of LNM according to the Partin nomogramsb < 0.0001
  Model E Multivariate 0.772c
 Probability of extracapsular extensiona based on MRI report 0.0002
 Probability of seminal vesicle invasiona based on MRI report 0.0004
  Model F Multivariate 0.714c
 Probability of seminal vesicle invasiona based on MRI report < 0.0001
 Probability of LMNa based on MRI report 0.0001
  Model G Multivariate 0.798c
 Probability of extracapsular extensiona based on MRI report < 0.0001
 Probability of LMNa based on MRI report 0.0001
  Model H Multivariate 0.813c
 Probability of extracapsular extensiona based on MRI report 0.0012
 Probability of seminal vesicle invasiona based on MRI report 0.0027
 Probability of LMNa based on MRI report 0.0004
  Model I Multivariate 0.892c
 Probability of extracapsular extensiona based on MRI report 0.0239
 Probability of seminal vesicle invasiona based on MRI report 0.0229
 Probability of LMNa based on MRI report 0.0110
 Probability of LNM according to the Partin nomogramsb 0.0005
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33, 34]. Since the introduction of the Partin staging nomograms in 1993, investigators have repeatedly validated 
their capacity to predict LNM of clinically localized prostate cancer [22, 24, 25]. In a study by Cagiannos et al. [2] the 
overall predictive accuracy of the Partin tables as measured by AUC was 0.74, while the AUCs for the three- and four-
variable nomograms developed by Cagiannos et al. were 0.76 and 0.78, respectively [2, 20]. In our study, the Partin 
nomograms-derived probability of LNM had an AUC of 0.899. 
Given the strength of the Partin nomograms, what place, if any, does MRI have in the presurgical evaluation of pros-
tate cancer and in lymph node staging in particular? The routine use of MRI for presurgical evaluation of prostate 
cancer is controversial because the high cost of the test might place a substantial burden on the health care system 
unless its use prevents unnecessary surgery or improves treatment planning and outcomes [35]. MRI has been 
shown to have incremental value in prostate cancer staging and treatment planning [26, 27]. MRI has also shown 
high specifi city for LNM detection; however, the low sensitivity of MRI (0-69%) in detecting LNMs has been an ob-
stacle to its widespread use. Table 1 is a summary of the results of the major studies on the use of MRI for prostate 
cancer LNM staging that have used surgical pathology as the standard of reference [6, 12]. 
The low sensitivity of MRI has been attributed mainly to the inability of cross-sectional imaging to detect metastases 
in normal-sized nodes [13, 14]. This limitation is especially important to consider in deciding when to use MRI in the 
current patient population because the incidence of LNM at diagnosis of prostate cancer has declined steeply and 
nodal metastases, when present, are often within normal-sized nodes. Tables 2 and 3 refl ect the eff ects of prostate 
cancer downstaging on our study population, which was greater than the patient populations of all the other stud-
ies that used surgical pathology as the standard of reference (Table 1). Our overall positive lymph node rate of 5% 
confi rms the decreasing incidence of LNM in prostate cancer patients [1, 2]. Therefore, our study should permit a 
contemporary assessment of the potential role of MRI in the current patient population. 
Our study shows that the sensitivity of MRI for nodal metastases (27.27%) has not improved compared with the 
historical results [6, 12] (Table 1). However, we have also shown that in the prediction of LNM, a model that included 
the Partin nomograms with MRI fi ndings regarding LNM, extracapsular extension, and seminal vesicle invasion had 
a signifi cantly greater AUC (0.892) than a model that included only MRI LNM fi ndings (AUC = 0.633; p < 0.01). 
A study by Harisinghani et al. [14] showed that MRI with lymphotropic superparamagnetic nanoparticles has both 
high sensitivity (100%) and high specifi city (95.7%) in detecting LNM. Although these fi ndings are promising, it 
would be helpful to have a means of determining which patients are most likely to benefi t from the use of nanopar-
ticles, because the incidence of LNM at the time of radical prostatectomy in current studies is only 5% or less [2, 27, 
28, 36]. Our data confi rm that MRI has high negative predictive value for LNM and indicate that a combination of 
endorectal and phased-array MRI with the Partin tables has high accuracy in predicting LNM. Furthermore, MRI pro-
vides anatomic information that is useful for treatment planning. We therefore suggest that combined endorectal 
and phased-array MRI be used in conjunction with the Partin tables in determining whether imaging with lympho-
tropic superparamagnetic nanoparticles is warranted. 
SUMMARY
The combination of Partin nomograms and MRI fi ndings regarding extracapsular extension, seminal vesicle inva-
sion, and LNM off ers high predictive value for LNM. Combined endorectal and phased-array MRI supplemented 
by the Partin nomograms could potentially be used to determine whether additional imaging with lymphotropic 
superparamagnetic nanoparticles is indicated.  
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ABSTRACT
Background: Because the recovery of erectile function and the avoidance of positive surgical margins are important 
but competing outcomes, the decision to preserve or resect a neurovascular bundle (NVB) during radical prostatec-
tomy (RP) should be based on the most accurate information concerning the location and extent of the tumor. In 
the current study, the authors determined the incremental value of endorectal magnetic resonance imaging (eMRI) 
in making this decision.
Methods: eMRI was performed in 135 patients preoperatively. For each NVB, tumor extension to the NVB and the 
need for NVB resection was judged by a surgeon on a scale from 1 (defi nite preservation) to 5 (defi nite resection) 
before and after reviewing eMRI with a radiologist. Histopathologic fi ndings were used as the standard of reference. 
The value of eMRI was assessed using binormal receiver operating characteristic (ROC) analysis adjusted for multiple 
observations per patient, and a mixed eff ects ordinal regression model was used for risk stratifi cation.
Results: Histopathologic examination determined that NVB resection was warranted in 44 of 270 NVBs (16%) be-
cause of posterolateral extracapsular extension (n = 29), positive surgical margins (n = 7), or both (n = 8). The areas 
under the ROC curves (AUC) were 0.741 for pre-MRI and 0.832 for post-MRI surgical planning (P < 0.01). MRI fi ndings 
suggested altering the surgical plan in 39% of NVBs (106 of 270 NVBs). When the surgeon judged that the NVB resec-
tion was defi nitely not necessary (165 NVBs), MRI confi rmed that decision in 138 NVBs (84%); the concordant deci-
sion was correct in 96% of the cases (133 of 138 NVBs). In 36 high-risk patients ( ≥ 75% probability of extracapsular 
extension), MRI fi ndings changed the surgical plan for 28 NVBs (78%); the change was found to be appropriate in 
26 cases (93%).
Conclusions: MRI was found to signifi cantly improve the surgeon’s decision to preserve or resect the NVB during 
radical prostatectomy.
© 2004 American Cancer Society.
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INTRODUCTION
Radical retropubic prostatectomy (RP) provides excellent long-term disease control for patients with clinically localized prostate carcinoma.[1] Erectile dysfunction is one of the possible complications after RP. Recov-ery of erectile function after RP is quantitatively related to the preservation of the neurovascular bundles 
(NVBs).[2] However, prostate carcinoma most commonly arises in the peripheral zone of the prostate, often posteri-
orly, just beneath the capsule. Among patients with extracapsular extension (ECE), the tumor is most often present 
posterolaterally in the region of the NVBs.[3-5] Therefore, if ECE is present in the area of the NVB, preservation of 
an NVB may compromise disease control and result in a positive surgical margin.[4][5] A positive surgical margin 
reportedly increases the probability of disease recurrence.[1][5] Consequently, surgeons often resect widely in areas 
of suspected ECE to avoid a positive surgical margin.[4][6][7] In spite of all precautions, positive surgical margins are 
still present in approximately 23-31% of RP specimens.[4][7]
The presence and location of ECE is diffi  cult to predict from clinical stage, serum prostate-specifi c antigen (PSA) lev-
el, and the biopsy Gleason grade, even when quantitative assessment of the extent of tumor in systematic biopsies 
is considered.[8] Previous studies of endorectal magnetic resonance imaging (eMRI) compared the MRI interpreta-
tions of independent readers with pathologic fi ndings, including seminal vesicle invasion (SVI) and the presence of 
ECE overall and in the area of the NVB.[9-14] To our knowledge, none of these studies has prospectively examined 
the impact of preoperative MRI on the surgical management decision to preserve or resect an NVB during RP. We 
undertook the current prospective study to determine the incremental value of preoperative eMRI on the decision 
to preserve or resect NVBs during RP, using step-section histopathologic fi ndings as the standard of reference.
MATERIALS AND METHODS
 
Study Population
This prospective, single-institution, cross-sectional study was conducted between March 2001 and February 2003. 
A total of 144 consecutive patients with biopsy-proven prostate carcinoma who were scheduled to undergo RP 
based on clinical assessment of the stage of the tumor were referred for eMRI by one of two attending urologists 
(P.T.S. and J.E.). All patients were scheduled to undergo RP before referral for MRI. Scheduling for MRI depended 
on the MRI schedule as well as the availability of the surgeon and radiologist because a joint prospective read-
ing was required prior to surgery. Patients who had previously undergone hormonal therapy, radiation therapy, 
or chemotherapy were excluded from the fi nal analysis. Patients were recruited as part of an ongoing National 
Institutes of Health-funded study of MRI for prostate carcinoma. Our institutional review board approved the study 
and informed consent was obtained from the patients. All patients underwent standard preoperative evaluation for 
prostate carcinoma, including history, physical examination, digital rectal examination (DRE), measurement of the 
serum PSA level, and sextant biopsy. Clinical stage was assigned using the 1992 International Union Against Cancer 
(UICC) TNM staging system.[15]
Of the 144 patients referred for eMRI, 135 fulfi lled the study inclusion criteria. Nine patients were excluded from the 
fi nal analysis because of presurgical hormonal treatment (six patients), radiation therapy (one patient), or combined 
chemotherapy and radiation therapy (two patients). Table 1 lists the clinical fi ndings of the 135 patients included in 
the data analysis. The median age of the patients was 58 years (range, 40-73 years). The median PSA level was 5.78 
ng/mL (mean, 6.17 ng/mL; range, 1.06-76.84 ng/mL). Sextant biopsy of the prostate was performed at the study in-
stitution (n = 28 patients) or at an outside institution (n = 107 patients). A single pathologist at the study institution 
center reviewed all biopsy specimens. The median interval from biopsy to MRI was 8 weeks (range, 1.4-84 weeks). 
The median interval between MRI and radical prostatectomy was 6.3 weeks (range, 0.1-29 weeks). 
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Table 1
MRI Technique
MRI was performed on a 1.5-Tesla whole body MR scanner (Signa®; GE Medical Systems, Milwaukee, WI). Patients 
were examined in the supine position, using the body coil for excitation and a pelvic-phased array coil (GE Medical 
Systems) in combination with a commercially available balloon-covered expandable endorectal coil (Medrad Inc., 
Pittsburgh, PA) for signal reception. T1-weighted, axial spin-echo images (Repetition Time/Echo Time [TR/TE] = 
700/8 milliseconds [msec], slice thickness of 5 mm, interslice gap of 1 mm, fi eld of view [FOV] of 24 cm, matrix of 256 
?192, frequency direction transverse, 1 excitation) were obtained from the aortic bifurcation to the symphysis pubis, 
and T2-weighted axial and coronal fast spin-echo images (TR/eff ective/TE = 5000/96 msec, echo train length of 16, 
slice thickness of 3 mm, interslice gap of 0 mm, FOV of 14 cm, matrix of 256 ?192, frequency direction anteroposterior, 
3 excitations) were obtained through the prostate and seminal vesicles. All MR images of each patient in the current 
study were reviewed by one of two independent readers (H.H. and F.V.C.).
MRI Interpretation
MRI interpretation included analysis of tumor location and evaluation of tumor ECE in the region of the NVB (pos-
terolateral). In addition, the image was evaluated for the presence of any ECE, SVI, or lymph node metastasis. Tumor 
was identifi ed on T2-weighted imaging when there was a nodular, mass-like area of low signal intensity. The fi nd-
ings used to diagnose ECE on eMRI have been described previously and include: 1) an irregular bulge of the gland 
margin, 2) a contour deformity with a stepoff  or angulated margin, 3) a breech of the capsule with direct tumor 
extension, 4) the obliteration of the rectoprostatic angle, and 5) asymmetry and/or tumor envelopment of the 
NVBs.[10-14] Both readers used the same MR criteria. The MRI likelihood for ECE was scored on a scale of 1 to 5 as 
follows: 1: no ECE; 2: probably no ECE; 3: possible ECE; 4: probable ECE; and 5: defi nite ECE. Only a single reading 
was performed for each patient. The choice of the MRI reader was determined by the availability of the radiologist 
at the time of interpretation. Although the readers diff ered with regard to years of experience, both had read > 500 
eMRIs of the prostate.
Determination of Pre-MRI and Post-MRI Surgical Plans
A data sheet was prepared for each patient by one of two independent coauthors (L.W. and D.C.W.) not involved in 
the image interpretation or clinical decision making. The data presented were DRE fi ndings, serum PSA level, and 
sextant biopsy results (including Gleason primary and secondary grade, tumor location, percentage of positive bi-
A. Distribution of Age, PSA Level, and Probability that the Tumor is Confi ned to the Prostate Pathologically
PSA (ng/mL)
Percent probability organ-confined tumor 
based on the staging nomogram of Partin 
staging nomogram[16][17] 
Age
(yrs)
< 4 4-10 > 10 ≤ 25 > 25 & < 75 ≥ 75
  No. of 
  patients 
  (n = 135)
23 95 17 18 93 24
  Median 58 2.99 5.78 12.71 22 63 77
  Range 40-73 1.06-3.82 4.05-9.67 10.20-76.84 6-25 27-67 77-78
B. Distribution of Clinical Stage (2002 TNM Classification) and Gleason Grade 
(Primary plus Secondary) on Each Side of the Prostate
Clinical stage (by side) Gleason grade (by side) 
T0 T1c T2a T2b T2c T3a 0 3+3 4+4 3+5 4+3 4+4 4+5
  No. of patients 18 190 30 15 14 3 81 129 31 1 10 13 5
  Percent 7% 70% 11% 6% 5% 1% 30% 47.7% 11.5% 0.4% 3.7% 4.8% 1.9%
  PSA: prostate-specific antigen.
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opsy cores, and the percentage of tumor-involved core tissue). Published Partin tables (2001 version)[16] were used 
to estimate (based on the preoperative stage, Gleason grade, and PSA level) the probability that the tumor was 
histopathologically confi ned to the prostate gland ( organ-confi ned ).[16][17] Using all available clinical information, 
the attending urologist formulated a surgical plan for each NVB on a scale from 1 (defi nite preservation) to 5 (defi -
nite resection), designated the  pre-MRI  plan. The attending urologist then reviewed the MR images in consultation 
with an attending radiologist and formulated the  post-MRI  surgical plan on the same 5-point scale. Therefore, the 
post-MRI plan was based on a combination of the clinical and MRI fi ndings. Intraoperative management was guided 
by the post-MRI plan, occasionally modifi ed by intraoperative fi ndings.
RP and Histologic Evaluation
RP was performed as previously described,[18] with nerve-sparing (n = 223 patients), partial nerve resection 
(n = 7 patients), or complete nerve resection (n = 40 patients). Once the prostate was removed, the specimen was 
coated with India ink (the right and left sides were inked in 2 colors) and fi xed in 10% buff ered formaldehyde.[19] 
The apical prostate was truncated and axial step-sections were obtained at 3-4-mm intervals in a plane perpendicu-
lar to the long axis of the prostate. The presence of tumor cells beyond the capsular margin defi ned ECE.
Standard of Reference
The standard of reference for the incremental value of MRI was based on histopathologic fi ndings from the surgical 
specimen. Regardless of the actual surgery performed, the  optimal  (appropriate) surgical plan was determined 
based on histopathologic fi ndings of ECE or positive surgical margins in the region of the NVB, posterolateral to 
the prostate. For each NVB, preservation was considered appropriate if the tumor did not extend outside the cap-
sule in the posterolateral region of the prostate and the adjacent surgical margin was negative. NVB resection was 
considered appropriate if there was ECE or if there was a positive surgical margin in the posterolateral region of the 
prostate.
Statistical Analysis
A total of 270 NVBs were evaluated in 135 patients. The eff ect of eMRI on NVB management was examined for the 
frequency and the appropriateness of change between the pre-MRI and post-MRI surgical plans. The surgical plan 
was recorded as more conservative or more aggressive according to whether it included NVB preservation or NVB 
resection, respectively. To compare the accuracy of the surgeon’s pre-MRI and post-MRI judgments, we used a re-
ceiver operating characteristic (ROC) curve approach. Specifi cally, we estimated the parameters of the ROC curves 
using a latent variable binormal model. The model included a random eff ect to account for the two observations 
per patient, right and left NVBs, both pre-MRI and post-MRI. Model estimates were obtained using maximum likeli-
hood and the accuracy of pre-MRI and post-MRI were compared using a likelihood ratio test.[20]
To investigate whether MRI provided a benefi t for both high-risk and low-risk patients, the Partin nomogram score 
was used as a continuous variable and the nomogram-MRI interaction was used as covariate in the ordinal regres-
sion model. To better visualize the results of the risk-group analysis we created low-risk and high-risk groups. If a 
patient’s chance of having organ-confi ned disease was > 75% as predicted by the published tables,[16] he was 
classifi ed as being at low risk; if the patient had a < 75% chance of having organ-confi ned disease, he was classifi ed 
as high risk. To assess the management change, we furthermore dichotomized the pre-MRI and post-MRI ratings as 
negative (1, 2, or 3) or positive (4 or 5).
Because Partin staging nomograms are not universally used, we performed an additional analysis using a simplifi ed, 
clinically defi ned, low-risk group (PSA level < 10 ng/ML, Gleason grade of 6, and clinical T1c or T2a disease). Further-
more, because the percentage of positive biopsy cores is often used as an indicator for NVB resection, correlation of 
the percentage of positive biopsy cores with the incremental value of MRI was performed as well.
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RESULTS 
Based on the histopathologic fi ndings, NVB resection was considered the appropriate surgery for 44 of 270 NVB 
sides (16%) because of posterolateral ECE (n = 29), positive surgical margins (n = 7), or both (n = 8). Overall, 32 pa-
tients had ECE; in 7 of these patients (22%) the ECE was located only anteriorly or anterolaterally and away from the 
NVB and therefore did not warrant NVB resection.
The post-MRI surgical plan, including the decision to preserve or resect the NVB, agreed with the pre-MRI clinical 
surgical plan for 164 of 270 NVBs (61%). The surgeon judged that NVB resection was defi nitely not necessary in 165 
NVBs and the eMRI confi rmed that decision in 138 NVBs (84%). Of the 138 NVB sites in which the clinical decision 
concurred with the post-MRI decision not to resect an NVB, the decisions were correct for 133 of the sites (96%). MRI 
fi ndings suggested a change in the surgical plan for 106 of 270 NVBs (39%). Thirty-nine NVBs had a more conserva-
tive surgical plan post-MRI; in 35 cases (90%), this change was appropriate. Overall, 67 NVBs had a more aggressive 
surgical plan post-MRI; in 45 cases (67%), this change was appropriate. Table 2 compares the pre-MRI and post-MRI 
surgical plans and shows the infl uence of MRI fi ndings and its appropriateness. Two representative cases are il-
lustrated in Figures 1 and 2. Table 3 lists the incremental eff ect of MRI stratifi ed by the likelihood of extraprostatic 
disease from published staging tables.[16][17] For patients with a high probability of extraprostatic disease (prob-
ability of organ-confi ned disease of  25%), MRI changed the NVB management in 28 of 36 sites (78%); in 26 of these 
28 sites (93%), the change was appropriate. In one patient, MRI suggested unilateral ECE with the involvement of 
NVB, prompting the more aggressive post-MRI surgical plan. At the time of surgery, no ECE was found in this patient, 
although there was extensive neural invasion within the prostate and a moderate-volume tumor (Fig. 3). 
Table 2. Pre-MRI and Post-MRI Surgical Plans According to the Surgeon’s Intended Probability of Preserving (1) or Resecting (5) 
the Ipsilateral NVB
MRI: magnetic resonance imaging; NVB: neurovascular bundle; NA: not applicable.
a Postmagnetic resonance imaging surgical plans were stratifi ed as  no change,   more conservative,  or  more aggressive  surgical approaches.
b When the surgeon judged that neurovascular bundle resection was defi nitely necessary (in 2 neurovascular bundles), the postmagnetic reso-
nance imaging plan confi rmed that decision as appropriate in 2 neurovascular bundles (100%)
 
Pre-MRI plan
Post-MRI plana
No change More conservative More aggressive
  NVB Score No. of  NVB No. of NVB Appropriate No. of NVB Appropriate No. of NVB Appropriate
  Preserve
1 165 138 133 NA NA 27 22
2 55 16 14 19 17 20 3
3 25 7 7 11 10 7 7
4 23 1 1 9 8 13 13
  Resect 5 2 2b 2 0 0 0 0
270 164 157 (96%) 39 35 (90%) 67 45 (67%)
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Table 3. Appropriateness of Changes in the Post-MRI Surgical Plans Grouped According to the Preoperative Probability that the 
Tumor Was Confi ned to the Prostate Pathologically[16][17]
Percent 
probability 
of organ-confined 
tumor
No change post-
MRI plan
More 
conservative 
post-MRI plan
More 
aggressive 
post-MRI plan
Appropriate 
post-MRI 
altered 
surgical 
plans
  Probability No. of NVB No. of NVB Appropriate No. of NVB Appropriate No. of NV Appropriate No. of NVB (%)
  > 75% 47 38 37 0 0 9 6 6/9 (67%)
  51-74% 127 91 86 11 9 25 13 22/36 (61%)
  26-50% 60 27 26 16 16 17 10 26/32 (81%)
  < 25% 36 8 8 12 10 16 16 26/28 (93%)
  Totals 266 162 155 39 35 65 45 80/104 (77%)
  MRI: magnetic resonance imaging; NVB: neurovascular bundles.
Figure 1. Case 1. Clinical stage T2a prostate carcinoma with a Glea-
son score of 7 in a 61-year-old patient with a prostate-specifi c antigen 
(PSA) level of 5.4 ng/mL. The premagnetic resonance imaging (pre-
MRI) surgical plan indicated probable preservation of the left neu-
rovascular bundle (NVB) (a score of 2 of 5, where 1 indicated defi nite 
preservation of the NVB and 5 indicated defi nite resection of the NVB) 
and probable resection of the right NVB (a score of 4 of 5). (A) An axial 
T2-weighted MRI image showed a large low-signal intensity tumor (T) 
in the left peripheral zone; there was obliteration of the rectoprostatic 
angle (arrowhead) and asymmetry of the NVB (arrow); both fi ndings 
indicate extracapsular extension (ECE) (MRI score of 5). No tumor was 
noted in the right peripheral zone. As a result, the surgical plan was 
changed and was more aggressive on the left NVB (changing from 2 
to 5) and less aggressive on the right NVB (changing from 4 to 1). (B) A 
corresponding histopathologic step-section map demonstrated es-
tablished ECE at the left posterior (base); all surgical margins were free 
of tumor. MRI fi ndings appropriately changed the clinical impression 
of the urologist and the surgical plan for the left and right NVB.
(Color version available in chapter 18).
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ROC curves for pre-MRI and post-MRI surgical plans are plotted in Figure 4. The area under the curve (AUC) was 0.741 
for pre-MRI and 0.832 for post-MRI. The diff erence between the two curves was found to be statistically signifi cant 
(P < 0.01), suggesting that MRI substantially improves the accuracy of the surgeon’s judgment with regard to the 
appropriateness of preserving or resecting NVBs. 
Table 4. Changes in the Post-MRI Surgical Plans Grouped According to the Preoperative Probability that the Tumor was Confi ned 
to the Prostate Pathologically as Defi ned by a PSA Level < 10 ng/mL, a Gleason Score < 6, and T1c or T2a Disease
MRI: magnetic resonance imaging; PSA: prostate-specific antigen; AUC: area under the curve.
  Risk category Pre-MRI AUC Post-MRI AUC
  Low 0.647 0.647
  High 0.783 0.983
  All 0.741 0.832
Figure 2. Case 2. Clinical stage T1c prostate carcinoma with a 
Gleason score of 9 in a 60-year-old patient with a prostate-specif-
ic antigen (PSA) level of 8.45 ng/mL. The premagnetic resonance 
imaging (pre-MRI) surgical plan indicated probable preservation 
of the right neurovascular bundle (NVB) (a score of 2 of 5, where 
1 indicated defi nite preservation of the NVB and 5 indicated defi -
nite resection of the NVB) and possible resection of the left NVB 
(a score of 3 of 5). (A) An axial T2-weighted MRI image showed a 
large low-signal intensity tumor (T) in the right peripheral zone. 
The contour of the gland was angulated and there was direct 
tumor extracapsular extension (ECE) (arrowheads), and envelop-
ment of the right NVB (arrow); fi ndings indicated right-sided ECE 
(MRI score of 5). There was no MRI evidence of left-sided ECE. As 
a result, the surgical plan was altered and was more aggressive 
with regard to the right NVB (changing from 2 to 5). The surgical 
plan for the left NVB remained unchanged. (B) A corresponding 
histopathologic step-section map showed established, poste-
rior, right-sided ECE. In this case, aggressive management of the 
right NVB was appropriate.
(Color version available in chapter 18).
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In the ordinal regression model, MRI retained its signifi cance (P < 0.01) and the nomogram also was found to be sig-
nifi cant (P < 0.01). The nomogram-MRI interaction had a negative sign, suggesting that the benefi t of MRI dissipates 
as the probability of having organ-confi ned disease increases, implying less benefi t for low-risk patients, although 
this fi nding did not reach statistical signifi cance (P = 0.08).
The analysis using a clinically defi ned low-risk group (PSA level < 10 ng/mL, a Gleason grade of 6, and clinical stage 
T1c or T2a disease) confi rmed the Partin staging nomogram analysis.[16][17] and showed that, for low-risk patients, 
the incremental value of MRI in the decision to change the surgical approach is minimal (Table 4). Similarly, when 
the data were dichotomized for the percentage of positive biopsy cores at 25% (observed median), MRI was found 
to have a greater incremental value for the high-risk group of patients (Table 5). 
 
Figure 3. Case 3. Clinical stage T1c prostate carcinoma with a 
Gleason score of 6 in a 55-year-old patient with a prostate-specif-
ic antigen (PSA) level of 6.31 ng/mL. The promagnetic resonance 
imaging (pre-MRI) surgical plan indicated defi nite preservation 
of both neurovascular bundles (NVBs) (a score of 1 of 5 for both, 
where 1 indicated defi nite preservation of the NVB and 5 indi-
cated defi nite resection of the NVB). (A) An axial T2-weighted 
MRI image demonstrated a focal low-signal intensity tumor (T) 
in the right peripheral zone. The tumor extended to the capsular 
margin in the region of the right NVB (arrow). Because the tumor 
abutted the right NVB, early extracapsular extension (ECE) could 
not be excluded (MRI score of 3). Consequently, the surgical plan 
was changed and was more aggressive with regard to the right 
NVB (changing from 1 to 3). MRI showed no tumor on the left. 
Thus, the surgical plan for the left NVB remained unchanged. (B) 
A corresponding histopathologic step-section map revealed no 
ECE and all surgical margins were free of tumor. In this case, MRI 
fi ndings inappropriately changed the surgical plan of the urolo-
gist with regard to the right NVB but confi rmed the decision to 
preserve the left NVB.
(Color version available in chapter 18).
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Table 5. Appropriateness of Changes in the Post-MRI Surgical Plans Grouped According to the Preoperative Probability that the 
Tumor Was Confi ned to the Prostate Pathologically as Dichotomized at 25% (Observed Median) for the Percentage of Positive 
Biopsy Cores
MRI: magnetic resonance imaging; AUC: area under the curve.
Analysis of the management change (no resection [score of 1-3] to resection [score of 4-5]) in the post-MRI surgical 
plan is presented in Table 6. The management change was initiated in 32 NVBs, and was found to be appropriate in 
29. Although the overall impact of MRI was found to be signifi cant, the benefi t was greatest in high-risk patients. In 
24 high-risk patients, the pre-MRI and post-MRI plans disagreed; in 22 of these patients, the post-MRI classifi cation 
was correct. These results indicate that adding MRI was useful for patients who had a low probability of organ-con-
fi ned disease. 
 
  Category Pre-MRI AUC Post-MRI AUC
  <0.25 0.736 0.695
  >0.25 0.742 0.925
  All 0.741 0.832
Figure 4. Graphic representation of the accuracy of the 
premagnetic resonance imaging (pre-MRI) and postmag-
netic resonance imaging (post-MRI) surgical plans using 
receiver operating characteristic (ROC) analysis. Solid line: 
pre-MRI (area under the curve = 0.741); dotted line: post-MRI 
(area under the curve = 0.832).
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Table 6. Summary of the Impact of MRI on Surgical Management
MRI: magnetic resonance imaging; NVBS: neurovascular bundles.
DISCUSSION
The role of eMRI in the staging of and surgical planning for prostate carcinoma continues to provoke controver-
sy.[18][21] A large multiinstitutional trial published in 1990 suggested that the accuracy of MRI for detecting ECE 
or SVI was low.[22] However, in the last decade MRI has improved considerably with technologic refi nements and 
increased reader experience.[9] Among other technologic improvements, and pertinent to the evaluation of the 
prostate gland, was the introduction of eMRI. eMRI technology provides a more detailed anatomic image of the 
prostate compared with body coil MRI technology.[10][23] The MRI data obtained in the late 1980s used MRI tech-
nology that is now obsolete; therefore, the data are not representative of current state-of-the-art imaging capabili-
ties. Furthermore, the 1990 multicenter study as well as most of the subsequent MRI studies focused on imaging 
pathologic correlation and MRI technology assessment.[9-11][21] We are unaware of any studies investigating the 
eff ect of preoperative eMRI on surgical management. However, the prognostic ability of preoperative MRI has been 
reported recently.[21][23-27] In a retrospective study of 1025 patients undergoing RP, T-stage classifi cation by MRI 
was found to be an additional independent predictor of postoperative PSA failure (P < 0.001) for patients at interme-
diate and high risk.[24] Although the study had a diff erent endpoint from the current report, it is interesting to note 
that both studies suggest that MRI is more helpful in patients with unfavorable prognostic features.
The results of the current study suggest two important management benefi ts of eMRI prior to RP: improved surgi-
cal planning in high-risk patients and the provision of appropriate reassurance for preserving NVB in other patients. 
In the current study, we used the 2001 version of the Partin staging tables[16][17] for risk stratifi cation because it is 
a validated predictive instrument that is widely used for patient counseling.[28][29] Patients with a probability of 
organ-confi ned tumor of  25% were considered to be high risk in the current study. MRI fi ndings changed the surgi-
cal plan in 78% of these high-risk patients; in 93% of these cases, the changes were appropriate. Despite the high 
clinical probability of extraprostatic disease in these patients, MRI correctly favored NVB preservation in 10 of 12 
NVBs (83%). In low-risk and intermediate-risk groups, MRI helped to provide appropriate reassurance in those cases 
in which NVB preservation was favored on the pre-MRI surgical plan. Overall, the strength of MRI for low-risk and 
intermediate-risk patients lies in a high negative predictive value (i.e., demonstration of the absence of tumor in the 
region of interest). In the high-risk group, MRI has incremental value in the clinical assessment additive to the Partin 
staging nomogram[16][17] a simplifi ed clinical risk stratifi cation (using PSA level, Gleason grade, and clinical disease 
stage), or the percentage of positive biopsy cores.
Limitations
The current study has several limitations. First, the study design and results are based on personal consultation be-
tween experienced urologists and radiologists, all of whom were aware of the clinical fi ndings, such as the location 
and percentage of positive biopsy cores and the percentage of tumor-involved core tissue. This multidisciplinary 
Pre-MRI plan Post-MRI plan No. of NVBs Appropriate
MRI affected surgical management 1, 2, 3 4, 5 15 14 (93%)
3, 4, 5 1, 2 17 15 (88%)
Overall 32 29 (91%)
MRI change in score did not affect management 1 2 18
2 1 19
4 5 13
5 4 0
1, 2 3 21
4, 5 3 3
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approach should optimize the interpretation of MRI fi ndings and allow an optimal assessment of the incremental 
eff ect of MRI; however, it might not be representative of widespread daily clinical practice. Second, refl ective of cur-
rent surgical practice, a high percentage of patients had favorable pathologic results. With such a small prior prob-
ability, and therefore a small number of patients who required NVB resection, statistical validation of incremental 
change was diffi  cult to ascertain and will require further analysis.
SUMMARY
eMRI prior to RP was found to improve the validity of the surgical decision to preserve or resect the NVB. Thus, 
preoperative eMRI can provide additional, critical information that allows treatment to be adjusted to an optimal, 
patient-specifi c therapy.
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ABSTRACT 
Purpose: We investigated whether the addition of MRI fi ndings to the pre-operative nomogram for predicting free-
dom from recurrence of prostate cancer would improve its predictive accuracy. Due to time constraints, comparison 
to actual biochemical recurrence events was not feasible. Instead, comparison was performed against a post-opera-
tive nomogram that predicts freedom from biochemical recurrence based on pathologic variables.
Methods: This study involved 592 consecutive patients with biopsy-proven prostate cancer who underwent MRI 
before radical prostatectomy. Pre-operative MRI reports were retrospectively reviewed and scores were assigned for 
the probability of biochemical recurrence on an arbitrary 7-point scoring system (scores increased with predicted 
pathologic stage). The MRI scoring system was combined with the Kattan pre-operative nomogram and linear 
regression analysis was performed to evaluate the combined model against the Kattan post-operative nomogram 
in predicting 10-year freedom from biochemical recurrence.
Results: Median follow-up was 22 months. Fifty-two (9%) patients experienced biochemical recurrence. The addi-
tion of MRI scores to the pre-operative nomogram signifi cantly improved the R-square value of the pre-operative 
nomogram in the total study cohort (0.58 vs. 0.53; p<0.01) and in a subset of patients (PSA≥10, Gleason score ≥7 on 
biopsy or clinical stage T2) at high risk for biochemical recurrence (0.61. vs. 0.58; p<0.01). 
Conclusion: The addition of MRI fi ndings, when converted into a scoring system, signifi cantly improves the accuracy 
of the Kattan pre-operative nomogram in predicting postoperatively determined recurrence-free probabilities. Fur-
ther work is required to give weighted values to the scoring system, and time is needed to allow comparison with 
actual events.
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INTRODUCTION
Optimal management of prostate cancer remains elusive. From diagnosis through staging, treatment plan-ning and follow-up, there is a need to maximize information.  A patient newly diagnosed with prostate cancer faces a number of treatment options. Predictions of their respective outcomes based on known 
factors can help both clinician and patient in choosing between them. To aid in patient counselling, pre-opera-
tive nomograms have been developed that give a prediction of the fi nal pathologic stage and an estimate of the 
chances of freedom from disease recurrence after radical prostatectomy (RP). Predictors have been limited to PSA, 
clinical stage, Gleason grade and quantitative assessment of cancer in core biopsies. 
Endorectal magnetic resonance imaging has been reported to improve detection of extracapsular extension 
(ECE),[1] seminal vesicle invasion (SVI)[2] and lymph node metastasis (LNM)[3] compared to  standard clinical vari-
ables alone. Although the National  Comprehensive Cancer Network recommends MRI for patients with clinical 
stage T3 or T4 or a nomogram risk of LNM greater than 20%,[4] it has been shown that MRI can assist in treatment 
planning[5-7] and prediction of pathologic stage for all patients with clinically localized prostate cancer.[8] The 
purpose of our study was to test the hypothesis that the addition of MRI fi ndings to an established preoperative 
nomogram would improve noninvasive prediction of freedom from biochemical recurrence.  
The gold standard for the accuracy of MRI in predicting pathologic stage is the surgical specimen. Biochemical 
recurrence of cancer is time dependent, and maturation of a dataset is required for enough events to occur for valid 
statistical analysis. In the Johns Hopkins series of 2404 men treated with RP, with a mean follow-up of 6.3 years, the 
overall actuarial recurrence-free rates at 5, 10 and 15 years were 84%, 74% and 66%, respectively.[9] 
As MRI has only recently begun to be used more freely, it would take many years for our cohort of patients to develop 
enough recurrence events to demonstrate whether the addition of MRI to the pre-operative nomogram improves 
its ability to predict recurrence. Therefore, in the present study, the “gold standard” we used for comparison was 
the predicted probability of freedom from biochemical recurrence calculated from the post-operative nomogram, 
which, given its use of pathologic variables, is more accurate than the pre-operative nomogram.[10]
 
METHODS
Patient Selection
This is a study of 592 consecutive patients with biopsy-proven prostate cancer who were referred for endorectal 
MRI prior to RP between January 2000 and October 2004. For all patients undergoing RP at our institution, clinical 
and pathologic data are prospectively entered into a computerized database. Institutional Review Board approval 
was granted for retrospective analysis of the data in this study. Clinical stage was assigned preoperatively according 
to the 2002 International Union Against Cancer TNM staging system. Patients who received neoadjuvant hormonal 
therapy, neoadjuvant chemotherapy, or prior radiation treatment to the pelvis were excluded from the analysis. Fol-
low-up included measurement of serum PSA and digital rectal examination every 3 months for the fi rst year after 
surgery, at 6-month intervals for the next 4 years, and annually thereafter. Cancer recurrence was defi ned as a serum 
PSA ≥ 0.2ng/ml and rising, clinical local or distant disease, or secondary therapy commenced at least 3 months after 
RP.
Needle biopsy specimens
All prostate biopsies were obtained using transrectal ultrasound guidance and were reviewed by dedicated uro-
pathologists. Each core containing cancer was assigned a primary and secondary Gleason grade. Patients referred 
from outside institutions had a review of their prostate biopsies and assignment of Gleason grade by an MSKCC 
pathologist. An overall Gleason score was given to each case by identifying the core with the highest Gleason score. 
The total number of cores obtained, the number of cores containing cancer, and the percentage of cancer in the 
cores were recorded.
Radical prostatectomy specimens
Whole-mount sections of prostate were prepared as previously described.[11] The location and extent of invasive 
tumors were identifi ed and precisely mapped in each section. Overall Gleason score was defi ned by the Gleason 
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score of the tumor with the highest Gleason score. Pathologic parameters recorded included the presence or ab-
sence of ECE, SVI, and LNM. The level of extension was recorded routinely as none, invasion into the capsule, focal 
extracapsular extension, or established extracapsular extension, with the latter two defi ning ECE. An organ-con-
fi ned tumor was defi ned as a tumor with no evidence of ECE, SVI, or LNM. The presence of tumor cells at the inked 
resection level was considered a positive surgical margin.
Endorectal MRI
Endorectal MRI was performed on a 1.5 Tesla whole-body magnetic resonance scanner (Signa Horizon scanner, 
General Electric Medical Systems, Milwaukee, WI). Patients were examined using a previously described protocol.1 
Pre-operative endorectal MRI reports from medical records were retrospectively reviewed by a radiologist (LW), 
who knew that all patients had been diagnosed with prostate cancer and treated with RP but was unaware of other 
clinical data or outcomes. An arbitrary 7-point scoring system was developed to predict the probability of biochem-
ical recurrence based on the MRI reports. The higher the score, the greater the probability of recurrence predicted. 
A score was retrospectively assigned for each MR report. The 7-point scoring system based on the TNM system was 
1. no tumor seen; 2. tumor seen, no ECE; 3. tumor seen, ECE cannot be ruled out; 4. unilateral ECE; 5. bilateral ECE; 6. 
SVI; 7. LNM. When multiple positive fi ndings on MRI were seen, the highest applicable score was assigned. 
Nomogram predictions
The pre-operative variables (PSA, clinical stage, biopsy Gleason score and biopsy core information) were used to 
determine the 10-year progression-free probabilities in each case using the Kattan pre-operative nomogram.[12] 
Similarly, post-operative variables (pre-treatment PSA, Gleason score, level of prostate capsular invasion, SVI, LNM 
and positive surgical margins) were used in the updated Kattan post-operative nomogram10 to calculate the 10-
year progression-free probabilities.
Statistical Analysis
Linear regression analysis was performed to assess the association between the predictors, the pre-operative no-
mogram with and without the addition of the MRI scores, and the post-operative nomogram.  Restricted cubic 
spline function was used on the predictor pre-operative nomogram. In addition to the signifi cance level of each 
variable, model r-squares were calculated. When the pre-operative nomogram was combined with the MRI scoring 
system in the model, bootstrapping with 200 resamples was used to calculate bias-corrected estimates of r-square. 
P < 0.05 was considered signifi cant. Software program S-Plus, version 2000, Insightful, Seattle, was used for data 
analysis.
 
RESULTS
The distribution of MRI scores predicting the probability of biochemical recurrence is shown in Table 1. The vast 
majority of cases, 417 (70%), were given a score of 2, signifying an MRI report of an organ-confi ned tumor. Including 
those patients in whom ECE could not be excluded, 81% (480) were considered organ-confi ned with MRI scores 
from 1 to 3. ECE, both unilateral and bilateral, was predicted in 94 (16%) cases, while SVI was predicted in 12 (2%) 
cases and LNM in 6 (1%) cases.
Comparison of the MRI scores with the pathologic stage showed that 86% (359/417) of patients with scores of either 
1 (no tumor seen) or 2 (tumor seen, no ECE) had no ECE. Of the patients with score 3 (ECE cannot be ruled out), 81% 
(50/62) had no ECE. Of the 94 patients predicted to have either unilateral ECE (score 4) or bilateral ECE (score 5), 77 
(82%) had pathological evidence of ECE. Of the 12 patients with score 6 (SVI), 11 (92%) had SVI, whereas LNM was 
present in only 3 of 6 predicted cases. Tests for sensitivity and specifi city were not calculated, as negative predic-
tions were not included in this model. 
Biochemical recurrence occurred in 52 (9%) patients and the median follow-up for those patients with no evidence 
of recurrence was 22 months. While only 9% of the cohort has experienced biochemical recurrence to date, the 
incidence of recurrence increased as the MRI scores increased: score 1, 0%; score 2, 5%; score 3, 10%; score 4, 15%; 
score 5, 22%; score 6, 58%; score 7, 67% (Table 1). 
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Using the post-operative nomogram results for freedom from recurrence as the endpoint to be predicted pre-
operatively, we found that prediction was signifi cantly better when the MRI scores were combined with the pre-
operative nomogram in a single model than when prediction was based on either the MRI scores or the preopera-
tive nomogram alone (Table 2). For the 10-year model to predict freedom from recurrence, the R-square values for 
the pre-operative nomogram and MRI scoring system were 0.53 and 0.28, respectively. Combination of these two 
models resulted in a signifi cant increase in the R-square value to 0.58 (p<0.01). 
We performed the same analysis on those patients who had specifi c pre-operative variables and were con-
sidered to be at higher risk of recurrence. These patients had Gleason score ≥ 7 on biopsy, clinical stage T2, or 
PSA ≥ 10, comprising 66% of the total study cohort. Similarly to the analysis for the entire cohort, the analy-
sis for this group of high-risk patients showed that the addition of the MRI scores to the pre-operative nomo-
gram resulted in a signifi cant increase in the R-square values for the 10-year prediction model, from 0.58 to 0.61
(p < 0.01) (Table 3).
  MRI Score Description Distribution Actual Recurrence
  1 No tumor seen 1 (0.2%) 0
  2 Tumor, no ECE 417 (70%) 20 (5%)
  3 Tumor, ECE not excluded 67 (11%) 6 (10%)
  4 ECE unilateral 85 (14%) 13 (15%)
  5 ECE bilateral 9 (1.5%) 2 (22%)
  6 SVI 12 (2%) 7 (58%)
  7 LNM 6 (1%) 4 (67%)
 Table 1. Distribution of cases according to MRI score, with actual recorded events of biochemical recurrence for each score
  Model 10-year preoperative nomogram (R-square)
  Pre-op nomogram 0.53
  MRI-score 0.28
Combination 0.58 (p<0.01)*
Table 2. R-square values for pre-operative 10-year nomogram, for associated MRI score, and for combinations of both in predict-
ing the biochemical recurrence-free probabilities derived from post-operative nomogram
*comparison of combination versus pre-op nomogram
  Model 10-year preoperative nomogram (R-square)
  Pre-op nomogram 0.58
  MRI-score 0.25
Combination 0.61 (p<0.01)*
Table 3. R-square values for pre-operative 10-year nomogram, for associated MRI score, and for combinations of both in predict-
ing the biochemical recurrence-free probabilities derived from post-operative nomogram in patients at higher risk of recurrence 
(clinical stage T2, biopsy Gleason score ≥ 7 or PSA > 10) 
*comparison of combination versus pre-op nomogram
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DISCUSSION
Our study demonstrates that the addition of MRI information to a pre-operative nomogram that includes only clini-
cal stage by digital rectal examination, Gleason grade and PSA signifi cantly improves the accuracy of prediction of 
freedom from biochemical recurrence. While the improvements in the R square values are modest, it should be 
noted that the R square values for the pre-operative nomograms themselves are modest. This is in contrast to the 
area under the receiver operating characteristic (ROC) curve, 0.75, that the pre-operative nomogram attains.[13] The 
limitation of this study is that we used the post-operative nomogram prediction as the endpoint to be predicted 
preoperatively, rather than trying to predict actual recurrence; this was necessary due to the small size of our dataset 
and the limited follow-up information available. While high MRI scores were associated with a substantial risk of ac-
tual recurrence (Table 1), there were too few recurrence events in our patient cohort to assess whether adding MRI 
fi ndings to the pre-operative nomogram increased its predictive accuracy based on actual events. Consequently, 
we used the post-operative nomogram prediction to estimate the probability of recurrence.
A number of clinical and pathological fi ndings have been reported to correlate with risk of recurrence. The degree 
of diff erentiation of a tumor, as given by the Gleason score, is a strong predictor of outcome and has been incor-
porated into nomograms that predict pathologic stage and risk of recurrence. However, there is often a disparity 
between the biopsy and fi nal pathological Gleason scores. As many as 54% of cases have a higher grade in the RP 
specimen than in the biopsy.[14] The design of the MRI scoring system in our study was based on predicted patho-
logic stage, with a higher score assigned to each increase in stage. It has been shown that higher pathologic stages 
are associated with higher rates of biochemical recurrence.[15,16] The 10-year biochemical recurrence-free prob-
abilities for patients with organ-confi ned disease, ECE, SVI and LNM were 92%, 71%, 37% and 7%, respectively.[15] 
Each of these parameters was a signifi cant predictor of recurrence on multivariate analysis, and the ability of MRI to 
successfully identify each of these parameters has been reported.[1-3,15]
A meta-analysis by Engelbrecht et al examining the performance of MRI in staging prostate cancer from 1984 to 
2000 revealed an accuracy variance from 50% to 92%.[8] Some of this variation may be explained by a recent study 
by Mullerad et al which showed the importance of using dedicated radiologists to analyze prostate images. The 
study demonstrated that genitourinary MR radiologists were signifi cantly better at predicting ECE on MRI than 
general body MR specialists.[1]
The ability to diagnose SVI was reported by Bernstein et al, who reviewed 124 clinical T1c patients who were imaged 
by MRI prior to surgery.[17] While by multivariate analysis MRI did not predict ECE, MRI and pre-operative PSA levels 
were predictors of SVI.  In a recent study comparing pre-operative MRI fi ndings to the pathological specimens from 
radical prostatectomy for 411 consecutive patients, the positive and negative predictive values of MRI for SVI were 
reported to be 78% and 94%, respectively.[2]
The presence of LNM is associated with very low rates of freedom from biochemical recurrence.  The conventional 
imaging criterion for the diagnosis of LNM is a nodal length of 7 mm.  Given the shortcomings (demonstrated 
in our study) of present imaging modalities in predicting LNM, MR lymphography is an exciting prospect. Initial 
work reported a sensitivity of 100% and a specifi city of 80%.[18] Harisinghani et al reported on 334 histologically 
assessed lymph nodes, of which 63 (19%) nodes from 33 (41%) patients had metastatic deposits; the sensitivity of 
MR lymphography was 91% compared with 35% for conventional MRI. The main advantage of MR lymphography is 
its ability to detect metastatic deposits in normal-sized nodes, which is important given that 75% of all the positive 
nodes were small enough to not meet the usual MRI radiological criterion.[3]
D’Amico et al investigated the addition of MRI to pre-operative variables to predict recurrence. A single MRI variable 
(MRI stage T3 versus MRI stage T2) was assessed and was found to be useful in only 19% of the cohort—i.e., those 
patients with a PSA between 10 and 20 ng/mL, a biopsy Gleason score ≤ 7 and a percentage of positive biopsies 
between 34% and 50%. In that sub-group, there was a two-fold increase in risk of recurrence from MRI stage T2 to 
MRI stage T3.[19] The paper demonstrated the benefi t, albeit in a minority of patients, of using MRI. In our study, we 
have extended the MRI predictions from a binary to a 7-point linear scale and included them in a nomogram that 
does not subdivide patients into risk categories.
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The value of MRI for predicting recurrence has also been studied using artifi cial neural networks (ANN). Poulakis et 
al. demonstrated that the combined use of pre-operative variables and pelvic coil MRI was superior to the Kattan 
nomogram in predicting recurrence.[20] They found that removing clinical stage from the model only marginally 
reduced the area under the ROC curve (0.897 versus 0.895). However, the use of ANN does not appear to have 
universal acceptance, and endorectal MRI has been shown to be superior to pelvic MRI and so might increase the 
accuracy of MRI predictions made with ANN.[21]
In this preliminary study, we have demonstrated that MRI information can be incorporated into a pre-operative 
nomogram to signifi cantly improve the prediction of biochemical recurrence-free probabilities. Further time is re-
quired to allow direct comparison with actual events and to investigate the utility of adding MR spectroscopic 
imaging fi ndings to the model once suffi  cient data on recurrence has been accrued. Similarly, the development of 
a weighted scoring system is desirable, as recurrence rates do not follow a linear pattern when compared to patho-
logic stage or Gleason score.
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ABSTRACT
Purpose: To investigate whether the signal intensity (SI) of prostate cancer on T2-weighted MR images correlates 
with the Gleason grade on whole-mount step-section pathology after radical prostatectomy (RP). 
Methods: This IRB-approved, HIPAA-compliant study included 74 patients who underwent endorectal MRI before 
RP with subsequent whole-mount step-section pathology between January 2001 and July 2004 and had no prior 
treatment; at least one lesion with bi-dimensional diameter product ≥ 20 mm2 of uniform Gleason grade 3 or 4 or 
with Gleason grade 5 components; and no high SI indicating postbiopsy changes on T1-weighted images.  SIs of 
prostate tumors, non-tumor prostatic tissue and internal obturator muscles were measured on uncorrected and 
corrected T2-weighted images. Correlations between Gleason grades and SI ratios (SIRs) were assessed using Kend-
all’s Tau-b.  SIRs in peripheral zone (PZ) and transition zone (TZ) lesions of the same Gleason grade were compared 
using an unpaired t-test.
Results: Seventy-nine Gleason grade 3, 8 Gleason grade 4, and 4 Gleason grade 4/5 lesions identifi ed at pathology 
were analyzed. Gleason grade correlated signifi cantly (p<0.05) with tumor-to-muscle SIR for PZ and TZ tumors on 
corrected (Tau-b = -0.50 and -0.35, respectively) and uncorrected (Tau-b = -0.51 and -0.33, respectively) images. 
Higher Gleason grades were associated with lower tumor-to-muscle SIRs. Non-tumor-to-muscle SIRs did not cor-
relate with patients’ Gleason grades. Tumor-to-muscle SIRs were lower in TZ than in PZ tumors (p<0.001). 
Conclusion: Higher Gleason grades were associated with lower tumor-to-muscle SIRs on T2-weighted MRI. SI evalu-
ation on T2-weighted MRI may facilitate noninvasive assessment of prostate cancer aggressiveness. 
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INTRODUCTION
Prostate cancer is a histologically heterogeneous and frequently multifocal disease (1, 2). Its biologic aggres-siveness varies greatly and is a key predictor of outcome (2-5).  The assessment of  prostate cancer aggressive-ness can help stratify patients for appropriate treatment (1, 6).
Since its initial description 40 years ago, the Gleason grading system has been the gold standard for measuring 
prostate cancer biological aggressiveness (7, 8) (9).    Gleason grades range from 1 to 5, indicating gradations from 
well to poorly diff erentiated prostate cancer.  When evaluating tumor aggressiveness, the pathologist assigns both 
a primary and a secondary Gleason grade. The primary grade is the pattern of cancer that is most prevalent; the sec-
ondary grade is the pattern of cancer that is the second most prevalent and that accounts for more than 5% of the 
examined specimen (if no pattern of cancer meets the latter criteria, the secondary grade is the same as the primary 
grade). As the Gleason grade increases, the likelihood of disease recurrence becomes greater (7, 8, 10). 
Endorectal coil magnetic resonance (MR) imaging is gaining acceptance as a tool for the noninvasive detection, 
localization and staging of prostate cancer (1, 11, 12). It has been established that prostate cancer typically dem-
onstrates lower signal intensity than healthy prostate tissue on T2-weighted MR imaging (13) (14). In addition, one 
study found that quantitative measurements of signal intensity on T2-weighted MR imaging, combined with con-
sideration of PSA levels, could improve diff erentiation between benign peripheral zone tissue and prostate cancer 
(15). Although metabolic data from MR spectroscopic imaging has been shown to correlate with Gleason grade 
(16), to the best of our knowledge, no previous studies have examined whether signal intensity on MRI might also 
correlate with Gleason grade. The purpose of our study was to investigate whether the signal intensity of prostate 
cancer on T2-weighted MR images correlates with the Gleason grade on whole-mount step-section pathology after 
radical prostatectomy. 
MATERIALS AND METHODS
Subjects
Between January 2001 and July 2004, 74 patients (median age, 57.5 years; age range, 32–72 years, median weight, 
86.6 kg; weight range, 59-125 kg) underwent endorectal MRI followed by radical prostatectomy with subsequent 
whole-mount step-section pathology and met the following criteria for inclusion in our study: no treatment re-
ceived before radical prostatectomy; at least one tumor of uniform Gleason grade 3 or 4 or with Gleason grade 5 
components, with a bi-dimensional diameter product of at least 20 mm2; and no high signal intensity indicative of 
postbiopsy changes on T1-weighted images. From October 2000 through June 2003, imaging occurred as part of 
an ongoing National Institutes of Health (NIH) study investigating the use of MR in patients with prostate cancer. 
All patients gave informed consent before enrollment in the prospective NIH study, which was compliant with the 
Health Insurance Portability and Accountability Act (HIPAA). From July 2003 to July 2004, prostate MR imaging oc-
curred as part of clinical practice for patient evaluation. For all patients, our institutional review board issued a waiver 
of authorization for the retrospective review of the MRI exams and clinical data, which was also HIPAA-compliant. 
The median time from biopsy to MRI was 35 days (range: 32 days before biopsy to 189 days after biopsy) and the 
median time from MRI to surgery was 29 days (range: 1 day to 164 days).  All patients had a tissue diagnosis of pros-
tate cancer on biopsy specimens. Age, weight, serum PSA level, and clinical stage were recorded from the patients’ 
medical records (--,--).   
MR imaging technique
Endorectal MRI was performed on a GE 1.5-Tesla whole-body magnetic resonance (MR) scanner equipped with 
both a pelvic phased-array coil (GE Medical systems, Milwaukee, WI) and a commercially available balloon-covered 
expandable endorectal coil (Medrad, Pittsburgh, PA) for signal reception. Patients were examined in the supine po-
sition.  T1-weighted axial and spin-echo images were obtained from the aortic bifurcation to the symphysis pubis 
using the following parameters: TR = 400-700 msec, TE = 10-14 msec, slice thickness = 5 mm, inter-slice gap = 1 mm, 
fi eld of view (FOV) = 24-26 cm, matrix 256 x 192, and 1 excitation. Thin-section, high spatial resolution axial, coronal, 
and sagittal T2-weighted fast spin-echo images of the prostate and seminal vesicles were obtained using the fol-
lowing parameters: TR = 3650-6917 msec, eff ective TE  =  78-135 msec, echo train length = 8-32, slice thickness = 
3-5 mm, inter-slice gap = 0 mm, and FOV = 14-20 cm, with a matrix of 256-320 x 192. The total time for setup and 
acquisition was approximately 30 minutes.
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Endorectal coil profi les were obtained from a phantom study performed by a medical physicist (--, 6 years of experi-
ence in MR research) and a radiologist (--6 years of research experience in prostate MR imaging) to identify signal 
intensity iso-surface on T2-weighted images. A spherical phantom consisting of saline doped with T1-shortening 
contrast agent to yield T1 values ~ 1 sec was surrounded with saline bags to mimic the typical loading of a patient 
and was imaged with the endorectal coil setup.  Corrected and uncorrected axial T2-weighted images were gen-
erated similar to those obtained from a prostate exam.  Images were exported to Matlab (MathWorks, Natick, MA) 
and signal intensity iso-surface profi les were generated both in the z-direction and as a function of distance to the 
endorectal coil in the in-plane direction on T2-weighted images. 
Image post-processing was performed with prostatic analytical coil correction (PACC) software (GE Medical Systems, 
Milwaukee, WI) on the axial T1- and T2-weighted MR images to correct for the reception profi le of the endorectal 
and external pelvic phased-array coils. All MRI data were transferred to the picture archiving and communication 
system (PACS) (GE Medical Systems, Milwaukee, WI) of our radiology department.
Pathologic Evaluation
Following prostate resection the specimen was step-sectioned as previously described (17) and reviewed by a 
pathologist (--, 8 years experience). Cancer foci were outlined in ink on whole-mount, apical, and seminal vesicle 
slices, so as to be grossly visible, and were then photographed to provide tumor maps. The greatest diameter and 
the greatest perpendicular diameter for each lesion on the whole-mount step-section maps were measured, and 
bi-dimensional products were calculated.  The locations of tumors were recorded (peripheral zone [PZ] or transition 
zone [TZ]; base, mid-gland or apex).  The pathologic stage and the presence of extraprostatic extension, seminal 
vesicle invasion, lymph node metastasis, and positive margins were also recorded. 
MR image analysis
MR images and whole-mount pathologic step-section slices were analyzed by a radiologist (--,6 years of research 
experience in MR imaging) and a  pathologist (--, 8 years experience). The whole-mount pathologic step-section 
slices were matched with the most closely corresponding T2-weighted MR images.
Tumors that had a bi-dimensional diameter product of at least 20 mm2 on whole-mount pathology maps and that 
were of uniform Gleason grade 3 or 4 or contained Gleason grade 5 components were analyzed; if a patient had 
more than one such tumor, the two largest were analyzed. On both corrected and uncorrected axial T2-weighted 
images, a round or elliptical region of interest (ROI) (area: 4-10 mm2) was placed on the center of the tumor using 
cross-referencing on PACS with reference to the pathological maps. When a tumor extended through both the PZ 
and the TZ, two separate ROIs were placed, one in the PZ and one in the TZ portion of the tumor.  The ROIs were 
placed so as not to include the prostate capsule or urethra. Mean signal intensities and standard deviations in the 
ROI were automatically calculated by PACS. For normalization, ROI measurements in non-tumor prostatic tissue and 
the internal obturator muscle were performed on both corrected and uncorrected images. To correct for signal 
inhomogeneity from the endorectal coil, two approaches were used for evaluating signal intensities on corrected 
and uncorrected images. On uncorrected T2-weighted axial images, the mapped iso-surface profi le obtained from 
the phantom study was used to guide ROI selection.  Round or elliptical ROIs (area: 4-10 mm2) were placed on non-
tumor prostatic tissue and internal obturator muscle along the signal intensity iso-surface of the tumor ROI. On 
T2-weighted axial images corrected with PACC software, ROIs were placed on contralateral non-tumor prostatic 
tissue symmetrically to the tumor ROI and on internal obturator muscle as close to the tumor as possible (distance 
range: 6 – 28 mm). The mean signal intensities measured by the ROIs were used to calculate the tumor-to-muscle 
and non-tumor-to-muscle signal intensity ratios (SIRs). 
Statistical analysis
On both the uncorrected and corrected images, Kendall’s Tau-b was used to examine correlations between Gleason 
grades and tumor-to-muscle and non-tumor-to-muscle SIRs.  An unpaired t-test was used to test for diff erences in 
tumor-to-muscle and non-tumor-to-muscle SIRs between PZ and TZ lesions of the same Gleason grade. In all statis-
tical methods, a P value of less than .05 was considered to indicate signifi cant diff erence. Analyses were performed 
with Intercooled Stata 8.0 for Windows (Stata Corporation, College Station, TX, 2003) and SAS for Windows 9.0 (SAS 
Institute, Cary, NC 2002).
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RESULTS
Patient and Lesion Characteristics 
Patient characteristics are summarized in Table 1. Seventy-four patients with a total of 91 lesions were included in 
the study. Seventeen patients each had two lesions analyzed. Fifty-nine (65%) of the 91 lesions were in the PZ and 
32 (35%) were in the TZ.  Seventy-nine of the lesions (87%) were Gleason grade 3, 8 (9%) were Gleason grade 4, and 
4 (4%) were mixed Gleason grade 4/5. At whole-mount step-section pathology, the median lesion diameter was 16 
mm (range 5-48 mm), the median greatest perpendicular diameter was 8 mm (range 4-38 mm), and the median 
bi-dimensional product was 144 mm (20-1824 mm). Figure 1 shows the endorectal profi le generated from the phan-
tom study, and Figure 2 shows how ROI measurements were performed in a typical case.  Table 2 lists the median 
values and ranges for the SIRs measured on the uncorrected and corrected images. 
Correlation of Signal intensity and Gleason score
A. Uncorrected Images 
Gleason grade correlated signifi cantly with tumor-to-muscle SIR for both PZ and TZ tumors (Tau-b = -0.51, p < 0.001 
and Tau-b = -0.33, p = 0.03 respectively), with higher Gleason grade tumors demonstrating lower SIRs (Table 3; Figs. 
2,3, and 4). The non-tumor-to-muscle SIRs in the PZ did not diff er signifi cantly across patients with diff erent Gleason 
grades (Tau-b = -0.06, p = 0.57), indicating that no signifi cant bias existed in our measurements (Table 3). 
Median Range
  Age 57.5 37 - 72
  Weight (kg) 86.6 59 - 125
  Pre RP PSA 5.05 0.8 - 76.8
N %
  Clinical Stage
 T1 47 64
 T2 25 34
 T3 2 3
  Path Stage
 T2 58 78
 T3 15 20
 T4 1 1
  ECE 16 22
  SVI 3 4
  LNM 4 5
  Positive Margins 12 16
Table 1. Patient Characteristics 
Note: PSA = serum prostate-specifi c antigen; PNI = perineural invasion on biopsy; ECE= Extraprostatic extension; SVI = seminal vesicle invasion; 
LNM=lymph node metastasis; RP= radical prostatectomy 
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B. Corrected Images 
Gleason grade correlated signifi cantly with tumor-to-muscle SIR for both PZ and TZ tumors (Tau-b = -0.50, p < 0.001 
and Tau-b = -0.35, p = 0.02 respectively) (Table 3; Fig. 4), with higher Gleason grade tumors demonstrating lower 
SIRs. The non-tumor-to-muscle SIRs demonstrated no signifi cant diff erence across patients with diff erent Gleason 
grades in the PZ (Tau-b = -0.02, p = 0.83) or in the TZ (Tau-b = -0.26, p = 0.11), indicating that no signifi cant bias 
existed in our measurements (Table 3). 
TZ tumor vs. PZ tumor
A. Uncorrected Images 
Gleason grade 3 lesions in the TZ had a signifi cantly lower (p<0.001) mean tumor-to-muscle SIR than Gleason grade 
3 lesions in the PZ (Table 3, Figs. 3 and 4). The numbers of Gleason grade 4 and 4/5 lesions in the TZ were too small 
for formal analysis.  
A B
C D
E
Figure 1: Generating iso-surface image profi les from 
the phantom study. (a) and (b) show the iso-surface 
and projections on a phantom, respectively; (c) and 
(d) show the corresponding signal intensity profi les 
for the confi gurations in (a) and (b). Signal intensity 
from the mid 1/3 of the balloon-covered expandable 
endorectal coil remained homogeneous in the z di-
mension (e).  
(Color version available in chapter 18).
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B. Corrected Images 
Gleason grade 3 lesions in the TZ had a signifi cantly lower (p<0.001) mean tumor-to-muscle SIR than Gleason grade 
3 lesions in the PZ (Table 3, Figs. 3 and 4). 
  Uncorrected images Median Range
  Tumor-to-muscle SIR 3.57 1.22 - 9.66
  Tumor-to-non-tumor SIR 0.67 0.22 - 3.91
  Non-tumor-to-muscle SIR 5.93 1.0 - 17.6
  Corrected images
  Tumor-to-muscle SIR 2.42 0.75
  Tumor-to-non-tumor SIR 0.69 0.22 - 1.01
  Non-tumor-to-muscle SIR 3.82 1.79 - 12.07
Table 2. Median and range of signal intensity ratios on uncorrected images and corrected images
Notes: SIR = signal intensity ratio
A
B C
Figure 2: 54-year-old male with Gleason grade 4 prostate cancer in the peripheral 
zone (PZ) (weight 100.2 kg, PSA 4.4 ng/ml, clinical stage T2b, pathologic stage T3b). 
(a) Whole-mount step-section pathologic tumor map shows an index lesion of Glea-
son grade 4 in left PZ. The black circle represents the area of Gleason grade 4. (b) 
On the corresponding transverse uncorrected T2-weighted MR image (repetition 
time msec/echo time msec, 4916.7/102.48; echo train length, 12; fi eld of view, 14 cm; 
section thickness, 3 mm; no section gap) ROIs were placed on the center of the tu-
mor (ROI-1) on non-tumor prostatic tissue (ROI-2) and on internal obturator muscle 
(ROI-3). The PZ tumor-to-muscle SIR was 2.27. The PZ non-tumor prostatic tissue-to-
muscle SIR was 4.86. (c) On the corresponding transverse T2-weighted MR image cor-
rected with prostatic analytical coil correction (PACC) software, ROIs were placed the 
center of the tumor using (ROI-4) on contralateral non-tumor prostatic tissue (ROI-5) 
and on internal obturator muscle (ROI-6). The PZ tumor-to-muscle SIR was 1.82. The 
PZ non-tumor prostatic tissue-to-muscle SIR was 3.44.
(Color version available in chapter 18).
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  Uncorrected images N Mean T/M SIR (SD) Tau-b P value*
  PZ Gleason grade 3 49 5.3 (1.65)
-0.51 <0.001  PZ Gleason grade 4 7 2.9 (0.60)
  PZ Gleason grade 5 3 2.05 (0.56)
  TZ Gleason grade 3 30 2.7 (0.65)
-0.33 0.03  TZ Gleason grade 4 1 1.66
  TZ Gleason grade 5 1 1.22
A
  Corrected images N Mean T/M SIR (SD) Tau-b P value*
  PZ Gleason grade 3 49 3.4 (1.2)
-0.50 <0.001  PZ Gleason grade 4 7 1.9 (0.40)
  PZ Gleason grade 5 3 1.2 ((0.41)
  TZ Gleason grade 3 30 2.1 (0.50)
-0.35 0.02  TZ Gleason grade 4 1 1.07
  TZ Gleason grade 5 1 0.75
B
Table 3. Mean tumor-to-muscle signal intensity ratios for peripheral zone and transition zone tumors by Gleason grade for (a) the 
uncorrected images and (b) the corrected images.
Notes: PZ= peripheral zone; TZ= transition zone; SD= standard deviation T/M SIR = tumor-to-muscle signal intensity ratio
Figure 3: 60-year-old male with Gleason grade 3 prostate cancers in the PZ and TZ (weight 80.7 kg, PSA 5.1 ng/ml, clinical stage T2b, pathologic 
stage T2c). (a) Whole-mount step-section pathologic tumor map shows an index lesion of Gleason grade 3 in the right TZ (dashed white arrow), 
and a second dominant lesion of Gleason grade 3 (black arrow) in the right posterior PZ. The outlined areas represent the two tumors. (b) Cor-
responding transverse T2-weighted MR image (TR/eff ective TE = 4000/103; echo-train length, 16; fi eld of view, 14 cm; acquisition matrix, 256 x 
192; section thickness, 3 mm; no section gap) corrected with PACC software shows the index Gleason grade3 lesion (dashed white arrow) in the 
TZ, and the second dominant Gleason grade 3 lesion (black arrow) in the PZ. The tumor-to-muscle SIR (1.77) in the TZ is lower than that in the PZ 
(3.99). Also note that the PZ tumor-to-muscle SIR in this Gleason grade 3 lesion (3.99) is higher than that of the Gleason grade 4 lesion (1.82) in a 
diff erent patient shown in Figure 2. 
(Color version available in chapter 18).
A B
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Base tumor vs. mid-gland tumor vs. apical tumor
A. Uncorrected Images 
The majority of Gleason grade 3 tumors were in the mid-gland and apex. The mean tumor-to-muscle SIRs for Glea-
son grade 3 lesions did not diff er signifi cantly between these two regions (Table 4). The numbers of Gleason grade 
4 and 4/5 tumors were too small for formal analysis. 
B. Corrected Images 
The mean tumor-to-muscle SIRs for Gleason grade 3 lesions did not diff er signifi cantly in the mid-gland and the 
apex of the prostate (Table 4).  
 
DISCUSSION
Endorectal MR imaging, with and without MR spectroscopic imaging, has the capacity to aid in the detection, 
localization, and staging of prostate cancer (18-23). Furthermore, MR spectroscopic imaging may have a role in the 
evaluation of tumor aggressiveness, since metabolic data from MRSI correlate with prostate cancer Gleason grade 
(16). However, to the best of our knowledge, the capacity of MRI alone to provide information about tumor aggres-
siveness has not been explored.  Engelhard et al used the SIR on T2-weighted MR imaging  and serum PSA level 
to diff erentiate benign disease from prostate cancer in the peripheral zone, using needle biopsy histopathological 
fi ndings as the standard of reference (15). Although their study did not address tumor aggressiveness specifi cally, it 
did suggest that quantitative evaluation of SIRs on MRI could provide more information than visual evaluation alone 
Figure 4: Box plots of tumor-to-muscle signal intensity ratios by Gleason grade in PZ and TZ. (a) PZ tumor on corrected T2 weighted images; (b) 
PZ tumor on uncorrected T2 weighted images. (c) TZ tumor on corrected T2 weighted images; (d) TZ tumor on uncorrected T2 weighted images. 
PZ= peripheral zone; TZ= transition zone; crosses =  mean for that group; box = middle 50% of values; black line in box = the group median; lines 
at ends of error bars = minimum/maximum values. 
A B
C D
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regarding the nature of the tissue in a lesion.  We therefore decided to investigate whether a correlation existed 
between SIRs on T2-weighted MR images and tumor Gleason grade on whole-mount step-section pathology after 
radical prostatectomy. We found that lower tumor-to-muscle SIRs were associated with higher Gleason grades, 
although there was some overlap between the SIRs for tumors of diff erent grades, perhaps due to tissue heteroge-
neity. We also found that for all Gleason grade 3 lesions, mean tumor-to-muscle SIRs were signifi cantly lower in the 
TZ than in the PZ. 
The use of an endorectal coil with a phased-array coil signifi cantly increases the SNR in MR imaging of the prostate 
and thereby improves tumor detection, localization and staging (15) (24, 25).However, it also creates obstacles to 
the comparison of signal intensities across subjects, since the signal intensity is substantially higher in regions close 
to the endorectal coil and drops off  rapidly with increasing distance from it (Fig. 1). This signal intensity profi le may 
vary from patient to patient depending on the orientation of the endorectal coil at insertion.  Furthermore, there 
may be signal variations along the z axis of the endorectal coil, and the anterior phased-array coil also contributes 
some signal.  For these reasons, signal intensity cannot be compared directly across MR prostate imaging subjects 
(26).  Two approaches may be used to solve this problem:1) image post-processing to correct for the reception 
profi les of endorectal and phased array coils (26), which is feasible with commercial software; and 2) acquisition of 
an endorectal coil profi le from a phantom to guide placement of ROIs along a uniform signal profi le, referred to as 
an iso-surface. The latter approach does not require image intensity correction. Both approaches were used in our 
study and showed consistent results, indicating that our fi ndings are unlikely to have been infl uenced by bias. Even 
though the phantom study showed that signal intensity from the mid 1/3 of the endorectal coil remained homoge-
  Uncorrected images Gleason 3 Gleason 4 Gleason 5
  Location in PZ N Mean T/M SIR (SD) N Mean (SD) N Mean (SD)
 Apex 21 5.6 (1.5) 4 2.7 (0.46) 0 -
 Mid-gland 25 5.3 (1.8) 1 3.9 1 2.6
 Base 3 3.8 (0.75) 2 2.8 (0.96) 2 1.8 (0.39)
  Location in TZ N Mean T/M SIR (SD) N Mean (SD N Mean (SD)
 Apex 5 2.75 (0.76) 1 1.66 0 -
 Mid-gland 24 2.7 (0.66) 0 - 0 -
 Base 1 2.5 0 - 1 1.22
A
  Corrected images Gleason 3 Gleason 4 Gleason 5
  Location in PZ N Mean T/M SIR (SD) N Mean (SD) N Mean (SD)
 Apex 21 3.4 (0.96) 4 1.8 (0.45) 0 -
 Mid-gland 25 3.5 (1.5) 1 24 1 1.7
 Base 3 2.6 (0.18) 2 2.0 (0.22) 2 0.96 (0.05)
  Location in TZ N Mean T/M SIR (SD) N Mean (SD N Mean (SD)
 Apex 5 2.5 (0.74) 1 1.07 0 -
 Mid-gland 24 2.0 (0.42) 0 - 0 -
 Base 1 2.1 0 - 1 0.75
B
Table 4. Mean tumor-to-muscle SIRs by Gleason grade and location (base, mid-gland, and apex of the peripheral zone or transition 
zone) of tumor within the prostate for (a) the uncorrected images and (b) the corrected images.  
Notes: PZ = peripheral zone; TZ = transition zone; SD= standard deviation; T/M SIR = tumor-to-muscle signal intensity ratio
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neous in the z dimension (Fig. 1), we performed all ROI measurements for the tumor, non-tumor prostate tissue and 
internal obturator muscle on the same axial MR image to minimize potential bias.  
Another potential source of error in quantifying prostate cancer signal intensity is the partial volume eff ect, which 
reduces the accuracy of measurements of small cancers as well as the outer edges of large cancers (27). To avoid 
the partial volume eff ect from adjacent non-tumor prostatic tissue, only the two largest lesions in the prostate that 
met the specifi ed size criteria were analyzed. Furthermore, using cross referencing on PACS, ROIs were placed on the 
centers of tumors to avoid tumor edge eff ects. 
Our analysis was based on Gleason grades assigned at the time of map-making, the dates of which preceded the 
new consensus on Gleason grading. The new consensus document, published in 2005, was largely based on em-
piric observation rather than validated data, and therefore we did not feel a strong need to re-evaluate the pathol-
ogy samples for the present study (9).  
One limitation of this study was the exclusion of a number of patients because of technical and clinical issues. Al-
though the time interval between biopsy and MR imaging was required to be at least 4 weeks, some patients still 
demonstrated substantial biopsy changes on T1-weighted images and corresponding signal loss at T2-weighted 
imaging, which made their data sets unusable. Other limitations were the relatively small numbers of tumors with 
uniform Gleason grade 4 or with Gleason grade 5 components in the study population, which prevented us from 
comparing the SIRs for such tumors in diff erent regions of the prostate.  
Our fi ndings suggest that in addition to providing anatomic information for tumor detection, localization and stag-
ing, T2-weighted endorectal MRI has the potential to allow noninvasive assessment of prostate cancer biological 
aggressiveness, which could help stratify patients for appropriate management. Future studies with larger numbers 
of patients and prospective quantitative T2 measurement may be needed to confi rm our fi ndings.
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ABSTRACT
The purpose of this article is to explain and illustrate the current status and potential applications of automated and 
color-coded post processing techniques for analysis of dynamic multiphasic gadolinium-enhanced MR imaging 
of the liver. Post processing of these images on dedicated workstations allows generation of time-intensity curves 
(TIC) as well as color-coded images, which provides useful information on (neo)-angiogenesis within a liver lesion, 
if necessary combined with information on enhancement patterns of surrounding liver parenchyma. Analysis of TIC 
and color-coded images provides an easy to interpret schematic presentation of tumor behavior, providing addi-
tional characteristics for adequate diff erential diagnosis. Inclusion of TIC and color-coded images as part of the rou-
tine abdominal MR imaging work-up protocol may help to further improve the specifi city of MR imaging fi ndings 
and may facilitate the diagnostic work-up of disease for detection, staging, and monitoring of anti-tumor therapy. 
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INTRODUCTION
In the analysis of liver diseases, dynamic multiphasic gadolinium-enhanced magnetic resonance (MR) imaging is routinely used as part of the imaging protocol, since it provides information on a multitude of parameters, including information on tumor angiogenesis related to tumor growth, tumor grade, metastatic potential and 
anti-tumor therapy response(1, 2). Since hepatic perfusion regarding blood fl ow per tissue unit is essential for analy-
sis and diff erential diagnosis of either focal or diff use liver abnormalities, quantifi cation of these parameters may 
facilitate improved evaluation of hepatic diseases(3). 
Analysis of hepatic enhancement is more complex compared to other abdominal organs such as kidneys, pancreas 
or spleen, because the blood infl ow of the liver is made up by two components, which include infl ow from both the 
hepatic artery and the portal vein(4, 5). These two vessels provide blood to the liver in two diff erent time settings, 
which are related to each other in the analysis of arrival, distribution and excretion of contrast media. Additionally, 
the analysis of data may potentially be infl uenced by diff erent fl ow curves, which include a typical arterial enhance-
ment curve (diastolic and systolic peaks) for the hepatic artery, and a continuous positive venous infl ow curve for 
the portal vein(6). 
In previous studies, several imaging methods for non-invasive quantifi cation of hepatic hemodynamics have been 
proposed(3). Ultrasound can be applied for quantifi cation by means of Doppler ultrasonography or contrast-en-
hanced ultrasonography(7-9). However, the main limitation of ultrasound examinations is that it is operator de-
pendent, hence with low reproducibility, and has low sensitivity(10). Computed tomography (CT) has been pro-
posed and evaluated for quantifi cation of enhancement patterns(11). With the introduction of modern multislice 
multidetector CT scanners, even more robust data can be obtained, allowing for a multitude of postprocessing 
techniques, but this remains yet to be defi ned(12). MR imaging is increasingly being used for analysis of liver dis-
eases. The unique ability of MR imaging to detect intrinsic tissue components, in combination with capability of 
multiphasic dynamic imaging after gadolinium administration render it a superior technique for both the detection 
and characterization of focal liver lesions, without radiation exposure(10). In addition, in the future, the combination 
of diff usion-weighted imaging of the liver, MR-elastography and perfusion imaging may provide additional tools 
to assess the liver function, enabling a combination of both morphologic and metabolic imaging in a one-step 
imaging protocol(13). MR imaging has been proposed as well for quantifi cation of hepatic perfusion and biliary 
excretion(14, 15), using diff erent types of contrast agents including T1-shortening agents, T2-shortening agents and 
macromolecular agents(16).
The purpose of this review article is to explain and illustrate the current status and potential applications of auto-
mated and color-coded post processing techniques for analysis of dynamic multiphasic gadolinium-enhanced MR 
imaging of the liver using state-of-the-art MR imaging exams.
MR imaging technique for dynamic multiphasic imaging
Breath-hold T1-weighted contrast-enhanced dynamic magnetic resonance imaging of the liver can be performed 
on any modern MR imaging unit, with a magnetic fi eld strength >1.0 Tesla (T). Because the introduction of parallel 
imaging has facilitated fast acquisition of sequences, with increased possibilities for dynamic contrast-enhanced 
imaging of the abdomen, this will be discussed shortly. 
Parallel MR imaging (pMRI) is based on a method to undersample K-space in order to reduce total scan time. Cur-
rently, pMRI is routinely available in all commercial MR scanners, including sensitivity-encoded imaging (SENSE), 
array spatial sensitivity encoding technique (ASSET), simultaneous acquisition of spatial harmonics (SMASH) and 
others(17, 18). The undersampling of the k-space data, with some loss of the signal-to-noise ratio (SNR), results in 
considerably increased temporal resolution which is essential for a better TIC fi t. Currently, pMRI is still being im-
proved, and new methods are being published on a regular basis(19-21).  
For dynamic contrast-enhanced imaging, scan protocols are tailored for the desired measurements. The choice of 
sequence and parameters therefore, will depend on anatomic coverage, acquisition times, susceptibility to artifacts 
resulting from magnetic fi eld inhomogeneities and need for quantifi cation(22). For dynamic multiphasic imaging, 
2D/3D T1-weighted sequences (gradient-recalled echo (GRE), saturation recovery / inversion recovery snapshot se-
quences, or echo-planar sequences) can be performed after administration of an intravenous bolus of 0.1 mmol/kg 
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of a non-liver-specifi c gadolinium-chelate such as Gd-DTPA (Magnevist, Schering AG, Berlin, Germany) or Gd-DTPA-
BMA (Omniscan, GE Healthcare, Oslo, Norway). To correct additionally for the loss in SNR by the use of pMRI, the 
total dosage may be slightly increased for compensation. Routinely, an injection rate of 3ml/s is used by means of 
a power injector, followed by a bolus of saline (15 or 20cc total). The higher injection rate compensates for the SNR 
loss due to the pMRI application.
Dynamic imaging of the liver entails imaging in at least four diff erent vascular phases that may be extended depend-
ing on performance of the system. The phases that should be included are: 1) precontrast phase, 2) arterial phase, 
3) portal (or equilibrium) phase and 4) delayed (or venous) phase). To accurately capture the arterial phase, a timing 
bolus technique can be applied, using 2cc of the same contrast agent with inject rate 3ml/s bolus followed by 15cc 
saline. The timing bolus technique and adjustment of the total amount of contrast according to the body weight 
will compensate for diff erences in cardiac output and distribution volume. The portal phase is usually acquired at 45 
seconds after the arterial phase, and the delayed phase at least 120 seconds after acquisition of the arterial phase(23-
25) . The sequence should be adjusted to obtain full anatomic coverage of the liver in each scanned phase within a 
maximum of one breath-hold period (<25 sec). Routinely, a slice thickness of 6-8 mm is used for 2D GRE sequences, 
which can be thinner (3 or 4mm) in 3D GRE sequences. Ideally, a time-resolved gadolinium-enhanced sequence 
should be applied to have more data points on the TIC. In the abdomen, however, due to the breath holding re-
quirements it is not always possible yet to have continuous scanning in order to obtain multiple scans within each 
vascular phase. Therefore, most body MRI centers acquire at least four distinct phases. 
With the introduction of higher-fi eld-strength magnets (3.0T), improved dynamic imaging of the abdomen became 
feasible through inherently increased SNR (theoretically on the order of 2), high performance gradient-systems and 
advanced software platforms. This has enabled increased spatial resolution, scanning with thinner slices or acceler-
ated scanning times, which is particularly useful for angiographic MR imaging(26, 27). 
Contrast agents for dynamic multiphasic imaging 
Dynamic multiphasic contrast-enhanced MR imaging may be performed with low- or high-molecular-weight 
agents, non-liver-specifi c gadolinium chelates or liver-specifi c gadolinium chelates. After injection into the intra-
vascular compartment, non-liver-specifi c gadolinium-chelates such as Magnevist and similar low molecular-weight 
agents are rapidly diluted in the circulating plasma volume. They rapidly leak out of this space into the extra-vascular 
(or extra-cellular) space (interstitium) and then equilibrate between the intravascular and interstitial spaces. Only 
1–2% at most of an administered dose enters cells(28). The non-liver-specifi c gadolinium-chelates that are most fre-
quently used in humans are extracellular agents. In these contrast agents, tissue enhancement depends on arterial 
input function, kinetic of distribution of blood into the capillary bed, leakage across the capillary walls, and volume 
of the interstitial space. However, they have inherent disadvantages in estimating blood volume and capillary per-
meability exclusive of the brain due to the high rate of their vascular extraction, even in normal vessels. 
Macromolecular contrast agents, also called blood pool agents, have been developed, such as gadopentetate 
dimeglumine–labeled albumin(29). Blood pool contrast agents have advantages for both spatial resolution and 
SNR at vascular imaging. However, the availability as well as the direct clinical applicability of blood pool agents is 
limited, due to the slow glomerular fi ltration rate (GFR) and weak and reversible protein-binding. 
The development of liver-specifi c gadolinium-chelates has increased the accuracy of MR for identifi cation and 
characterization of focal liver lesions(30). Liver-specifi c gadolinium chelates including gadobenate dimeglumine 
(Gd-BOPTA) and gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) with a fi rst phase of 
extracellular distribution give both dynamic (morphologic) and late phase (functional) information useful for lesion 
characterization(30). They combine the properties of a conventional extracellular  gadolinium-chelate with those of 
an agent targeted specifi cally to the liver and behave in a manner analogous to conventional gadolinium-chelates 
during the dynamic phase of contrast enhancement(31) In the delayed phase it improves the impact of MRI for the 
detection of liver lesions(30). Some liver-specifi c contrast agents such as mangafodipir (Teslascan, Mn-DPDP, Amer-
sham, GE Health Care) or superparamagnetic iron-oxide particles (SPIO) have no dynamic imaging capability. The 
possibility of sequential administration of gadolinium chelates and Teslascan in a single visit to obtain both dynamic 
and late imaging was proposed(32). However, such combinations are highly undesirable because of the high cost, 
complex combined T1-shortening eff ects of two agents, and recently described potential neurotoxic side eff ects 
(Parkinson-like progressive extrapyramidal disorder) of Teslascan(33). 
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Post-processing hardware and software
Currently, several vendors provide software packages to facilitate the post processing of gadolinium-enhanced 
dynamic MRI data on a workstation. For example, Easy Vision (Philips), which runs the Quantitative Analysis pack-
age; and 2) Advantage Windows (GE), which supports the Functool package. The Easy Vision package provides the 
display of a reference image, a subtraction imaging, and nine functional images: relative enhancement, maximum 
enhancement, maximum relative enhancement, wash-in rate, wash-out rate, brevity-of-enhancement, area-under-
curve, time-to-peak, T0. Advantage Windows can display a subtraction imaging, and seven functional images: mean 
time to enhance, time to maximum enhancement, positive enhancement integral, negative enhancement integral, 
signal enhancement ratio, maximum slope of increase, and maximum slope of decrease in enhancement. Both 
software packages allow the display of the time-intensity curves and statistics of region-of-interest (ROI), either as 
a graph or a table format. 
 
Time intensity curves and derived parameters
The software package analyses these data over time, to provide a plotted corrected graph which illustrates the 
step-wise changes in enhancement over time in diff erent vascular phases after contrast administration(34). The 
pharmaco-kinetic time intensity curves (TIC) model provides a number of diff erent parameters that can be used to 
characterize specifi c tumor enhancement patterns. These parameters can be used to obtain data on microvessel 
density, fl ow through the vessels, vascular resistance, capillary wall permeability, composition of the extracellular 
space, and venous outfl ow. Currently the two most widely applied models for analyzing dynamic MRI Gd-DTPA data 
are shutter-speed model proposed by Charles S. Springer Jr.and Tofts model proposed by Paul S. Tofts(35, 36).
The color-coded images are based on qualitative pixel-wise display of various quantitative modeling parameters, 
which can be derived from the quantitative data of the TIC at each pixel. This method provides an automatic conver-
sion of kinetic contrast information into easy to interpret color-scaled images, which provides a quick overview of 
degree and heterogeneity of enhancement within the tissue. 
The generation of time intensity curves (TIC) is based on signal intensity measurements obtained by defi ning re-
gion-of-interest areas on the color-coded images, which are placed by the operator. To correct for minimal diff er-
ences in signal intensity in images acquired before and after injection of the contrast agent, measurements for 
TIC generation are based on subtracted images only. Subtracting the analyzed contrast-enhanced image with the 
precontrast image, acquired at the same level, creates these subtractions. This is performed automatically by the 
software program. It is important to note that semi-automated interpretation of dynamic examination may suff er 
from respiratory motion, which may potentially cause a varying position of the liver in the z-axis over time. In our 
experience, this is most frequently encountered in sub-cm focal lesions located under the diaphragm.  
An example of a baseline TIC illustrates that a number of parameters can be derived, including specifi c enhance-
ment patterns such as maximum intensity, maximum enhancement, time to peak, wash-in- and wash-out rate, and 
brevity of enhancement (Fig. 1). In literature(37), a number of typically shaped TIC have been described (Fig. 2). Type 
I (steady enhancement) curve shows continuously increasing signal intensity within the lesion, which is considered 
a benign feature. Type II enhancement curve shows a steep increase in signal intensity in the fi rst phases after con-
trast administration, which becomes less steep in the more delayed phases, sometimes with plateau formation. This 
type of curve is considered to be an indicator of viable tumor with stable microcirculation. Type III enhancement 
curve shows steep arterial enhancement, with loss of signal intensity in the delayed phases, rendering the curve to 
a negative slope, which is interpreted as washout of contrast within the tumor. This is considered a strong indicator 
of malignancy, proliferating edge of tumor or vessels. 
TIC is determined by contrast agent in the intravascular and extravascular compartments. During the fi rst pass, 
the contrast agent is predominantly intravascular and contrast enhancement refl ects perfusion and blood volume. 
Delayed enhancement is determined by the passage of contrast agent into and out of the extravascular space, as 
determined by rate constants ktrans and kep.
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Time intensity curves and color-coded imaging of focal and diff use liver lesions
Benign liver lesions 
According to the currently used nomenclature for hepatocellular focal liver lesions, two types of liver lesions exist: 
regenerative and neoplastic or dysplastic lesions(41). Regenerative lesions include regenerative nodules, segmental 
or lobar hyperplasia, and focal nodular hyperplasia. Neoplastic or dysplastic lesions include hepatocellular adeno-
ma, dysplastic foci, dysplastic nodules, and hepatocellular carcinoma (HCC). 
Hepatocellular lesions with benign growth behavior are common, and include cysts, hemangiomas, focal nodular 
hyperplasia (FNH) and hepatocellular adenomas, although the latter one is referred to as neoplastic lesion because 
of rare reports of malignant transformation(23, 42). To illustrate the role of the subtraction images, and the time-
intensity curves in various types of benign lesions, examples of hemangioma, hepatocellular adenoma, and FNH 
are provided below.
Figure 1: Basic time-intensity curve 
Figure 2: Typical time-intensity curves (TIC)
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Hemangiomas are the most common hepatic neoplasms, with an incidence between 0.4-20%(43). Hemangiomas 
are lesions with long T2 values, so they have high signal intensity on T2-weighted images. Also, they maintain their 
signal intensity on images with longer echo times that illustrates the lesion consists of multiple fl uid-fi lled spaces. 
The vast majority of hemangiomas show a typical peripheral nodular enhancement pattern with complete fi ll-in of 
the entire lesion over time. This enhancement pattern is of a typical benign lesion with a Type I curve (Fig. 3). 
Hepatocellular adenoma often occur in young adult women and are associated with the used of birth control 
pills(42). Liver adenomas vary in signal intensity on T1- and T2- weighted images. Characteristically, liver adenomas 
show a transient blush in the arterial phase of the dynamic Gadolinium-enhanced images, and fade to isointensity 
on delayed images (Fig. 4).
Focal nodular hyperplasia (FNH) most commonly occurs in adult female patients, but can also occur in 10-20% 
of men(44). FNH is not related to the use of birth control pills and is solitary in 2/3 of cases. FNH is mostly slightly 
hypointense on T1- and slightly hyperintense to the liver on T1-weighted images, and 10-49% of the cases show 
a central scar with high signal on T2-wighted images(44, 45). Typically, FNH shows very intense homogeneous en-
hancement in the arterial phase, with fading to isointensity in the delayed phase. The central scar is enhanced on 
delayed images. Even though FNH is a benign liver lesion, typically, this type of lesion does not show a Type I, but 
rather a Type III enhancement curve.  The exact reason for this is not clear, but it is important to notice that in the 
delayed phase, the enhancement curve of FNH remains higher than the liver, indicating absence of washout. The 
time-intensity curve for FNH is characterized as showing signs of “arterialization” (steep enhancement) in the fi rst 
part of the curve and subsequently showing signs of “hepatization” (curve running slightly above but parallel to the 
curve of the liver), as was described in a recent study assessing the MR imaging fi ndings of FNH (Fig. 5)(45). 
Defi nitions of parameters derived from TIC or multicompartment pharmacokinetic modeling:
T0  Time of arrival of contrast infl ow, which determines the arrival moment of the contrast agent at the tissue.
S0  Intensity before arrival of contrast infl ow.
1. Maximum intensity: absolute peak value of curve.
2. Maximum enhancement: diff erence between peak value and S0.
3. Time to peak (uptake speed): time between T0 and time of peak intensity.
4. Wash in rate: maximum slope between T0 and time of peak intensity, which determines the maximum 
 rate of contrast agent uptake during the acquisition and can adequately estimate the degree of early 
 strong enhancement of tumor tissue..
5. Wash out rate: absolute value of maximum slope between time of peak intensity and last measurement 
 point, which determines the maximum rate of contrast agent outfl ow during the acquisition.
6. Brevity of enhancement: time between wash in and wash out.
7. Relative enhancement: percentage of signal intensity increases between the post-contrast and the 
 pre-contrast signal intensities respectively. Relative enhancement  refl ects the plasma volume and is 
 highly correlated with microvessel density
8. Maximum relative enhancement: percentage of signal intensity increase between the maximum post 
 contrast and the pre-contrast signal intensities. 
9. Area under curve: sum (integral) of the area underneath the time intensity curve.
10. Volume transfer constant (ktrans): the constant determines the passage of contrast agent into the 
 extravascular compartment from the intravascular compartments.  ktran approximates to endothelial 
 permeability surface area product (kfp)
11. Rate constant (kep): the constant determines the passage of contrast agent out of the extravascular 
 compartment to the intravascular compartments. kep is highly infl uenced by the vessel permeability 
 and is highly correlated with microvessel density(38) and relative blood volume (rBV)(39, 40). 
12. Extracellular extravascular space (Ve): the constant determines leakage volume of fractional interstitial 
 space. Ve  is the volume of extravascular extracellular space per unit volume of tissue(38)
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Malignant liver lesions
Malignant liver lesions are common, and include primary liver lesions such as HCC, which develops in a step-wise 
fashion in patients with cirrhotic liver disease. In this sequence, dysplastic foci may develop into dysplastic nodules, 
and eventually in HCC. Metastatic liver disease is a major health problem, which occurs most commonly in patients 
with colorectal malignancies. To illustrate the role of the subtraction images, color-coded images, and the TIC in 
primary and secondary liver lesions, examples of HCC and liver metastasis are provided below.
Figure 3: Hemangioma
40-year-old female with a 48×35mm hemangioma in the right lobe of the liver. A) (Color-coded parameter image from the arterial phase, calcu-
lated using relative enhancement) Nodular enhancement in the periphery of the lesion. B) (Color-coded parameter image from the delayed phase, 
calculated using relative enhancement) Complete fi ll-in of the entire lesion.  The lesion is entirely red. C) (T2-weighted image, TR/TE= 1059/99.4 
msec) High signal intensity, lobulated and well-circumscribed lesion typical for hemangioma. D) The time-intensity curve from the ROI of the le-
sion (green curve) refl ects the steady enhancement of hemangioma (atypical Type I curve). The time-intensity curve from the ROI of the blue curve 
(line 3) shows normal liver parenchyma enhancement, and line 2 represents the signal intensity within the aorta at the acquired vascular phase. 
Note: decremental value in color spectrum: red > orange > yellow > green > blue > indigo > violet.
(Color version available in chapter 18).
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HCC is the most common primary malignancy of the liver and occurs most frequently in males(1). HCC is solitary 
in 50%, multifocal in 40%, and diff use in 10% of the cases. Often, HCC will show a moderately high signal on T2-
weighted images. HCC typically shows intense enhancement of the tumor in the arterial phase (high wash-in rate) 
and looses much of its contrast in later phases (high wash-out rate). In later phases, most HCC’s show enhancement 
of a tumor capsule. A combination of high signal intensity on T2-weighted images and the enhancement pattern 
described above, particularly in a patient with pre-existing hepatitis or cirrhosis, is considered diagnostic for HCC. 
HCC’s demonstrate Type III enhancement curves, in which the delayed phase images show a lower signal intensity 
of the lesion compared to the lesion (washout) (Fig. 6-8). Fibrolamellar HCC is an uncommon variety of HCC, which 
often occurs, in young female patients(23). At MRI, fi brolamellar HCC may show some overlap with FNH, including 
Figure 4: Hepatocellular adenoma
32-year-old female with a hepatocellular adenoma in the right lobe of liver and a hemangioma in the left lobe of the liver. A) (Subtraction image 
from the arterial phase) Hypervascular lesion. B) (Color-coded parameter image from the arterial phase, calculated using relative enhancement) 
Homogeneous blush of the lesion. C) (Color-coded parameter image from the portal phase, calculated using relative enhancement) Isointensity of 
the lesion with the surrounding liver. D) (Delayed fat-suppressed T1-weighted image) Isointensity of the adenoma in the right lobe of the liver and 
homogeneously enhanced hemangioma in the left lobe of the liver. Note: decremental value in color spectrum: red > orange > yellow > green 
> blue > indigo > violet.
(Color version available in chapter 18).
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Figure 5: Focal nodular hyperplasia
32-year-old female, with large focal nodular hyperplasia 
(FNH) in the left liver lobe. A) (Subtraction image from the 
arterial phase) Intense homogeneous enhancement of the 
lesion. B) (Color-coded parameter image from the arterial 
phase, calculated by using relative enhancement) Homo-
geneous intense enhancement of the lesion. C) (Color-cod-
ed parameter image from the portal phase, calculated by 
using relative enhancement) The lesion is almost isointense 
to the liver. D) (Color-coded parameter image from the de-
layed phase, calculated by using relative enhancement) 
Delayed enhancement of the central scar. E) (Color-coded 
parameter image, calculated by using maximum enhancement) The absolute values of enhancement of the lesions are higher than the liver. F) 
(Color-coded parameter image, calculated by using wash-out rate) This lesion has a similar wash-out rate as the surrounding liver. G) (T2- weighted 
image (TR/TE=1500/80 msec) The lesion is only slightly hyperintense to the liver. H) The time-intensity curve of the lesion (green curve) parallels 
the curve of the aorta in the arterial phase, indicating a very steep enhancement (Type III).  In the delayed phases it parallels the curve of the liver, 
refl ecting its benignity as well as its similarity to the normal liver tissue. Note: decremental value in color spectrum: red > orange > yellow > green 
> blue > indigo > violet.
(Color version available in chapter 18).
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arterial enhancement and presence of a fi brous central scar. Important diff erences between FNH and fi brolamellar 
HCC include: 1) a more pronounced and homogeneous enhancement in the arterial phase for FNH, and hetero-
geneous, less pronounced arterial enhancement for fi brolamellar HCC; and 2) presence of washout in the delayed 
phase in fi brolamellar HCC and persistent higher signal intensity in the delayed phase after contrast administration 
in FNH.  Time-intensity curves as well as the color-coded images may further facilitate the distinction between 
fi brolamellar HCC and FNH.
Liver metastases are the most common malignant tumors of the liver. Optimal evaluation with MR imag-
ing includes detection as well as characterization. Characterization is important because patients with 
known primary malignancies commonly have small hepatic lesions that are benign cysts or hemangiomas. 
In addition, accurate assessment of the segmental extent of the metastatic disease may have a substantial impact 
on patient management. Liver metastases are generally low on T1-and moderately high on T2-weighted images. 
Figure 6: Hepatocellular carcinoma
62-year-old male with hepatocellular carcinoma (HCC) in the right liver lobe. A-D) Four images illustrating the typical four phases of dynamic gado-
linium enhanced sequence, including the pre-contrast phase (A), arterial phase (B), portal phase (C), and delayed phase (D). Note that the HCC is 
intensely enhancing in the arterial phase and shows wash-out in the delayed phases with late enhancement of a pseudocapsule. 
(Color version available in chapter 18).
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Small hypervascular metastases may show intense enhancement in the arterial phase. Most commonly, liver me-
tastases show a peripheral irregular ring of enhancement. The color-coded images may provide more information 
concerning the vascularity of the lesions. The time-intensity curves of liver metastases most closely fi t into the Type 
II enhancement curves. The enhancement pattern is similar to the surrounding liver in the arterial phase, but with 
diff erent behavior in the later phases, including the portal and delayed phases. In these phases, the intensity of en-
hancement is routinely lower than the surrounding liver, resulting in a Type II enhancement curve which is located 
below the enhancement curve of the surrounding hepatic stroma (Fig. 9). 
Diff use liver lesions
Diff use liver parenchymal abnormalities may include a wide variety of disease entities, such as hepatitis, cirrho-
sis, hemochromatosis, steatosis, and diff use malignancies(1, 23). Acute hepatitis may present with reversible 
Figure 7: Hepatocellular carcinoma
The same patient as in Figure 6. A-B) (Two subtraction images from the arterial and portal phases, respectively) Improved visualization of the HCC. 
C-D) (Two color-coded parameter images from the arterial and portal phases, respectively, calculated by using relative enhancement) Heteroge-
neous enhancement of the lesion, i.e. the lesion is enhancing more intensely in the center than in the periphery (more red in the center) (C), and 
lost contrast in the center (sign of a high wash-out rate), with enhancing pseudocapsule (more red in the periphery of the lesion) (D). 
(Color version available in chapter 18).
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Figure 8: Hepatocellular carcinoma
The same patient as in Figures 6-7.  This fi gure shows vari-
ous parameters as color-coded images. A) (Color-coded 
parameter image, calculated by using T0) The lesion has 
a shorter T0 (i.e. enhances earlier) than the surrounding 
liver. B) (Color-coded parameter image, calculated by using 
time-to-peak (TTP)) The center of this lesion has a shorted 
TTP as compared to the pseudocapsule. This indicates that 
the peak of contrast reaches the center of the lesion in an 
earlier phase. C) (Color-coded parameter image, calculated 
by using wash-in rate) The center of this lesion has a lower 
wash-in rate as compared to the pseudocapsule. D) (Color-
coded parameter imaging, calculated by using wash-out rate) The center of the lesion has a slightly higher wash-out rate than the surrounding 
liver. E) (Color-coded parameter image, calculated by using brevity-of-enhancement) The time between the wash-in rate and wash-out rate is 
longer in the center of this lesion as compared to the surrounding liver. F) (Color-coded parameter image, calculated by using area-under-curve) 
The pseudocapsule of this lesion received a higher dosage of contrast agent than the center of the lesion. G) (T2- weighted image (TR/TE=1500/80 
msec) Slightly hyperintensity in the center as well as the pseudocapsule of the lesion. H) The time-intensity curve shows that the lesion (green 
curve) enhances more than the liver and less than aorta in the arterial phase, and loses contrast in the later phases (sign of wash-out). Please note 
that the curve, unlike the curve in the FNH (see Figure 5H), is not parallel to the curve of the liver in any phase. Note: decremental value in color 
spectrum: red > orange > yellow > green > blue > indigo > violet.
(Color version available in chapter 18).
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Figure 9: Liver metastasis  
56-year-old female with a large hepatic metastasis from 
sigmoid carcinoma. A) (Substraction image from the portal 
phase) Irregular ring enhancement of the lesion as well as 
a faint enhancement in the center of the lesion. B) (Color-
coded parameter image from the arterial phase, calculated 
by using relative enhancement) Faint enhancement of the 
lesion. C) (Color-coded parameter image from the portal 
phase, calculated by using relative enhancement) Irregular 
ring of enhancement in the periphery of the lesion, where-
as the more central parts of the lesion are enhanced less 
than the surrounding liver. D) (Color-coded parameter im-
age from the delayed phase, calculated by using relative enhancement) The lesion has enhanced slightly more than in the previous phase, whereas 
the liver has lost some of its contrast. Therefore, the conspicuity of lesion has decreased. E) (Color-coded parameter image, calculated by using 
wash-in rate) The periphery of the lesion has a higher wash-in rate than the center of the lesion. F) (Color-coded parameter image, calculated by 
using the maximum relative enhancement) The central parts of the lesion enhance less than the surrounding liver. G) (T2- weighted image (TR/
TE=1500/80 msec) The periphery of the lesion is slightly hyperintense to the liver. H) The time-intensity curve of the lesion (green curve) shows 
that the lesion is enhancing similar to the liver in the arterial phase. In the portal phase, there is the greatest diff erence in enhancement between 
the lesion and the surrounding liver. In the delayed phase, the lesion shows slight further increase in enhancement, whereas, the liver loss some 
contrast. Therefore, the conspicuity of the lesion decreases after the portal phase. Note: decremental value in color spectrum: red > orange > yel-
low > green > blue > indigo > violet.
(Color version available in chapter 18).
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heterogeneous patchy enhancement of the hepatic stroma in the arterial phase. In the portal and delayed phases, the 
abnormal enhancement pattern is occult. To illustrate the role of the subtraction images and the color-coded im-
ages in detection of diff use liver parenchymal disease as well as monitoring of therapy, an example of acute hepa-
titis in a patient with primary sclerosing cholangitis before and after medical treatment with Prednison is provided 
(Fig 10). 
DISCUSSION 
Post-processing of dynamic gadolinium-enhanced MRI exams of the abdomen allows generation of the color-
coded images and time-intensity curves(46). The information may further improve the diagnostic capability of MRI 
at high temporal and spatial resolution. Unlike the original gadolinium-enhanced images, the color-coded images 
provide information concerning the intra-tumoral distribution of vessels (vascular density) as well as the nature of 
the vascular wall (intact or immature and leaky blood vessels). This may contribute to a better understanding of 
Figure 10: Diff use parenchymal liver disease 
Diff use liver disease, before and after medical treatment. 59 year-old male with primary scleros-
ing cholangitis with an acute hepatitis in the left and part of the right liver. Images A-D were 
performed prior to medical treatment, while images E-H were performed after a three-month 
treatment with Prednison. A) (Subtraction image from the arterial phase) Abnormally increased 
enhancement of the liver parenchyma in the left and part of the right liver. B) (Color-coded 
parameter image from the arterial phase, calculated by using relative enhancement) The het-
erogeneous increased enhancement of the liver. C) (Color-coded parameter image from the 
portal phase, calculated by using relative enhancement ) The abnormalities are less well de-
picted in this phase. D) (Color-coded parameter image from the delayed phase, calculated by 
using relative enhancement) No abnormalities at all. E) (Subtraction image from the arterial 
phase, after treatment) Substantially less abnormal enhancement of the liver parenchyma. F) 
(color-coded parameter image from the arterial phase, after treatment, calculated by using rela-
tive enhancement)  Decreased heterogeneous increased enhancement of the liver. G and H) 
(Two color-coded parameter images from the portal and delayed phases calculated by using 
relative enhancement) The abnormalities have become occult. Note: decremental value in color 
spectrum: red > orange > yellow > green > blue > indigo > violet.
(Color version available in chapter 18).
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tumor enhancement patterns and angiogenesis, and hence may result in improved characterization of tumors. As 
described in literature(47), tumors do not grow beyond 2 mm3 in size as a result of hypoxia unless angiogenesis, a 
process of the development of new capillaries derived from host tissues allow tumors to grow exponentially. 
The enhancement mechanisms behind dynamic gadolinium-enhanced MRI 
Because of the unique dual blood supply of the liver (arterial and portal), hepatic lesions probably have diff erent 
contrast kinetics as compared to lesions in other organs with only a single (arterial) blood supply. Therefore, the 
generated TICs of focal liver lesions should always be compared with the curves of the surrounding liver. 
The mechanisms behind the diff erential contrast enhancement are thought to include diff erences in tumor perfu-
sion and the levels of tumor capillary wall permeability and hydrostatic pressure. The growth of a tumor, and its as-
sociated angiogenesis, is often rapid and disordered, leading to: 1) a relatively high fraction of immature blood ves-
sels; 2) abnormal basal membranes in the vessel wall with relative lack of pericytes or smooth muscle associations 
with endothelial cells which render the vessels more “leaky” or permeable (providing an access point for contrast 
agents); 3) tumor vessels are tortuous, vary in diameter, and tend toward excessive branching and shunt formation; 
4) intermittent or unstable blood fl ow with acutely collapsing vessels; and 5) hydrostatic pressure diff erences be-
tween tumors and normal tissue, partly reduced or absent lymphatics which may infl uence contrast agent uptake. 
Blood volume, blood fl ow, mean transit time and microvascular permeability–surface area product are all, in prin-
ciple, quantifi able through analysis of dynamic gadolinium-enhanced MRI by using pharmaco-kinetic models(36). 
Tumor regions with dense neovasculature may enhance more rapidly compared to other regions. The position of 
these regions is related to the distribution of viable blood supply within the tumor. In necrotic or cystic regions, 
vascular density can be extremely low, whereas in highly active regions, the vascular density can be high. 
Dynamic contrast-enhanced MR imaging proposed as an in-vivo marker of angiogenesis
Due to its high quality and reproducible measurements, dynamic contrast-enhanced MR imaging is being proposed 
as an in-vivo marker of angiogenesis(22, 48) with the advantage over the “gold standard” of direct histologic quan-
tifi cation of angiogenesis with discrepancy between “true” functional and histologic microvessel density: 20% to 
85% of microvessels are perfused at any given time depending on the microenvironment(22, 39). Dynamic contrast-
enhanced MR imaging may help defi ne the pharmacological response and dose of vascular endothelial growth fac-
tor (VEGF)-mediated angiogenesis inhibitors, such as PTK787/ZK 222584, an orally active inhibitor of VFGF receptor 
tyrosine kinases, for further clinical development in patients with advanced colorectal cancer(49). 
Functional CT versus dynamic contrast-enhanced MRI
Functional CT using multidetector row, as with dynamic contrast-enhanced MRI, has also been proposed for evalu-
ation of tumor vascularity. Both techniques are easily incorporated into routine examinations  and provide reliable 
quantitative perfusion data, although for both imaging modalities, there remains a lack of consensus regarding op-
timal acquisition technique, type of analysis method, and surrogate measurement to use(22). There are diff erences 
between the two imaging modalities in acquisition techniques, mathematical analysis, measurement parameters, 
and propensity to artifacts(22). The benefi t of functional CT is the direct linear relationship between CT attenuation 
value and contrast agent concentration. The functional CT analysis technique includes deconvolution, distributed 
parameter model. Unfortunately, the risks of contrast agent reactions and potential biologic hazards from radiation 
exposure to the patients (especially oncologic patients that undergo repeated scans to monitor therapy response) 
are associated with functional CT. The radiation burden associated with a functional CT acquisition protocol is de-
termined by the number of images in the sequence and the tube current (mAs) used for each image.  Dynamic 
contrast-enhanced MRI does not involve the use of ionizing radiation, which is a particular advantage for serial 
examinations to monitor treatment response. The choice between functional CT and dynamic contrast-enhanced 
MRI depends on machine availability, doctor expertise, tumor location, desired parameters, and the requirement of 
decreased radiation burden(22).
The benefi ts of the color-coded images and time-intensity curves 
Color-coded images can provide information concerning focal as well as diff use disease processes. This reduces the 
risk of creating regions-of –interest (ROI) containing more than one tissue type, and makes further ROI analysis more 
accurate. In addition, the color-coded images combine both the enhancement pharmaco-kinetics of tissues and 
morphology, and visualize the enhancement changes over time. 
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The generation of time-intensity curves by placing regions-of–interest (ROI) has two benefi ts over functional im-
ages: 1) sampling only a limited number of pixels at once increases the signal-to-noise ratio; and 2) small spatial 
misregistration between points only introduce small errors. However, there are also some drawbacks. The time-in-
tensity curves are insensitive to regional variation in the parameter being examined, small foci of high or low signal 
intensity may be missed as they are averaged out within an ROI, and diff use disease may be diffi  cult to analyze. Pa-
tient motion might lead to faulty time-signal intensity curves at each pixel, and hence to faulty functional images.
The parameters derived from the time-intensity curves, which is the basis of the color-coded images have contri-
butions from MR imaging protocols. Therefore, it may be diffi  cult to compare the results of studies from diff erent 
institutions. Application of pharmaco-kinetic modeling has the potential to standardize these results(22).. 
CONCLUSION
In conclusion, the generation of color-coded images and time-intensity curves based on dynamic multiphasic 
gadolinium-enhanced MR imaging data sets provides new opportunities for research. Moreover, it facilitates the 
diagnostic work-up of hepatic disease for the detection, staging, therapeutic monitoring; and development of anti-
tumor drugs. 
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GENERAL DISCUSSION
Role of MRI in the staging and treatment of prostate cancer
Prostate cancer aff ects men of all races, cultures and ethnic backgrounds and is a major public health burden as well as an economic burden throughout the world (1-3). It is the most common non-cutaneous cancer and the third leading cause of cancer death in men in the United State and European Union (1, 3, 4). An estimated 
234,460 new cases of prostate cancer will be diagnosed in the United States and 27,350 people will die of the dis-
ease in 2006 (1). A wide discrepancy exists between the number of men diagnosed and those dying from prostate 
cancer. In East Asian countries such as Japan, prostate cancer mortality remains lower than in Western industrial 
ccountries, but it has been continuously and dramatically rising over the past 40 years (5). At routine autopsies pros-
tate cancer can be detected in 8.2-10% of men (6, 7). Prostate cancer is an age-related disease and our population is 
aging rapidly, so the number of new cases will grow substantially (1, 8). 
The high incidence of prostate cancer, combined with earlier detection, downstaging at the time of diagnosis, and 
the slow natural progression of the disease, has made its management a complex and controversial issue (1, 9-12). 
The American Cancer Society found that from 1995 to 2001, 91% of prostate cancer cases were of a local or regional 
stage at diagnosis, as compared with 74% from 1986 to 1991 , and patients had a 5-year relative (ie, adjusted for 
life expectancy) survival rate of 100% from 1995 to 2001 (1) (13). The 100% 5-year relative survival rate for all stages 
indicates that prostate tumors have a slow growth rate and allow for prolonged survival, even in patients with 
metastases at diagnosis (14, 15). However, the downstaging has been accompanied by an unfortunate trend of 
overdetection and overtreatment of biologically insignifi cant disease (16-19). As localized prostate cancer more fre-
quently contains biologically indolent features and patient and  physician anxiety and societal pressures favor active 
intervention, a large population of men is being ‘overtreated’ (16). Autopsy studies indicated that the “overdetected” 
cancers never impacted patient longevity (17). Primary therapies with curative intent (surgery or radiation) provide 
excellent long-term cancer control but are accompanied by a risk of treatment-related morbidity. Conversely, the 
understandable appeal of watchful waiting or active surveillance is balanced by the potential harm of missing a 
window of curative opportunity for a cancer destined to progress (20). One challenge clinicians and patients face in 
the modern PSA era is to diff erentiate men who have disease destined to progress and cause morbidity/ mortality 
from those who will not require immediate, or possibly even delayed, therapeutic intervention (21-23).  
Depending on patient age at diagnosis, the stage and aggressiveness of the tumor, the potential side-eff ects of 
the treatment, and patient comorbidity (24-26), the options for treatment may include deferred therapy, androgen 
ablation, radical surgery, and various forms of radiation therapy (brachytherapy, external beam irradiation, including 
intensity-modulated radiation therapy (IMRT), and combinations) (27, 28). Recent studies have suggested that most 
patients with clinically localized prostate cancer will undergo some type of local therapy in an attempt to cure the 
disease (29-42). Radical prostatectomy is still the most commonly recommended treatment for patients with a life 
expectancy of at least 10 years (9, 43). Because the most common treatment side-eff ects – erectile dysfunction and 
urinary incontinence – are serious, there is a growing demand for patient-specifi c therapies that can reduce treat-
ment morbidity while maximizing treatment benefi ts (44, 45). Patients with prostate cancer have to choose from 
a wide range of treatments, and the decision signifi cantly aff ects both quality of life and survival. An important 
objective prior to any cancer therapy is to obtain a comprehensive and accurate knowledge of tumor location, size, 
locoregional extent, and biologic potential. Better tools are needed to help physicians and patients decide what 
type of treatment is most appropriate, or whether any treatment is needed at all (10, 46-48).
There are a number of clinical parameters and clinical nomograms to help with the choice of treatment (45, 49-54). 
To aid in patient counseling, the National Comprehensive Cancer Network (NCCN) guidelines defi ne low risk as a 
PSA less than 10 ng/mL, a Gleason score of 6 or lower, and a T stage of T2a or lower; the guidelines defi ne high risk as 
a PSA of more than 20 ng/mL, a Gleason score of 8 or higher, or T2c; intermediate risk is defi ned as a PSA of 10 to 20 
ng/mL, T2b, or a Gleason of 7 (55). Patients with low-risk disease may be treated with prostatectomy or radiotherapy 
alone. Patients with intermediate risk disease are usually treated with radiotherapy and a short duration (less than 
6 months) of hormonal ablation (medical castration using a gonadotropin-releasing hormone analog), and those 
with high-risk disease are usually treated with radiotherapy and a long duration of hormonal ablation (37, 56). To 
replace somewhat arbitrary combinations of individual clinical variables, nomograms have been developed that 
give a prediction of the fi nal pathologic stage and an estimate of the chances of freedom from disease recurrence 
and aid in the choice of treatment (45, 52-54, 57-60). The Partin staging nomogram (also called the “Partin Tables”) , 
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which is based on clinical stage, Gleason score, and serum PSA level, was fi rst published in 1993 and was updated in 
1997 and again in 2001 to predict the pathological stage at radical prostatectomy in men with prostate cancer (57, 
59, 60). Other nomograms, such as Kattan’s nomograms, have been developed to predict stage, individual features 
of stage (e.g., SVI, ECE), or recurrence, using variables such as the extent and location of cancer in systemic biopsy 
results, the percentage or number of biopsy cores positive for cancer, or the highest Gleason sum in any core (43, 
52, 61-63). As an important advance in accurate prediction for clinical medicine , the nomograms allow calculation 
of the continuous probability of a particular outcome and tend to outperform both expert clinicians and predictive 
instruments based on risk grouping (45, 59). The nomograms are validated predictive instruments widely used for 
individual patient counseling and important decision making (64-70). Despite the strong predictive ability and the 
cost-eff ectiveness of the nomograms, there is room for improved accuracy of prediction, particularly since clinical 
staging in the nomograms, is based only on digital rectal examination (DRE) and biopsy-determined Gleason grade, 
although valuable, is subject to sampling error (71-74). Moreover, the nomograms are limited because they do not 
incorporate the results of imaging studies that could guide interventions to control local disease. Thus, a technique 
that noninvasively demonstrates the presence, extent, and aggressiveness of prostate cancer could contribute in-
cremental value to clinical nomograms and variables and make a substantial contribution to the decision-making 
process for individualized treatment (46-48, 75, 76). 
Although reports on the value of MRI in prostate cancer management have been contradictory, there is no doubt 
that MRI has an essential role to play in making safer, more individualized therapies possible (10, 77-80). In the last 
decade MRI has improved considerably with technologic refi nements and increased reader experience. State-of-
the-art techniques, such as use of an endorectal coil, MR spectroscopic imaging (MRSI), faster imaging sequences, 
more powerful gradient coils, image post-processing and picture and communication systems (PACS) provide 
greater resources for improved interpretation of MR images of the prostate by experienced radiologists (46-48, 
75, 81-86). The determination of treatment options should benefi t from an imaging modality that allows non-in-
vasive visualization of the primary tumor and measurement of its extent. This dissertation addresses the ability of 
state-of-the-art MRI/MRSI to non-invasively improve prostate cancer staging, treatment planning, and evaluation 
of recurrence-free probabilities and aggressiveness, together with the potential clinical application of color-coded 
parameter imaging derived from postprocessing of dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) of 
abdominal tumors. First the role of MRI and MRSI in prostate cancer staging will be discussed, with specifi c attention 
to the detection of organ-confi ned prostate cancer (OCPC), extracapsular extension (ECE), seminal vesicle invasion 
(SVI), and lymph node metastasis (LNM). Then the uses of MRI in pre-surgical planning will be examined, and the 
eff ect of MRI monitoring on recurrence rates and on the determination of cancer aggressiveness — as well as some 
post-processing issues — will be discussed.  Finally, I shall make recommendations for diagnostic MRI of prostate 
cancer based on this overview of the literature.
Role of MRI/MRSI in prostate cancer staging
While historically, the staging of prostate cancer was based on the Jewett classifi cation system, in the last 10 years 
TNM (tumor-node-metastasis) staging has prevailed. At present, however, TNM staging system is in common use 
particularly in the USA. TNM staging of prostate cancer has undergone a number of modifi cations, the latest ones 
having been made in 2002 by the American Joint Committee on Cancer (AJCC). The 2002 revised TNM system, 
shown in Table 1, is clinically useful and precisely stratifi es newly diagnosed cancer (87). Most importantly, clinicians 
must distinguish between patients with pathologically organ-confi ned prostate cancer (OCPC) (pT2a-b) considered 
good surgical candidates and those with non-organ-confi ned prostate cancer (pT3-4). If cancer extends outside the 
prostate, the chances of cure are substantially diminished and the surgical or radiation treatment planning must be 
adapted to ensure complete eradication of the cancer (88).  
TNM staging of prostate cancer is largely dependent on imaging. Due to high spatial resolution, superior con-
trast resolution, multiplanar capability, and a large fi eld of view, MRI has higher accuracy in the assessment of 
unilateral or bilateral OCPC (pT2a-b), ECE (pT3a) and SVI (pT3b), and the invasion of adjacent structures (stage 
T4) than CT, ultrasound and DRE. MR spectroscopy indirectly increases the accuracy of MR staging by provid-
ing information on tumor volume and location and shows great promise in the diff erentiation of indolent from 
aggressive disease (46-48, 75, 89-93). This MR information can help patients make the best decision about which 
treatment to select and can help the surgeon plan the operation to be sure all cancer is removed while the critical 
nerves and the sphincter are not removed. Other advantages of improved cancer staging include a better stratifi ca-
tion of patients in clinical trials, the possibility of monitoring the progress of patients who select watchful waiting 
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or other minimally aggressive cancer management options, and the guidance and assessment of emerging local 
prostate cancer therapies. However, the literature shows a wide range (from 50% to 92%) in the accuracy of local 
staging by MRI. Despite the high specifi city of MRI, its widely varying sensitivity and substantial interobserver vari-
ability (ECE: specifi city 47-99%, sensitivity 22-80%; SVI: specifi city 81–99%, sensitivity 23–80%; LNM: specifi city 78.7-
98.46%, sensitivity 0-69%)(10, 46-48, 75, 76, 80, 84, 89, 94-110) make its routine use in the local staging of prostate 
cancer controversial.
(1) Detection of OCPC (pT2a-b)
A cancer completely confi ned to the prostate is defi ned as pT2a-b. After radical prostatectomy (RP), patients with 
pT2a-b cancer have an excellent prognosis, as more than 90% of them are free from biochemical recurrence at 5 
years (9). Pretreatment knowledge of OCPC is important for treatment selection and planning, regardless of whether 
the treatment method ultimately chosen is watchful waiting, surgery, or radiation therapy (111-115). Radical prosta-
tectomy in patients with pathologically organ-confi ned cancer results in a survival rate comparable with that of 
age-matched controls without prostate cancer (52, 116). The study described in Chapter 2 investigated the contri-
bution of MR to the Partin Tables in predicting OCPC in 229 patients who underwent endorectal MRI and 383 who 
Evaluation of the (primary) tumor (‘T’)
TX cannot evaluate the primary tumor
T0 no evidence of tumor
T1 tumor present, but not detectable clinically or with imaging
T1a tumor was incidentally found in less than 5% of prostate tissue resected (for other reasons) 
T1b tumor was incidentally found in greater than 5% of prostate tissue resected
T1c tumor was found in a needle biopsy performed due to an elevated serum PSA
T2 the tumor can be felt (palpated) on examination, but has not spread outside the prostate
T2a the tumor is in half or less than half of one of the prostate gland’s two lobes
T2b the tumor is in more than half of one lobe, but not both
T2c the tumor is in both lobes
T3 the tumor has spread through the prostatic capsule (if it is only part-way through, it is still T2)
T3a the tumor has spread through the capsule on one or both sides
T3b the tumor has invaded one or both seminal vesicles
T4
the tumor has invaded adjacent structures other than seminal vesicles (e.g., bladder neck, 
external sphincter, rectum, levator muscles, and/or pelvic wall)
Evaluation of the regional lymph nodes (‘N’)
NX cannot evaluate the regional lymph nodes
N0 there has been no spread to the regional lymph nodes
N1 there has been spread to the regional lymph nodes
Evaluation of distant metastasis (‘M’)
MX cannot evaluate distant metastasis 
M0 there is no distant metastasis
M1 there is distant metastasis
M1a the cancer has spread to lymph nodes beyond the regional ones
M1b the cancer has spread to bone
M1c  the cancer has spread to other sites (regardless of bony involvement) 
Table 1.  TNM Staging of Prostate Cancer (AJCC 6th edition (2002)(87)
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underwent combined endorectal MRI–MRSI before radical prostatectomy (46). Since the introduction of the Partin 
Tables in 1997, investigators have repeatedly validated the nomograms’ capacity to help predict the pathologic 
stage of clinically localized prostate cancer (64-66). In 2001, the nomograms were updated based on a more con-
temporary cohort of disease features (57). The accuracy of the staging nomograms in predicting OCPC is high, with 
reports of the area under the ROC curve ranging from 0.79 to 0.82 (64-66). Despite the strong predictive ability and 
the cost-eff ectiveness of the staging nomograms, there is room for improved accuracy of prediction, particularly 
since clinical staging in the staging nomograms is based only on digital rectal examination. Moreover, the staging 
nomograms cannot assist in the localization of ECE, which is critical for optimal treatment planning (57, 117).  
The data demonstrated that MR fi ndings contributed signifi cant incremental value (P ≤ .02) to the nomograms in 
the overall study population. The contribution of MR fi ndings was signifi cant in all risk groups but was greatest in 
the intermediate- and high-risk groups (P < .01 for both). Overall, in the prediction of OCPC, the area under the ROC 
curve for the staging nomograms was 0.80, while the area under the ROC curve for the staging nomograms plus 
MR fi ndings was 0.88; the diff erence was signifi cant (P < .01). In the combined endorectal MRI–MRSI group, the areas 
under the ROC curves were 0.81 for the staging nomograms and 0.90 for the staging nomograms plus MR fi ndings; 
the diff erence was signifi cant (P < .01).The contribution of MR spectroscopic imaging fi ndings to endorectal MR 
imaging in the prediction of OCPC was also assessed in the study. The magnitude and extent of metabolic abnor-
mality on MR spectroscopic images is indicative of tumor aggressiveness, volume, and stage (118, 119). Accuracy 
in the prediction of OCPC with MR was higher when MR spectroscopic imaging was used, but the diff erence was 
not signifi cant. The results showed that MR fi ndings (from endorectal MR imaging or combined endorectal MR 
imaging–MR spectroscopic imaging) contribute signifi cant incremental value to clinical staging nomograms in the 
prediction of OCPC. The incorporation of endorectal MR imaging into future staging nomograms for the prediction 
of OCPC may therefore be warranted. 
(2) Detection of ECE (pT3a)
A cancer that extends through the prostatic capsule into the periprostatic adipose tissue is defi ned as pT3a tumor 
(9). ECE is an important predictor of tumor progression because it is associated with greater risk of a positive surgi-
cal margin, recurrence and a decreased chance of long-term cancer control (9, 120-122). Accurate determination of 
ECE before treatment may alter treatment selection and planning (52, 121). Awareness of the presence and likely 
location of ECE would allow surgeons to plan radical prostatectomy more carefully, with the aim of resecting the 
cancer completely and minimizing the risk of damaging surrounding tissues important to recovery of sexual func-
tion (52, 81, 123). The value of MRI staging was demonstrated in a 5-year follow-up study of 1,025 men with prostate 
cancer who were staged radiologically before prostatectomy (124). Endorectal MRI stages T3a (ECE) or T3b (SVI) had 
a signifi cantly worse prognosis than endorectal MRI stages T2a-b (OCPC). A decision analysis model suggested that 
preoperative MRI was cost-eff ective in patients with a moderate or high risk of ECE (95). A multivariate analysis of en-
dorectal MRI fi ndings and other preoperative variables (PSA level, clinical stage, Gleason score, percentage of cancer 
in biopsy cores, and perineural invasion) in Chapter 3 showed that endorectal MRI fi ndings were signifi cant presurgi-
cal predictors of ECE in patients with prostate cancer, and added incremental value to clinical variables (75). Areas 
under the ROC curves for two models, with and without endorectal MR imaging fi ndings, were 0.838 and 0.772, 
respectively (P = .022). Endorectal MRI fi ndings had a larger AUC than any of the clinical or histologic variables, a high 
negative predictive value and a high positive predictive value (0.743, 83.8% and 74.5%, respectively). On endorectal 
MRI, the criteria for extracapsular extension include a contour deformity with a step-off  or angulated margin; an 
irregular bulge or edge retraction; a breach of the capsule with evidence of direct tumor extension; obliteration of 
the recto-prostatic angle; and asymmetry of the neurovascular bundles (78, 105, 108).
While transaxial planes of section are essential in the evaluation of ECE, the utility of combining transaxial and coro-
nal plane images using PACS cross-referencing to facilitate the diagnosis of extracapsular extension was shown in 
the study described in Chapter 6 (84). The study investigated 255 consecutive patients who underwent endorectal 
MRI before radical prostatectomy. In detecting ECE, the two radiologists had higher AUCs using cross-referencing 
(their AUCs increased from 0.66 to 0.87, and from 0.69 to 0.86; p<0.001 for both). The weighted kappa was 0.56 with 
MRI alone and 0.76 with cross-referencing, indicating fair to good inter-reader agreement. Sensitivity/specifi city for 
ECE with MRI alone and with cross-referencing, respectively, was 44%/85% and 68%/95% for reader 1 and 56%/78% 
and 74%/95 for reader 2.  
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As medicine advances, ever-narrowing subspecialties evolve, and patients benefi t from the added clinical exper-
tise. Interpretation of prostate MRI examinations is important, and limited reader experience remains a barrier to 
greater acceptance of MRI use for preoperative imaging in many centers. Early reports demonstrated interobserver 
variability in MR imaging fi ndings (125-127). The addition of MRSI to MRI has been shown to signifi cantly increase 
staging accuracy for inexperienced readers and thus reduce interobserver variability (89). Chapter 4 reviewing pre-
prostatectomy endorectal MRI fi ndings for 344 consecutive patients with biopsy-proven prostate cancer showed 
that, overall, endorectal MRI fi ndings were signifi cant predictors of ECE and added signifi cant incremental value to 
clinical variables when the images were interpreted by genitourinary radiologists experienced in MRI of the prostate 
(AUC 0.854 vs. 0.760, P = 0.019), but not when they were interpreted by general body MRI radiologists (AUC 0.813 
vs.0.788, P = 0.31) (76). In the genitourinary MR imaging radiologists’ group of patients, the AUC for endorectal MR 
imaging fi ndings (0.833) was superior to that of all other predictors tested (0.566–0.701). In the general body MR 
imaging radiologists’ group of patients, AUC for endorectal MR imaging fi ndings (0.646) was similar to that of the 
clinical predictors (0.582–0.793).This suggests that the recent improvement in the performance of MRI can be attrib-
uted to increased reader experience as well as to the maturation of MRI technology (e.g. faster imaging sequences, 
more powerful gradient coils, and post-processing image correction), and better understanding of morphological 
criteria used to diagnose ECE or SVI. These results may also explain the frustration over the use of endorectal MRI for 
prostate cancer evaluation. 
(3) Detection of SVI (pT3b)
Seminal vesicle invasion (SVI) is defi ned as the extension of cancer into the muscular layer of the seminal vesicle 
(9). SVI is an important predictor of tumor progression because it is associated with increased risks of lymph node 
metastasis, recurrence(121, 122, 128-130). The criteria for SVI on endorectal MRI include contiguous low-signal-inten-
sity tumor extension from the base of the gland into the seminal vesicles; tumor extension along the ejaculatory 
duct (non-visualization of the ejaculatory duct); asymmetric decrease in the signal intensity of the seminal vesicles; 
and decreased conspicuity of the seminal vesicle wall on T2 weighted images (78, 104). Prediction of SVI before 
treatment may infl uence treatment selection in favor of radiation therapy instead of surgery. Furthermore, while 
resection of the seminal vesicles has been a standard component of radical prostatectomy, it has recently been 
suggested that if SVI can be confi dently ruled out, the surgeon may wish to spare the seminal vesicles during radical 
prostatectomy to prevent long-term loss of urinary continence (131).  
Chapter 5 investigated 573 patients who underwent endorectal MRI before surgery for prostate cancer and had sys-
tematic needle biopsy results available for the base of the prostate (47). The results show that the Kattan nomogram 
(based on serum PSA, biopsy Gleason grade, clinical staging, and systematic needle biopsy cores from the base of 
the prostate) plus endorectal MRI (0.87) had a signifi cantly larger AUC than either endorectal MRI alone (0.76) or the 
Kattan nomogram alone (0.80; P<0.05 for both). On surgical histopathology 4.9% of the patients had evidence of 
SVI. This result is consistent with the dramatic downstaging of prostate cancer at the time of diagnosis that has oc-
curred over the last two decades (1). In the literature, serum PSA levels and Gleason grade are signifi cantly associated 
with SVI on both univariate and multivariate analysis (63, 118, 132). Our study results demonstrated that MRI, %Ca 
(greatest percentage of cancer in all biopsy cores), PSA, clinical stage, Gleason grade, and PNI (perineural invasion) 
were all signifi cantly associated with SVI on univariate analysis, while MRI, Gleason Grade, PSA and %Ca were sig-
nifi cantly associated with SVI on multivariate analysis. These results show that MRI can add signifi cant incremental 
value to clinical variables in the prediction of SVI
Chapter 6 demonstrated the use of PACS cross-referencing, which automatically links axial, coronal and sagittal 
planes of section, to facilitate noninvasive evaluation of SVI (84). We investigated 255 consecutive patients who un-
derwent endorectal MRI before radical prostatectomy. In detecting SVI, the AUCs of the two radiologists increased 
with cross-referencing (from 0.62 to 0.87, p=0.007 and from 0.73 to 0.90, p=0.056 for readers 1 and 2, respectively). 
Sensitivity/specifi city for SVI with MRI alone and with cross-referencing, respectively, was 38%/81% and 62%/93% 
for reader 1 and 62%/84% and 69%/94% for reader 2. PACS cross-referencing is particularly helpful in displaying the 
junction of the seminal vesicles and the central zone of the prostate. The results showed that PACS cross-referencing 
signifi cantly improves the detection of prostate cancer SVI by 3D MRI.  
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(4) Detection of lymph node metastasis
The presence of LNM at the time of prostate cancer diagnosis is associated with a high probability of progression 
after treatment and a poor prognosis (133-135). The risk of dying of prostate cancer at 10 years is much higher for 
patients with positive nodes than for patients with negative nodes (134).  Pretreatment knowledge of prostate 
cancer LNM is important for patient counseling and appropriate treatment selection and planning. The PSA level 
recommended by the American Urological Association (AUA) for identifying patients who are at high risk for devel-
oping lymph node metastases is 15 ng/mL. There is, however, a wide variation in the cut-off  values for PSA reported 
in the literature (136). The conventional criterion for detection of metastatic lymph nodes on imaging is a short axis 
of 8 mm (137). MRI and CT have similar effi  cacy in detecting lymph node metastases, with both modalities having 
low sensitivity. The low sensitivity of MRI has been attributed mainly to the inability of cross-sectional imaging to 
detect metastases in normal-sized nodes (137, 138). Promising results by Harisinghani et al. have been reported for 
the use of ultra-small, super-paramagnetic iron oxide particles as an aid to diagnosing lymph node metastases 
(LNM) by MRI (137, 139). These particles are taken up by normal nodal tissue but not by metastatic tissue, providing 
tissue contrast within the lymph node and allowing detection of metastases. The sensitivity of MRI for LNM may be 
increased through use of these compounds, since they appear to permit detection of metastases in normal-sized 
nodes (137, 139). Chapter 7 described a study of 411 consecutive patients with clinically localized prostate cancer 
who underwent endorectal MRI before surgery (48). The overall positive lymph node rate of 5% confi rmed the de-
creasing incidence of LNM in prostate cancer patients (1). The results showed that MRI was an independent statisti-
cally signifi cant predictor of LNM (p = 0.002), with sensitivity and specifi city of 27.27% and 98.46%, respectively, and 
positive predictive value and negative predictive value of 50% and 95.99%, respectively. On multivariate analysis, 
prediction of lymph node status using the model that included all MRI variables (ECE, SVI, and LNM) along with the 
Partin nomogram results had a signifi cantly greater AUC than the univariate model that included only MRI LNM fi nd-
ings (AUC = 0.892 vs 0.633, respectively; p < 0.01). The study data confi rmed the high negative predictive value of 
MRI for LNM and indicated that a combination of endorectal and phased-array MRI with the Partin tables had high 
accuracy in predicting LNM. As MRI also provides anatomic information that is helpful in treatment planning, these 
fi ndings suggest that MRI, in conjunction with the Partin tables, may be useful for determining whether further 
imaging with lymphotropic superparamagnetic nanoparticles is warranted. 
The use of MRI in presurgical planning
Risk-adjusted, patient-specifi c therapy designed to maximize cancer control while minimizing the risks of complica-
tions is being mandated (10, 81). Such an approach requires accurate characterization of the cancer location and 
extent. Optimal treatment for prostate cancer is best selected based on clinical TNM stage, Gleason grade and PSA 
level. The decision to treat should also take into account patient age, disease stage, associated medical illnesses, and 
the patient’s personal preferences. 
Historically, in 1905 Hugh Hampton Young reported radical prostatectomy utilizing a transperineal approach (140). 
In 1982 Patrick Walsh fi rst described nerve sparing radical prostatectomy (141). The procedure was a revolutionary 
discovery to remove the prostate and seminal vesicles completely while preserving erectile function in previously 
potent men. Despite its obvious attractions, the nerve sparing procedure proved to be controversial (116, 142). In 
1997, Peter Scardino, and Rahul Nath performed the fi rst nerve grafting during a radical prostatectomy in order to re-
store sexual function after radical prostatectomy, though this procedure is still considered experimental (143-145).
Most cancers treated today are not palpable, and apart from the information obtained by ultrasound and biopsy, 
the surgeon has limited information about the size, location and extent of the cancer. Impotence (erectile dysfunc-
tion) is one of the possible complications after RP. Karakiewicz et al surveyed 2415 men treated for localized prostate 
cancer by radical prostatectomy and found a 75% rate of erectile dysfunction (146). Impotence after RP is quantita-
tively related to the resection of the neurovascular bundles (NVBs) that closely run along two sides of the prostate 
and control the blood fl ow to the penis and erections (147). However, prostate carcinoma most commonly arises in 
the peripheral zone of the prostate, often posteriorly, just beneath the capsule. A positive surgical margin reportedly 
increases the probability of disease recurrence (121, 148). Consequently, surgeons often resect widely in areas of sus-
pected ECE to avoid a positive surgical margin (144, 149, 150). In spite of all precautions, positive surgical margins are 
still present in approximately 23-31% of RP specimens (149, 151). The surgeon’s ultimate goal is to excise the cancer 
completely while preserving the nearby normal structures, thus avoiding positive surgical margins and minimizing 
the chances of recurrence and allowing recovery of sexual function. Because the recovery of erectile function and 
the avoidance of positive surgical margins are important but competing outcomes, the decision to preserve or re-
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sect a neurovascular bundle during radical prostatectomy should be based on the most accurate information con-
cerning the location and extent of the tumor. As we have seen from Chapters 2, 3, 5, and 7, the inclusion of MRI/MRSI 
fi ndings in clinical nomograms and variables improves the prediction of cancer extent (OCPC, ECE, SVI and LNM), 
thereby improving patient selection for local therapy. Furthermore, as described in Chapter 8, information from MRI 
can assist in pre-surgical planning. The study involved 135 patients with biopsy proved prostate cancer (81). All pa-
tients underwent an assessment from the urologist as to the need for neurovascular bundle resection. This decision 
was based on DRE, PSA, biopsy results, percentage of positive biopsy cores, the percentage of tumor involved in 
each core and the Partin nomogram. After this assessment the urologist reviewed the MRI in consultation with the 
radiologist, and the surgeon’s assessment of the need for neurovascular bundle (NVB) resection was recorded. The 
areas under the ROC curves were 0.741 for pre-MRI and 0.832 for post-MRI surgical planning (p<0.01). MRI fi ndings 
suggested altering the surgical plan in 39% (106/270) of NVBs. When the surgeon judged that the NVB resection was 
defi nitely not necessary (165 NVBs), MRI confi rmed that decision in 138 NVBs (84%); the concordant decision was 
correct in 96% of the cases (133 of 138 NVBs). In 36 high-risk patients ( 25% probability of organ-confi ned prostate 
cancer), MRI fi ndings changed the surgical plan for 28 NVBs (78%); the change was found to be appropriate in 26 
cases (93%).The study found that MRI signifi cantly improved the surgeon’s decision to preserve or resect the neu-
rovascular bundle(s). Such decisions are especially important in high-risk patient groups (81). MRI can help to refi ne 
the surgical plan, to maximize the preservation of periprostatic tissues (important for recovery of urinary and sexual 
function), and to minimize the risk of positive surgical margins. Thus, preoperative MRI can provide additional, criti-
cal information that allows treatment to be adjusted to an optimal, patient-specifi c therapy.
 MRI in the assessment of recurrence-free probabillities
An estimated one third of patients treated with radical prostatectomy later experience biochemical recurrence as 
defi ned by increases in prostate-specifi c antigen (PSA) levels (21, 56, 152). The natural history of biochemical recur-
rence after radical prostatectomy can be long but variable. Early identifi cation, before detectable PSA is measured, 
of men likely to ultimately experience disease progression would be useful in considering early adjuvant therapy 
(153-156). Accurate identifi cation of the risk of disease recurrence would also be particularly useful in clinical trials to 
assure comparability of treatment and control groups or to identify appropriate candidates for investigational treat-
ment (157, 158). To aid in patient counseling, pre-operative nomograms have been developed that give an estimate 
of the chances of freedom from disease recurrence after RP rather than placing the patient in a risk group (61, 157). 
The nomograms are graphic representations of a statistical model, with scales for calculating the prognostic weight 
of a value for each individual variable (54, 157). Nomograms tend to outperform both expert clinicians and predic-
tive instruments based on risk grouping. In general, nomograms are validated using patients treated at academic 
centers (45, 68, 159). Although current nomograms are limited in their application and accuracy, eff orts are continu-
ously under way to improve them and to develop novel instruments for other end points. 
Chapter 9 described a study that investigated whether the addition of MRI fi ndings could signifi cantly improve the 
accuracy of a preoperative nomogram for predicting biochemical recurrence, using post-operative predictions of 
biochemical recurrence as the standard of reference. The study included 592 consecutive patients with biopsy-
proven prostate cancer who were referred for endorectal MRI prior to RP. The design of the MRI scoring system in 
the study was based on the predicted pathologic stage; a higher score was assigned to each increase in stage, as it 
has been shown that higher pathologic stages are associated with higher rates of biochemical recurrence (121, 154). 
The 10-year biochemical recurrence-free probabilities for patients with OCPC, ECE, SVI and LNM were previously 
reported to be 92%, 71%, 37% and 7%, respectively (121). Each of these parameters was a signifi cant predictor of 
recurrence on multivariate analysis, and the ability of MRI to successfully identify each of these parameters has been 
demonstrated in chapters 2-7. The addition of MRI scores to the pre-operative nomogram signifi cantly improved 
the R-square value of the pre-operative nomogram in the total study cohort (0.58 vs. 0.53; p<0.01) and in a subset 
of patients (PSA≥10, Gleason score ≥7 on biopsy or clinical stage T2) at high risk for biochemical recurrence (0.61. 
vs. 0.58; p<0.01). The study suggests that the addition of MRI fi ndings can signifi cantly improve the accuracy of the 
Kattan pre-operative nomogram in predicting postoperatively determined recurrence-free probabilities.
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Role of MRI in assessing prostate cancer aggressiveness
One of the most challenging characteristics of prostate cancer is its variable biologic aggressiveness, (43, 160-162). 
Noninvasive assessment of tumor aggressiveness for prostate cancer management may provide important diag-
nostic information and therefore help stratify patients for appropriate treatment (10).
The Gleason scoring system assigns increasing pattern grades as the glands formed by the prostate epithelial cells 
become more poorly diff erentiated, the margins of the tumor become more poorly defi ned, and the degree of stro-
mal invasion increases (163, 164). The system remains one of the most powerful prognostic predictors of prostate 
cancer nearly 40 years after its initial description. It is endorsed as the primary grading system for prostate cancer 
by the World Health Organization (WHO), the Armed Forces Institute of Pathology Fascicle on Prostate Cancer, the 
Association of Directors of Anatomic and Surgical Pathology, and the College of American Pathologists (165). The 
Gleason grading system was updated at the 2005 United States and Canadian Academy of Pathology Annual Meet-
ing (166-168).
Chapter 10 investigated seventy-four patients who underwent endorectal MRI before radical prostatectomy with 
subsequent whole-mount step-section pathology between January 2001 and July 2004 and had no prior treat-
ment; at least one lesion with bi-dimensional diameter product ≥ 20 mm2 of uniform Gleason grade 3 or 4 or with 
Gleason grade 5 components; and no high signal intensity indicating postbiopsy changes on T1-weighted images. 
The results showed that Gleason grade correlated signifi cantly (p<0.05) with tumor-to-muscle signal intensity ratio 
for peripheral zone and transition zone tumors on corrected (Tau-b = -0.50 and -0.35, respectively) and uncorrected 
(Tau-b = -0.51 and -0.33, respectively) images. Higher Gleason grades were associated with lower tumor-to-muscle 
signal intensity ratios, although there was some overlap between the signal intensity ratios for tumors of diff erent 
grades, perhaps due to tissue heterogeneity.  Non-tumor-to-muscle signal intensity ratios did not correlate with 
patients’ Gleason grades. Tumor-to-muscle signal intensity ratios were lower in transition zone than in peripheral 
zone tumors for all Gleason grade 3 lesions, (p<0.001). This study demonstrates that T2-weighted endorectal MRI 
has the potential to allow noninvasive assessment of prostate cancer biological aggressiveness, which could help 
stratify patients for appropriate management. 
Color-coded parameter imaging derived from post-processing of DMGE-MRI of abdominal tumors
Post-processing of dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) of the abdomen allows generation 
of color-coded parameter images and time-intensity curves. Chapter 11 illustrates the current status and potential 
applications of automated and color-coded post processing techniques for analysis of dynamic multiphasic gado-
linium-enhanced MR imaging of abdominal tumors.
The color-coded images are qualitative pixel-wise displays of various parameters, which are derived from the quan-
titative data of the time-intensity curves at each pixel or compartment pharmacokinetic modeling (169-171). Analy-
sis of the time-intensity curves and the derived parameters are very helpful in quantitative characterization of tumor 
enhancement patterns and tumor angiogenesis related to tumor growth, grade, and metastatic potential (83, 171-
187). In addition, the parameters may also improve the specifi city of MRI fi ndings and help to facilitate monitoring 
of anti-tumor therapy response (176, 177, 188).
Prostate cancer is hypervascular cancer. Typically prostate cancer will demonstrate earlier signal enhancement 
(higher wash-in rate than benign prostate tissue) and will lose much of its contrast in later phases (higher wash-out 
rate than benign prostate tissue), especially in the relatively less enhancing peripheral zone but a large overlap of 
the wash-in/out rates between prostate cancer and benign prostate tissue in transitional zone (175, 189-197). The 
optimal parameter is relative enhancement parameter for discrimination of cancer from normal tissue in peripheral / 
transitional zone tissue. The second best parameter is maximum enhancement in the peripheral zone and wash-out 
in the transitional zone (196). Color-coded parameter images can assist in determining established / minimal ECE 
in peripheral zone / transitional zone and SVI (198). Prostate cancer has a Type III curve. The time-intensity curves as 
well as the color-coded parameter are useful for prostate cancer detection and localization and staging and have 
potential in monitoring the eff ects of therapy and detecting tumor microvessel density and permeability (175, 184, 
190-194, 198, 199).
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The mechanisms behind the diff erential contrast enhancement are thought to include diff erences in tumor perfu-
sion and the levels of tumor capillary wall permeability and hydrostatic pressure. The growth of a tumor, and its 
associated angiogenesis, is often rapid and disordered, leading to: 1) a relatively high fraction of immature blood 
vessels; 2) abnormal basal membranes in the vessel wall with relative lack of pericytes or smooth muscle asso-
ciations with endothelial cells which render the vessels more “leaky” or permeable (providing an access point for 
contrast agents); 3) tumor vessels are tortuous, vary in diameter, and tend toward excessive branching and shunt 
formation; 4) intermittent or unstable blood fl ow with acutely collapsing vessels; and 5) hydrostatic pressure diff er-
ences between tumors and normal tissue, partly reduced or absent lymphatics which may infl uence contrast agent 
uptake. Vascular endothelial growth factor, VEGF, has a role to play in increasing the permeability of these vessel 
walls. Blood volume, blood fl ow, mean transit time and microvascular permeability–surface area product are all, in 
principle, quantifi able through analysis of dynamic gadolinium-enhanced MRI by using pharmaco-kinetic models 
(170, 171, 176-178, 184, 186, 190-194, 198, 200-207). Tumor regions with dense neovasculature may enhance more 
rapidly compared to other regions. The position of these regions is related to the distribution of viable blood sup-
ply within the tumor. In necrotic or cystic regions, vascular density can be extremely low, whereas in highly active 
regions, the vascular density can be high.
The color-coded parameter images can provide information concerning focal or diff use disease processes. This 
reduces the risk of missing areas of pathology, and reduces the risk of creating regions-of-interest (ROI) containing 
more than one tissue type, and makes further ROI analysis more accurate. In addition, the color-coded parameter 
images combine both the enhancement pharmaco-kinetics of tissues and morphology, and visualize the enhance-
ment changes over time.
The parameters derived from the time-intensity curves, which are the basis of the color-coded parameter images, 
have contributions from contrast dose as well as MR pulse sequence parameters. Therefore, it is diffi  cult to compare 
the results of studies from diff erent institutions. Application of pharmaco-kinetic modeling has the potential to 
standardize the results from separate groups. The patient motion might lead to faulty time-signal-intensity curves 
at each pixel, and hence to faulty functional images.
The color-coded parameter images are limited by the necessary trade-off  between temporal resolution, spatial 
resolution, and slice coverage. A high temporal resolution is needed at the expense of spatial resolution and slice 
coverage. When the color-coded parameters are suffi  ciently accurate, it could be possible to lower temporal resolu-
tion and therefore increase spatial resolution (which is essential in locating small tumors) and slice coverage (208). 
Prospects and recommendations for further research
The 1.5-Tesla (1.5T) MR scanner used in the studies described in Chapters 2-11 is becoming more widely available in 
the routine clinical setting to depict and stage prostate cancer. The introduction of an endorectal coil and fast spin-
echo sequences enabled the acquisition of T2-weighted images of the prostate and its surrounding structures with 
a high spatial resolution within clinically acceptable examination times. Despite the relatively high spatial resolution 
that routinely can be acquired, Clearly there is still substantial room for improvement, as refl ected in the widely 
varying staging accuracy (50% to 92%) with low sensitivity and considerable inter-reader variability (ECE: specifi city 
47-99%, sensitivity 22-80%) reported in the literature (10, 46-48, 75, 76, 80, 84, 89, 94-110).
Future improvements in MR imaging: 3T, new coils
“Science and technology is an endless frontier,” the eminent American physicist Vannevar Bush once said. MRI as an 
imaging modality for one-stop prostate imaging remains in evolution, even revolution, and advances are continu-
ously being made in accuracy (86, 208, 209).
As 3T MR scanners become more available, body imaging at high fi eld strength and improved coil design is becom-
ing the subject of intensive research (208, 210-212). Theoretically, increasing static magnetic fi eld strength (B0) from 
1.5T to 3T will result in a theoretical doubling of the signal-to-noise ratio (SNR). This in turn can be used to achieve 
greater spatial resolution and/or reduce scanning time. However, chemical shift and susceptibility artifacts also 
increase linearly with B0. Improvements in coil design include the use of rigid coils with higher signal and the intro-
duction of a susceptibility-matched agent into the rectum to reduce distortions relating to the interface of rectal air 
and tissue. The following advantages can be expected from imaging of prostate cancer with higher fi eld strength 
and improved coil design:
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(1) Increased spatial resolution due to increased signal-to-noise ratio (SNR) may improve the detection of micro-
scopic extracapsular extension. Microscopic extracapsular extension is (ECE) defi ned as the presence of no more 
than a few malignant cells immediately outside the capsule on no more than 2 sections. The 10-year risk of recur-
rence (clinical, radiological or biochemical) was 32% in patients with microscopic ECE compared to 42% in patients 
with more established ECE, suggesting that microscopic ECE is nearly as important as macroscopic ECE with respect 
to prognosis (9). 
(2) Higher fi eld strength should provide increased spectral and spatial resolution for spectroscopic imaging, but 
new pulse sequences will have to be designed for overcoming fi eld inhomogeneities and citrate J-modulation is-
sues. Signifi cant improvement in metabolite resolution in magnetic resonance spectroscopy with prostate cancer 
should be expected. 
(3) Faster scanning may help to reduce image artifacts related to patient motion and rectal peristalsis.
(4) Finally, dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) should achieve increased SNR and faster 
image acquisition, with a signifi cantly better trade-off  between temporal and spatial resolution.
Recommendations for further research
(1) Chapter 4 demonstrates that prostate cancer patients benefi t from the subspecialization of radiologists in geni-
tourinary imaging. Further study of the role of reader experience and the learning curve in the interpretation of 
prostate imaging would be helpful. 
(2) The studies described in Chapters 2-5 and 7-9 were not designed to assess MRI technology, but to assess the 
value of MRI as applied in the clinical setting, during radiologists’ regular clinical assignments. Accordingly, the read-
ers had access to clinical data such as PSA level and biopsy results when available in the patient’s medical record. 
As each exam was evaluated only once, interobserver and intraobserver variability could not be assessed. Further 
prospective multi-institutional studies would be helpful to confi rm our fi ndings. Such studies, however, should be 
designed with the knowledge that the quality of the images and the experience and training of the interpreter play 
an essential role in determining whether MRI can provide value in the care of patients with prostate cancer. 
(3) Further research is needed to assess the potential clinical applications of 3T MRI scanners, new coils, and new MRI 
techniques (e.g., diff usion-weighted imaging, dynamic contrast-enhanced imaging, and multimodality MR imag-
ing) in prostate cancer management.
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GENERAL SUMMARY AND CONCLUSIONS
The high incidence of prostate cancer, combined with downstaging at diagnosis and the slow natural progres-sion of the disease, has made its management a complex and controversial issue. Endorectal MRI is emerging as the most accurate imaging modality for the local anatomic assessment of prostate cancer. This dissertation 
assesses the value of current State-of-the-Art endorectal MRI in clinical practice and discusses the promise of the 
modality for improving prostate cancer management. 
MR images allow noninvasive assessment of the local extent of prostate cancer (including organ-confi nement, ex-
tracapsular extension, seminal vesicle invasion and lymph node metastasis) and can provide an indication of tumor 
aggressiveness based on signal intensity; thus MRI can assist in local staging and assessment of recurrence-free 
probabilities while providing surgeons with a visual road-map for optimal treatment planning. MRSI of the pros-
tate depicts the altered metabolism associated with prostate cancer. The addition of 1H MRSI to MRI has further 
improved the accuracy of MR imaging in prostate cancer staging. It may become possible to use MRI/1H MRSI 
to achieve more precise stratifi cation of patients in clinical trials, to monitor the progress of patients who select 
watchful waiting or minimally aggressive cancer therapies, and to guide and assess emerging local prostate cancer 
therapies. The second part of this dissertation illustrates the potential clinical application of color-coded parameter 
imaging derived from postprocessing of dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) of abdomi-
nal tumors. With more refi ned techniques, such as high-fi eld imaging, and with more experienced readers and 
more uniform image interpretation, the MR imaging–MR spectroscopy approach will have a tremendous capacity 
to improve patient care. 
Chapter 2 shows that MR fi ndings (from endorectal MRI or combined endorectal MRI/MRSI) contribute signifi cant 
incremental value to clinical staging nomograms in the prediction of organ-confi ned prostate cancer (OCPC) in all 
risk groups (low, intermediate, and high). The incorporation of endorectal MR imaging into future staging nomo-
grams for the prediction of OCPC may therefore be warranted, particularly since clinical staging in the current stag-
ing nomograms is based only on digital rectal examination. Moreover, unlike MRI, the staging nomograms cannot 
assist in the localization of ECE, which is critical for optimal treatment planning. It is worth noting that in the study, 
the accuracy of radiologists’ predictions of OCPC was higher in the combined MR group (MRI+MRSI) than in the 
endorectal MR imaging. 
Chapter 3 indicates that endorectal MR imaging fi ndings are signifi cant presurgical predictors of extracapsular ex-
tension (ECE) in patients with prostate cancer and add incremental value to clinical variables. At univariate analysis, 
all variables were associated with ECE. At ROC univariate analysis, endorectal MR imaging fi ndings had the largest 
area under the ROC curve. At multivariate analysis, serum PSA level, greatest percentage of cancer in all core biopsy 
specimens, and endorectal MR imaging fi ndings were predictors of ECE. A model containing endorectal MR imag-
ing fi ndings had a signifi cantly larger area under the ROC curve than a model containing only clinical variables. In 
addition, endorectal MR imaging fi ndings are spatially localized, and therefore, unlike clinical variables, they have 
the potential to allow tailored treatment modifi cations. 
Chapter 4 demonstrates that endorectal MR imaging fi ndings can be signifi cant predictors for ECE in patients 
with prostate cancer, after controlling for PSA level, Gleason score, greatest percentage of cancer in all core biopsy 
specimens, percentage of cancer-positive core specimens in all core biopsy specimens, PNI, and clinical stage of 
tumor. A comparison of the ROC curves drawn from the results of readings performed by genitourinary MR imaging 
radiologists and general body MR imaging radiologists showed that endorectal MR imaging fi ndings added value 
to all other predictor variables only when MR images were interpreted by genitourinary MR imaging radiologists. 
In the genitourinary radiologist group endorectal MR imaging fi ndings displayed a combination of sensitivity and 
specifi city that was superior to that of all other predictors tested. In the general body radiologist group, however, 
the combination of sensitivity and specifi city of endorectal MR imaging fi ndings was similar to that of the clinical 
predictors. Advances in technology and in the expertise of radiologists dedicated to the genitourinary fi eld sug-
gest that endorectal MR imaging could play an increasingly useful role in the treatment of patients with prostate 
cancer. 
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Chapter 5 shows that endorectal MRI fi ndings can contribute signifi cant incremental value to the Kattan nomo-
gram for predicting SVI. On both univariate and multivariate analysis, endorectal MRI fi ndings were a signifi cant 
presurgical predictor of seminal vesicle invasion. 
Chapter 6 shows that a PACS cross-referencing tool allows radiologists to more accurately interpret prostate MR 
imaging, improving prostate cancer tumor staging by MRI. In the detection of ECE and SVI, radiologists performed 
substantially better when using MRI with PACS cross-referencing rather than MRI alone. PACS cross-referencing is 
particularly helpful in displaying the junction of the seminal vesicles and the central zone of the prostate. 
Chapter 7 describes a study showing that incorporation of the Partin nomogram results with MRI fi ndings regard-
ing both extracapsular extension and seminal vesicle invasion improves the MR prediction of LNM in patients with 
prostate cancer. The study confi rmed that MRI has a high negative predictive value and an exceptionally high speci-
fi city in the prediction of LNM compared with clinical and histological variables. As MRI also provides anatomical 
information that is useful in treatment planning, it could potentially be used along with the Partin nomogram to 
determine whether additional imaging with lymphotropic superparamagnetic nanoparticles is indicated. 
Chapter 8 shows that review of preoperative MRI fi ndings signifi cantly improves the surgeon’s decision to preserve 
or resect the NVB(s) during radical prostatectomy. Preoperative MRI improved surgical planning in high-risk patients 
and provided appropriate reassurance for preserving the NVB(s) in other patients. The strength of MRI for low-risk 
and intermediate-risk patients lies in a high negative predictive value (i.e., demonstration of the absence of tumor 
in the region of interest). 
Chapter 9 shows that the addition of MRI fi ndings signifi cantly improves the accuracy of the Kattan pre-operative 
nomogram in predicting postoperatively determined recurrence-free probabilities in the total study cohort and in a 
subset of patients (PSA≥10, Gleason score ≥7 on biopsy or clinical stage T2) at high risk for biochemical recurrence. 
Chapter 10 discusses a study demonstrating that MRI has potential in the noninvasive assessment of prostate 
cancer biological aggressiveness. First, there is a signifi cant correlation between prostate cancer Gleason grade and 
tumor-to-muscle signal intensity ratio on T2-weighted MR images; a higher Gleason grade is associated with a lower 
tumor-to-muscle signal intensity ratio. Second, on T2-weighted MR images, Gleason grade 3 cancer in the transition 
zone has a signifi cantly lower tumor-to-muscle signal intensity ratio than Gleason grade 3 cancer in the peripheral 
zone of the prostate.
Chapter 11 is restricted to current reviews of major topics in radiology and brief case reports on postprocessing of 
dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) of the abdominal tumors. Post-processing of dynamic 
multiphasic gadolinium-enhanced MRI (DMGE-MRI) of the abdomen allows the generation of color-coded param-
eter images and time-intensity curves that provide new opportunities for research and for improving the detection, 
staging and therapeutic monitoring of disease and the development of anti-tumor drugs. First the color-coded 
parameter images and time-intensity curves contribute to a better understanding of tumor enhancement patterns 
and angiogenesis, and hence may result in improved quantitative characterization of tumors. Second, the mecha-
nisms behind the diff erential signal enhancement of dynamic multiphasic gadolinium-enhanced MRI (DMGE-MRI) 
are thought to include diff erences in tumor perfusion and the levels of tumor capillary wall permeability and hy-
drostatic pressure. Third, the time-intensity curves and only a small number of parameters need to be displayed 
as color-coded parameter images on a workstation. These robust parameters include: 1) relative enhancement; 2) 
wash-in rate; 3) wash-out rate; 4) brevity of enhancement.
In Chapter 12, the results of all the studies mentioned above are discussed in relation to one another and to the 
current literature. Recommendations for clinical practice are made.
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CONCLUSIONS
The following overall conclusions can be made: 
1. In patients with prostate cancer, endorectal MR imaging non-invasively improves pretreatment staging 
 and treatment planning and the evaluation of recurrence-free probabilities; it can also provide an indication 
 of cancer aggressiveness.
2. The incorporation of endorectal MR fi ndings into future nomograms for the prediction of prostate cancer 
 stage and freedom from biochemical recurrence is warranted.
3. Advances in technology, such as a PACS cross-referencing tool, and in the expertise of radiologists dedicated 
 to the genitourinary fi eld suggest that endorectal MR imaging can play an increasingly useful role in prostate 
 cancer management.
4. Information from preoperative MR imaging allows the surgeon to signifi cantly refi ne the surgical plan, 
 maximizing the preservation of periprostatic tissues (important for recovery of urinary and sexual function)
5. Inclusion of time-intensity curves and color-coded images as part of the routine abdominal MR imaging 
 work-up protocol facilitates the diagnostic work-up of disease for detection, staging, and monitoring of 
 anti-tumor therapy.
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SAMENVATTING
De hoge incidentie van prostaatkanker in combinatie met een vroegere opsporing, downstaging ten tijde van de diagnose en de langzame natuurlijke voortgang van deze ziekte heeft de beheersing ervan tot een complexe en controversiële kwestie gemaakt. De meest nauwkeurige beeldvormende modaliteit voor de 
lokale anatomische beoordeling van prostaatkanker blijkt MRI te zijn. 
Dit proefschrift presenteert de huidige toepassing van geavanceerde MRI in de klinische praktijk en bespreekt de 
verwachtingen van deze modaliteit voor een betere beheersing van prostaatkanker. MR-beelden maken een niet-
invasieve beoordeling van de lokale omvang (met inbegrip van OC, ECE, SVI en LNM) en verandering van de signaa-
lintensiteit mogelijk, waardoor deze behulpzaam kunnen zijn bij de lokale stadiëring en bij het bepalen van de kans 
op agressieve tumoren en de kans dat tumoren niet zullen terugkeren, terwijl het artsen voorziet van een visuele 
routekaart voor de behandelingsplanning om ervan verzekerd te zijn dat de kanker in zijn geheel wordt verwijderd 
en dat kanker op de lange termijn beter kan worden bestreden zonder dat de kritieke zenuwen en de sfi ncter die 
de geslachts- en urinefunctie regelen verwijderd hoeven te worden. MRSI van de prostaat geeft een beeld van 
het veranderde metabolisme dat verband houdt met prostaatkanker. Door 1H MRSI toe te voegen aan MRI is de 
nauwkeurigheid van MR bij de stadiëring van prostaatkanker nog verder verbeterd. Wellicht wordt het mogelijk om 
door middel van MRI/1H MRSI in klinische proeven een preciezere stratifi catie van patiënten te bewerkstelligen, 
om de voortgang te bewaken bij patiënten die kiezen voor oplettend afwachten of minimaal agressieve kanker-
therapieën, en om nieuwe lokale prostaatkankertherapieën te begeleiden en te beoordelen. Het tweede deel van 
het proefschrift beschrijft de potentiële klinische toepassing van kleurgecodeerde parameterbeeldvorming die is 
afgeleid van de nabewerking van dynamische meerfasige met gadolinium verbeterde MRI (DMGE-MRI) van ab-
dominale tumoren: prostaatkanker als één van paradigma’s. Met meer verfi jnde technieken, zoals beeldvorming 
met hoge veldsterkte, meer ervaren lezers en een meer uniforme beeldinterpretatie, zal de benadering van MRI en 
MR-spectroscopie belangrijke kansen bieden om de patiëntenzorg te verbeteren.
In Hoofdstuk 2 wordt aangetoond dat MR-bevindingen (op basis van endorectale MRI of een combinatie van 
endorectale MRI en MR-spectografi sche beeldvorming) aanzienlijke incrementele waarde toevoegen de klinische 
stadiëringsnomogrammen bij de predictie van orgaanbeperkte prostaatkanker. Hierdoor kan worden gewaarborgd 
dat endorectale MRI in de toekomst deel zal uitmaken van stadiëringsnomogrammen voor de predictie van or-
gaanbeperkte prostaatkanker. Ten eerste is er, ondanks het krachtige predictievermogen en de kosteneff ectiviteit 
van de stadiëringsnomogrammen, ruimte voor verbetering van de nauwkeurigheid van de predictie, vooral omdat 
de klinische stadiëring bij de stadiëringsnomogrammen uitsluitend gebaseerd is op digitaal rectaal onderzoek. 
Bovendien kunnen de stadiëringsnomogrammen niet gebruikt worden voor het lokaliseren van ECE, wat voor een 
optimale behandelingsplanning essentieel is. Ten tweede is het oppervlak onder de ROC-curve door de toevoeging 
van MR-bevindingen zowel bij de groep met een laag risico als bij de groepen met een middelmatig en hoog risico 
aanzienlijk groter geworden. Ten derde is de nauwkeurigheid van de predictie van orgaanbeperkte prostaatkanker 
door radiologen bij de groep met een combinatie van MR (MRI + MRSI) groter dan bij de groep met endorectale 
MRI.
In Hoofdstuk 3 wordt aangegeven dat de bevindingen op basis van endorectale MRI bij patiënten met prosta-
atkanker belangrijke prechirurgische predictoren van ECE zijn en incrementele waarde toevoegen aan klinische 
variabelen. Ten eerste werden bij de univariate analyse alle variabelen in verband gebracht met ECE. Bij de univari-
ate analyse van de ROC bleek het oppervlak onder de ROC-curve bij de bevindingen op basis van endorectale MRI 
het grootst te zijn. Bij de multivariate analyse waren het PSA-gehalte in het serum, het percentage kanker bij alle 
kritieke biopten en de bevindingen op basis van endorectale MRI predictoren van ECE. Een model met daarin de 
bevindingen op basis van endorectale MRI heeft onder de ROC-curve een aanzienlijk groter oppervlak dan een 
model met uitsluitend klinische variabelen. Bovendien zijn de bevindingen op basis van endorectale MRI ruimtelijk 
gelokaliseerd en bieden deze hierdoor in tegenstelling tot klinische variabelen mogelijkheden voor maatwerk in de 
behandeling.
In Hoofdstuk 4 wordt aangetoond dat de bevindingen op basis van endorectale MRI bij patiënten met prosta-
atkanker belangrijke predictoren van ECE kunnen zijn na rekening te hebben gehouden met het PSA-gehalte, de 
Gleason-score, het hoogste percentage kanker in alle kernbiopten, het percentage kankerpositieve kernbiopten bij 
alle kernbiopten, PNI en de klinische stage van de tumor. Uit een vergelijking van de ROC-curves, getekend op basis 
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van de resultaten van de metingen die zijn verricht door radiologen met behulp van MRI van de genitourinaire 
tractus en door radiologen met behulp van MRI van het lichaam in zijn algemeenheid, is gebleken dat de bevind-
ingen op basis van endorectale MRI alleen waarde toevoegen aan alle andere predictievariabelen wanneer de MR-
beelden worden geïnterpreteerd door de radiologen die gewerkt hadden met MRI van de genitourinaire tractus. 
Ten eerste lieten de bevindingen op basis van endorectale MRI door de groep radiologen van de genitourinaire 
tractus een combinatie van gevoeligheid en specifi citeit zien die beter was dan bij alle andere geteste predictoren. 
Bij de groep radiologen die gewerkt hadden met MRI van het lichaam in zijn algemeenheid, leek de combinatie 
van gevoeligheid en specifi citeit van de bevindingen op basis van endorectale MRI echter op die van de klinische 
predictoren. Ten tweede voegen de bevindingen op basis van endorectale MRI aanzienlijke waarde toe bij de di-
agnose van ECE bij patiënten met prostaatkanker wanneer MR-beelden worden geïnterpreteerd door radiologen 
met ervaring in MRI van de prostaat. De ontwikkelingen in de technologie en in de deskundigheid van radiologen 
die gespecialiseerd zijn in de genitourinaire tractus wijzen erop dat de endorectale MRI een steeds nuttigere rol zou 
kunnen spelen bij de behandeling van patiënten met prostaatkanker.
In Hoofdstuk 5 wordt aangegeven dat de bevindingen op basis van endorectale MRI aanzienlijke incrementele 
waarde kunnen toevoegen aan het Kattan-nomogram voor de predictie van SVI. Hoewel verdere bevestigende 
onderzoeken van meerdere centra nuttig zouden zijn, gaan wij ervan uit dat MRI een belangrijke rol kan spelen bij 
de aan behandeling voorafgaande niet-invasieve evaluatie van prostaatkanker, met inbegrip van de predictie van 
SVI. Ten eerste zijn de bevindingen op basis van endorectale MRI na univariate en multivariate analyse een belan-
grijke prechirurgische predictor van aantasting van de zaadblaasjes (seminal vesicle-invasie). Ten tweede wordt er 
door het toevoegen van de bevindingen op basis van endorectale MRI aanzienlijke incrementele waarde toege-
voegd aan het Kattan-nomogram voor de predictie van SVI. 
Hoofdstuk 6 beschrijft het PACS-referentiehulpmiddel dat radiologen in staat stelt om de MRI van de prostaat 
nauwkeuriger te interpreteren waardoor de stadiëring van prostaatkankertumoren door MRI aanzienlijk wordt ver-
beterd. Bij het opsporen van ECE en SVI presteerden radiologen bij het toepassen van MRI met PACS-referentie 
aanzienlijk beter dan met alleen MRI. PACS-referentie is vooral nuttig voor beeldvorming van de verbinding tussen 
de zaadblaasjes en de centrale zone van de prostaat.
In Hoofdstuk 7 wordt nader ingegaan op het feit dat de MR-predictie van LNM bij patiënten met prostaatkanker 
wordt verbeterd wanneer de resultaten van Partin-nomogrammen en de bevindingen van MRI betreff ende ex-
tracapsulaire extensie en seminal vesicle-invasie mede in beschouwing worden genomen. Ten tweede zou een 
combinatie van endorectale en gefaseerde reeks MRI’s, aangevuld met de Partin-nomogrammen, gebruikt kun-
nen worden om te bepalen of aanvullende beeldvorming met lymfotropische superparamagnetische nanodeeltjes 
geïndiceerd is. Ten derde wordt bevestigd dat erMRI in vergelijking met klinische en histologische variabelen een 
hoge negatieve predictieve waarde en een uitzonderlijk hoge specifi citeit heeft bij de predictie van LNM. Ten vierde 
verschaft erMRI als zodanig anatomische informatie die nuttig is voor de behandelingsplanning.
In Hoofdstuk 8 wordt de incrementele waarde van endorectale magnetische resonantiebeeldvorming (eMRI) voor 
deze voorbehandelingsplanning bepaald. Door een preoperatieve MRI kan de chirurg veel beter bepalen of de 
NVB moet worden behouden of operatief moet worden verwijderd tijdens radicale prostatectomie, en daardoor 
aanvullende kritieke informatie verschaff en zodat de behandeling optimaal kan worden afgestemd op de patiënt. 
Ten eerste leidde eMRI voorafgaand aan RP bij patiënten met een hoog risico tot een betere chirurgische planning, 
en zorgde deze bij de andere patiënten voor de nodige geruststelling omdat de NVB kon worden behouden. Bij de 
groep met een hoog risico heeft MRI incrementele waarde bij de klinische beoordeling als aanvulling op het Partin-
stadiëringsnomogram, een vereenvoudigde klinische risicostratifi catie (met gebruikmaking van het PSA-gehalte, de 
Gleason-score en het klinische ziektestadium) of het percentage positieve biopsiescores. Ten tweede hielp MRI bij 
de groepen met een laag en middelmatig risico om voor de nodige geruststelling te zorgen in die gevallen waarin 
behoud van de NVB in de chirurgische planning vóór de MRI de voorkeur genoot. Voor patiënten met een laag 
en middelmatig risico ligt de kracht van MRI in een hoge negatieve predictiewaarde (d.w.z. aantonen dat er in de 
betreff ende regio geen tumoren aanwezig zijn).
In Hoofdstuk 9 wordt aangegeven dat de toevoeging van de bevindingen op basis van MRI tot een aanzienlijke 
verbetering leidt van de nauwkeurigheid van het preoperatieve Kattan-nomogram bij de predictie van postopera-
tief bepaalde waarschijnlijkheden van het niet-terugkeren van de kanker bij de totale onderzoekscohort en bij een 
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deelgroep van patiënten (PSA ≥10, Gleason-score ≥7 na biopsie of klinisch stadium T2) met een hoog risico van 
biochemische herhaling. 
In Hoofdstuk 10 wordt aangetoond dat MRI mogelijkheden biedt bij de niet-invasieve beoordeling van de agres-
siviteit van prostaatkanker. Ten eerste toont de signaalintensiteit van prostaatkanker op een T2-gewogen MRI een 
duidelijk verband met de pathologische Gleason-graad. De prostaattumor-spierverhouding op een T2-gewogen 
MRI toont een duidelijk negatief verband met de Gleason-score die is verkregen op basis van chirurgische patholo-
gie. Ten tweede zijn de PZ-tumor-spiersignaalverhoudingen hoger dan die bij TZ.
Hoofdstuk 11 is beperkt tot actuele besprekingen van belangrijke onderwerpen op het gebied van radiologie en 
korte casusverslagen over de nabewerking van een dynamische meerfasige met gadolinium versterkte MRI (DMGE-
MRI) van de abdominale tumoren: prostaatkanker als één van paradigma’s. De nabewerking van een dynamische 
meerfasige met gadolinium versterkte MRI (DMGE-MRI) van het abdomen maakt het mogelijk om kleurgecodeerde 
parameterbeelden en tijdsintensiteitscurves te genereren die nieuwe kansen bieden voor onderzoek en verbeter-
ing van de diagnostiek van ziekten voor de opsporing, stadiëring, therapeutische bewaking en ontwikkeling van 
medicijnen voor het bestrijden van tumoren. Ten eerste dragen de kleurgecodeerde parameterbeelden en tijdsin-
tensiteitscurves op basis van de farmacokinetische modellering bij aan een beter begrip van tumorversterkingspa-
tronen en angiogenese, en kan daardoor resulteren in een betere kwantitatieve karakterisering van tumoren. Ten 
tweede wordt gedacht dat de mechanismen achter de diff erentiaalsignaalversterking van dynamische, meerfasige 
met gadolinium versterkte MRI (DMGE-MRI) verschillen bevatten in tumorperfusie en de mate van hydrostatische 
druk en permeabiliteit van de capillaire wand van de tumor. Ten derde hoeven op een werkstation alleen de tijdsin-
tensiteitscurves en slechts een klein aantal parameters te worden weergegeven als kleurgecodeerde parameter-
beelden. Deze krachtige parameters zijn onder andere: 1) de relatieve versterking; 2) de instroomsnelheid (WIR); 3) 
de uitstroomsnelheid (WOR); 4) de korte duur van de versterking.
In Hoofdstuk 12 worden de resultaten van alle bovengenoemde onderzoeken besproken, zowel in relatie tot 
elkaar als in relatie tot de actuele literatuur. Er worden aanbevelingen voor de klinische praktijk gedaan.
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Figure 1. Graph shows comparison of ROC curves of seven 
variables for prediction of ECE. Area under ROC curve for MR 
imaging fi ndings is 0.743. Diagonal line indicates area under 
ROC curve of 0.500 (ie, no separation between patients with 
and patients without ECE). Predictor variables treated as 
continuous variables except for Gleason score (categorized 
as 3 + 2, 3 + 3, and 3 + 4 vs 3 + 5, 4 + 3, 4 + 4, 4 + 5, and 5 + 5) 
and clinical stage of cancer (categorized as T1c vs T2a, T2b, 
and T2c). % Ca = greatest percentage of cancer in all core 
biopsy specimens, % of Pos Cores = percentage of cancer-
positive core specimens in all core biopsy specimens.
CHAPTER 3
Figure 1d: Images in a 55-year-old man with a small palpable clini-
cal stage T2 prostate nodule and PSA level of 0.80 ng/mL. Sextant 
biopsy results showed Gleason grade 3 + 3 cancer involving 10% 
of submitted tissue from the right side (50% of the cores) and no 
perineural invasion. By using staging nomograms, the likelihood 
of OCPC was determined to be 81%. (a–c) T2-weighted fast spin-
echo MR images. (a) Transverse 3-mm-thick MR (4900/118) image 
shows OCPC (arrow) in the right apex. (b) Sagittal 4-mm-thick MR 
(6000/97) image shows a focus of cancer (arrow) in the right apex 
and midgland. (c) Coronal 3-mm-thick MR (4666/96) image shows 
cancer (arrow) in the right apex and midgland. (d) Whole-mount se-
rial section of the removed prostate shows organ-confi ned cancer 
(arrow) involving the right posterior quadrant of the prostate. 
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Figure 1. Graph shows ROC curves of univariate analy-
sis results for all predictors of ECE. Predictors analyzed as 
continuous variables are indicated (*). Gleason score was 
categorized as 3 + 2 and 3 + 3 versus 3 + 4, 4 + 3, 3 + 5, 4 + 
4, 4 + 5, and 5 + 5. Clinical stage of tumor was categorized 
according to TNM classifi cations as T1c versus T2a, T2b, and 
T2c. Diagonal line indicates area under ROC curve of 0.500. 
General MRI = endorectal MR imaging fi ndings for general 
body radiologist group, % Ca = greatest percentage of can-
cer in all core biopsy specimens, GU MRI = endorectal MR 
imaging fi ndings for genitourinary radiologist group, % of 
Pos Cores = percentage of cancer-positive core specimens 
in all core biopsy specimens. 
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Figure 1c: pT4 prostate cancer (clinical stage T2b with 
PSA level of 12.42 ng/mL) and bilateral seminal vesicle 
involvement in a 63-year-old man. Sextant biopsy re-
sults showed Gleason grade 4 + 3 tumors involving 
50% of the total submitted tissue on both sides (94% of 
total submitted cores were positive) and PNI in left pe-
ripheral and transition zones. According to the Kattan 
staging nomogram, the likelihood of SVI was 18%. (a) 
Transverse T2-weighted fast spin-echo 3-mm-thick MR 
image (4900/118 [repetition time msec/eff ective echo 
time msec]) and (b) coronal T2-weighted fast spin-echo 
3-mm-thick MR image (4666/96) show bilateral SVI (ar-
rows). (c) Whole-mount pathologic step section shows 
prostate cancer with bilateral seminal vesicle involve-
ment. The green circle represents the area with a Glea-
son grade of 3, and the black circle represents the area 
with a Gleason grade of 4 or a mixture of Gleason grades 
4 and 5. LSV = left seminal vesicle, RSV = right seminal 
vesicle. 
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Fig. 1D: 53-year-old man with clinical stage 
T1c prostate carcinoma with Gleason score 
of 3 + 3 and prostate-specifi c antigen level 
of 11.9 ng/mL. MRI without PACS cross-ref-
erencing indicated possible extracapsular 
extension (ECE) at right base and possible 
right seminal vesicle invasion (SVI) (scores 
of 3 and 3, respectively). However, MRI with 
PACS cross-referencing indicated defi nite 
ECE and defi nite SVI (scores of 5 and 5, re-
spectively). Histologic photograph shows 
whole-mount sections that confi rm pres-
ence of ECE (red) at right base and right 
seminal vesicle invasion (blue). RSV = right 
seminal vesicle. 
CHAPTER 6
Fig. 2D: 63-year-old man with clinical stage T1c prostate carcinoma with 
Gleason score of 4 + 4, prostate-specifi c antigen level of 12.9 ng/mL. MRI 
without PACS cross-referencing indicated possible extracapsular extension 
(ECE) at left base and possible left seminal vesicle invasion (SVI) (scores of 3 
and 3, respectively). However, cross-referenced MR images (A-C) indicated 
no ECE and no SVI (scores of 1 and 1, respectively). Histopathologic pho-
tograph shows whole-mount sections confi rming absence of extracapsu-
lar extension and seminal vesicle invasion at left base. RSV = right seminal 
vesicle, LSV = left seminal vesicle. 
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Fig. 3: Graph shows results of receiver operating characteristic 
analysis for detection of extracapsular extension with MRI alone 
and MRI with PACS cross-referencing. R1 = reviewer 1, R2 = review-
er 2, MRI = MRI alone, PACS = MRI with PACS cross-referencing, AUC 
= area under curve. 
Fig. 4: Graph shows results of receiver operating characteristic 
analysis for detection of seminal vesicle invasion with MRI with 
PACS cross-referencing and MRI alone. R1 = reviewer 1; R2 = review-
er 2; MRI = MRI alone; PACS = MRI with PACS cross-referencing, AUC 
= area under curve. 
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Fig. 1: Graph shows that each multivariate model had 
greater area under receiver operating characteristic 
curve (AUC) than model A (green) (Table 7), which in-
cluded only MRI fi ndings for lymph node metastasis 
(LMN). Model combining MRI fi ndings for seminal vesicle 
invasion and LNM (model F) (red) had greater AUC than 
model A: 0.714 vs 0.633, respectively (p = 0.08). Model 
combining MRI fi ndings for extracapsular extension and 
LNM (model G) (blue) had greater AUC than model A: 
0.798 vs 0.633, respectively (p = 0.15). Model combining 
MRI fi ndings for extracapsular extension, seminal vesicle 
invasion, and LNM (model H) (yellow) had greater AUC 
than model A: 0.813 vs 0.633, respectively (p = 0.11). Mod-
el combining MRI fi ndings for extracapsular extension, 
seminal vesicle invasion, and LNM and Partin tomogram 
prediction of LNM (model I) (black) had signifi cantly 
greater AUC than model A: 0.892 vs 0.633, respectively 
(p < 0.01). 
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Figure 1. Case 1. Clinical stage T2a prostate carcinoma with a Glea-
son score of 7 in a 61-year-old patient with a prostate-specifi c anti-
gen (PSA) level of 5.4 ng/mL. The premagnetic resonance imaging 
(pre-MRI) surgical plan indicated probable preservation of the left 
neurovascular bundle (NVB) (a score of 2 of 5, where 1 indicated defi -
nite preservation of the NVB and 5 indicated defi nite resection of the 
NVB) and probable resection of the right NVB (a score of 4 of 5). (A) 
An axial T2-weighted MRI image showed a large low-signal intensity 
tumor (T) in the left peripheral zone; there was obliteration of the 
rectoprostatic angle (arrowhead) and asymmetry of the NVB (arrow); 
both fi ndings indicate extracapsular extension (ECE) (MRI score of 
5). No tumor was noted in the right peripheral zone. As a result, the 
surgical plan was changed and was more aggressive on the left NVB 
(changing from 2 to 5) and less aggressive on the right NVB (changing 
from 4 to 1). (B) A corresponding histopathologic step-section map 
demonstrated established ECE at the left posterior (base); all surgical 
margins were free of tumor. MRI fi ndings appropriately changed the 
clinical impression of the urologist and the surgical plan for the left 
and right NVB.
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Figure 2. Case 2. Clinical stage T1c prostate carcinoma with a 
Gleason score of 9 in a 60-year-old patient with a prostate-specif-
ic antigen (PSA) level of 8.45 ng/mL. The premagnetic resonance 
imaging (pre-MRI) surgical plan indicated probable preservation 
of the right neurovascular bundle (NVB) (a score of 2 of 5, where 
1 indicated defi nite preservation of the NVB and 5 indicated defi -
nite resection of the NVB) and possible resection of the left NVB 
(a score of 3 of 5). (A) An axial T2-weighted MRI image showed a 
large low-signal intensity tumor (T) in the right peripheral zone. 
The contour of the gland was angulated and there was direct 
tumor extracapsular extension (ECE) (arrowheads), and envelop-
ment of the right NVB (arrow); fi ndings indicated right-sided ECE 
(MRI score of 5). There was no MRI evidence of left-sided ECE. As 
a result, the surgical plan was altered and was more aggressive 
with regard to the right NVB (changing from 2 to 5). The surgical 
plan for the left NVB remained unchanged. (B) A corresponding 
histopathologic step-section map showed established, poste-
rior, right-sided ECE. In this case, aggressive management of the 
right NVB was appropriate.
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Figure 3. Case 3. Clinical stage T1c prostate carcinoma with a 
Gleason score of 6 in a 55-year-old patient with a prostate-specif-
ic antigen (PSA) level of 6.31 ng/mL. The promagnetic resonance 
imaging (pre-MRI) surgical plan indicated defi nite preservation 
of both neurovascular bundles (NVBs) (a score of 1 of 5 for both, 
where 1 indicated defi nite preservation of the NVB and 5 indi-
cated defi nite resection of the NVB). (A) An axial T2-weighted 
MRI image demonstrated a focal low-signal intensity tumor (T) 
in the right peripheral zone. The tumor extended to the capsular 
margin in the region of the right NVB (arrow). Because the tumor 
abutted the right NVB, early extracapsular extension (ECE) could 
not be excluded (MRI score of 3). Consequently, the surgical plan 
was changed and was more aggressive with regard to the right 
NVB (changing from 1 to 3). MRI showed no tumor on the left. 
Thus, the surgical plan for the left NVB remained unchanged. (B) 
A corresponding histopathologic step-section map revealed no 
ECE and all surgical margins were free of tumor. In this case, MRI 
fi ndings inappropriately changed the surgical plan of the urolo-
gist with regard to the right NVB but confi rmed the decision to 
preserve the left NVB.
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Figure 1: Generating iso-surface image profi les from 
the phantom study. (a) and (b) show the iso-surface 
and projections on a phantom, respectively; (c) and 
(d) show the corresponding signal intensity profi les 
for the confi gurations in (a) and (b). Signal intensity 
from the mid 1/3 of the balloon-covered expandable 
endorectal coil remained homogeneous in the z di-
mension (e).  
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Figure 2: 54-year-old male with Gleason grade 4 prostate cancer in the peripheral 
zone (PZ) (weight 100.2 kg, PSA 4.4 ng/ml, clinical stage T2b, pathologic stage T3b). 
(a) Whole-mount step-section pathologic tumor map shows an index lesion of Glea-
son grade 4 in left PZ. The black circle represents the area of Gleason grade 4. (b) 
On the corresponding transverse uncorrected T2-weighted MR image (repetition 
time msec/echo time msec, 4916.7/102.48; echo train length, 12; fi eld of view, 14 cm; 
section thickness, 3 mm; no section gap) ROIs were placed on the center of the tu-
mor (ROI-1) on non-tumor prostatic tissue (ROI-2) and on internal obturator muscle 
(ROI-3). The PZ tumor-to-muscle SIR was 2.27. The PZ non-tumor prostatic tissue-to-
muscle SIR was 4.86. (c) On the corresponding transverse T2-weighted MR image cor-
rected with prostatic analytical coil correction (PACC) software, ROIs were placed the 
center of the tumor using (ROI-4) on contralateral non-tumor prostatic tissue (ROI-5) 
and on internal obturator muscle (ROI-6). The PZ tumor-to-muscle SIR was 1.82. The 
PZ non-tumor prostatic tissue-to-muscle SIR was 3.44.
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Figure 3: 60-year-old male with Gleason grade 3 prostate cancers in the PZ and TZ (weight 80.7 kg, PSA 5.1 ng/ml, clinical stage T2b, pathologic 
stage T2c). (a) Whole-mount step-section pathologic tumor map shows an index lesion of Gleason grade 3 in the right TZ (dashed white arrow), 
and a second dominant lesion of Gleason grade 3 (black arrow) in the right posterior PZ. The outlined areas represent the two tumors. (b) Cor-
responding transverse T2-weighted MR image (TR/eff ective TE = 4000/103; echo-train length, 16; fi eld of view, 14 cm; acquisition matrix, 256 x 
192; section thickness, 3 mm; no section gap) corrected with PACC software shows the index Gleason grade3 lesion (dashed white arrow) in the 
TZ, and the second dominant Gleason grade 3 lesion (black arrow) in the PZ. The tumor-to-muscle SIR (1.77) in the TZ is lower than that in the PZ 
(3.99). Also note that the PZ tumor-to-muscle SIR in this Gleason grade 3 lesion (3.99) is higher than that of the Gleason grade 4 lesion (1.82) in a 
diff erent patient shown in Figure 2. 
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Figure 3: Hemangioma
40-year-old female with a 48×35mm hemangioma in the right lobe of the liver. A) (Color-coded parameter image from the arterial phase, calcu-
lated using relative enhancement) Nodular enhancement in the periphery of the lesion. B) (Color-coded parameter image from the delayed phase, 
calculated using relative enhancement) Complete fi ll-in of the entire lesion.  The lesion is entirely red. C) (T2-weighted image, TR/TE= 1059/99.4 
msec) High signal intensity, lobulated and well-circumscribed lesion typical for hemangioma. D) The time-intensity curve from the ROI of the le-
sion (green curve) refl ects the steady enhancement of hemangioma (atypical Type I curve). The time-intensity curve from the ROI of the blue curve 
(line 3) shows normal liver parenchyma enhancement, and line 2 represents the signal intensity within the aorta at the acquired vascular phase. 
Note: decremental value in color spectrum: red > orange > yellow > green > blue > indigo > violet.
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Figure 4: Hepatocellular adenoma
32-year-old female with a hepatocellular adenoma in the right lobe of liver and a hemangioma in the left lobe of the liver. A) (Subtraction image 
from the arterial phase) Hypervascular lesion. B) (Color-coded parameter image from the arterial phase, calculated using relative enhancement) 
Homogeneous blush of the lesion. C) (Color-coded parameter image from the portal phase, calculated using relative enhancement) Isointensity of 
the lesion with the surrounding liver. D) (Delayed fat-suppressed T1-weighted image) Isointensity of the adenoma in the right lobe of the liver and 
homogeneously enhanced hemangioma in the left lobe of the liver. Note: decremental value in color spectrum: red > orange > yellow > green 
> blue > indigo > violet.
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Figure 5: Focal nodular hyperplasia
32-year-old female, with large focal nodular hyperplasia 
(FNH) in the left liver lobe. A) (Subtraction image from the 
arterial phase) Intense homogeneous enhancement of the 
lesion. B) (Color-coded parameter image from the arterial 
phase, calculated by using relative enhancement) Homo-
geneous intense enhancement of the lesion. C) (Color-cod-
ed parameter image from the portal phase, calculated by 
using relative enhancement) The lesion is almost isointense 
to the liver. D) (Color-coded parameter image from the de-
layed phase, calculated by using relative enhancement) 
Delayed enhancement of the central scar. E) (Color-coded 
parameter image, calculated by using maximum enhancement) The absolute values of enhancement of the lesions are higher than the liver. F) 
(Color-coded parameter image, calculated by using wash-out rate) This lesion has a similar wash-out rate as the surrounding liver. G) (T2- weighted 
image (TR/TE=1500/80 msec) The lesion is only slightly hyperintense to the liver. H) The time-intensity curve of the lesion (green curve) parallels 
the curve of the aorta in the arterial phase, indicating a very steep enhancement (Type III).  In the delayed phases it parallels the curve of the liver, 
refl ecting its benignity as well as its similarity to the normal liver tissue. Note: decremental value in color spectrum: red > orange > yellow > green 
> blue > indigo > violet.
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Figure 6: Hepatocellular carcinoma
62-year-old male with hepatocellular carcinoma (HCC) in the right liver lobe. A-D) Four images illustrating the typical four phases of dynamic gado-
linium enhanced sequence, including the pre-contrast phase (A), arterial phase (B), portal phase (C), and delayed phase (D). Note that the HCC is 
intensely enhancing in the arterial phase and shows wash-out in the delayed phases with late enhancement of a pseudocapsule. 
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Figure 7: Hepatocellular carcinoma
The same patient as in Figure 6. A-B) (Two subtraction images from the arterial and portal phases, respectively) Improved visualization of the HCC. 
C-D) (Two color-coded parameter images from the arterial and portal phases, respectively, calculated by using relative enhancement) Heteroge-
neous enhancement of the lesion, i.e. the lesion is enhancing more intensely in the center than in the periphery (more red in the center) (C), and 
lost contrast in the center (sign of a high wash-out rate), with enhancing pseudocapsule (more red in the periphery of the lesion) (D). 
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Figure 8: Hepatocellular carcinoma
The same patient as in Figures 6-7.  This fi gure shows vari-
ous parameters as color-coded images. A) (Color-coded 
parameter image, calculated by using T0) The lesion has 
a shorter T0 (i.e. enhances earlier) than the surrounding 
liver. B) (Color-coded parameter image, calculated by using 
time-to-peak (TTP)) The center of this lesion has a shorted 
TTP as compared to the pseudocapsule. This indicates that 
the peak of contrast reaches the center of the lesion in an 
earlier phase. C) (Color-coded parameter image, calculated 
by using wash-in rate) The center of this lesion has a lower 
wash-in rate as compared to the pseudocapsule. D) (Color-
coded parameter imaging, calculated by using wash-out rate) The center of the lesion has a slightly higher wash-out rate than the surrounding 
liver. E) (Color-coded parameter image, calculated by using brevity-of-enhancement) The time between the wash-in rate and wash-out rate is 
longer in the center of this lesion as compared to the surrounding liver. F) (Color-coded parameter image, calculated by using area-under-curve) 
The pseudocapsule of this lesion received a higher dosage of contrast agent than the center of the lesion. G) (T2- weighted image (TR/TE=1500/80 
msec) Slightly hyperintensity in the center as well as the pseudocapsule of the lesion. H) The time-intensity curve shows that the lesion (green 
curve) enhances more than the liver and less than aorta in the arterial phase, and loses contrast in the later phases (sign of wash-out). Please note 
that the curve, unlike the curve in the FNH (see Figure 5H), is not parallel to the curve of the liver in any phase. Note: decremental value in color 
spectrum: red > orange > yellow > green > blue > indigo > violet.
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Figure 9: Liver metastasis  
56-year-old female with a large hepatic metastasis from 
sigmoid carcinoma. A) (Substraction image from the portal 
phase) Irregular ring enhancement of the lesion as well as 
a faint enhancement in the center of the lesion. B) (Color-
coded parameter image from the arterial phase, calculated 
by using relative enhancement) Faint enhancement of the 
lesion. C) (Color-coded parameter image from the portal 
phase, calculated by using relative enhancement) Irregular 
ring of enhancement in the periphery of the lesion, where-
as the more central parts of the lesion are enhanced less 
than the surrounding liver. D) (Color-coded parameter im-
age from the delayed phase, calculated by using relative enhancement) The lesion has enhanced slightly more than in the previous phase, whereas 
the liver has lost some of its contrast. Therefore, the conspicuity of lesion has decreased. E) (Color-coded parameter image, calculated by using 
wash-in rate) The periphery of the lesion has a higher wash-in rate than the center of the lesion. F) (Color-coded parameter image, calculated by 
using the maximum relative enhancement) The central parts of the lesion enhance less than the surrounding liver. G) (T2- weighted image (TR/
TE=1500/80 msec) The periphery of the lesion is slightly hyperintense to the liver. H) The time-intensity curve of the lesion (green curve) shows 
that the lesion is enhancing similar to the liver in the arterial phase. In the portal phase, there is the greatest diff erence in enhancement between 
the lesion and the surrounding liver. In the delayed phase, the lesion shows slight further increase in enhancement, whereas, the liver loss some 
contrast. Therefore, the conspicuity of the lesion decreases after the portal phase. Note: decremental value in color spectrum: red > orange > yel-
low > green > blue > indigo > violet.
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Figure 10: Diff use parenchymal liver disease 
Diff use liver disease, before and after medical treatment. 59 year-old male with primary scleros-
ing cholangitis with an acute hepatitis in the left and part of the right liver. Images A-D were 
performed prior to medical treatment, while images E-H were performed after a three-month 
treatment with Prednison. A) (Subtraction image from the arterial phase) Abnormally increased 
enhancement of the liver parenchyma in the left and part of the right liver. B) (Color-coded 
parameter image from the arterial phase, calculated by using relative enhancement) The het-
erogeneous increased enhancement of the liver. C) (Color-coded parameter image from the 
portal phase, calculated by using relative enhancement ) The abnormalities are less well de-
picted in this phase. D) (Color-coded parameter image from the delayed phase, calculated by 
using relative enhancement) No abnormalities at all. E) (Subtraction image from the arterial 
phase, after treatment) Substantially less abnormal enhancement of the liver parenchyma. F) 
(color-coded parameter image from the arterial phase, after treatment, calculated by using rela-
tive enhancement)  Decreased heterogeneous increased enhancement of the liver. G and H) 
(Two color-coded parameter images from the portal and delayed phases calculated by using 
relative enhancement) The abnormalities have become occult. Note: decremental value in color 
spectrum: red > orange > yellow > green > blue > indigo > violet.
